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ABSTRACT 
 
Objective: 
Determine the impact of clinically used anti-resorption drug alendronate (ALN) 
on bone cells and the capacity of bone to regenerate, and to provide insights into 
the interplay between cancer stem cells and osteocytes/osteoblasts and 
mesenchymal stem cells using a three-dimensional (3D) live cancer-bone 
interactive model. 
Methods: 
Co-cultures of live mouse neonatal calvarial bone and cancer cells, PC3 prostate 
and breast MDA-MB-231, in a roller tube model system in the absence and 
presence of alendronate (ALN) and osteoprotgrin (OPG). These models were used 
under conditions whereby the two naturally occurring bone remodeling stages 
were dissociated, viz., bone resorption and formation. The used media and 
calvarial bones were evaluated by chemical, biochemical, histological and 
quantitative histomorphometric analyses.   
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Results: 
These studies revealed that cancer cells are unaffected to BP treatment in the 
presence of bone and colonize live bone irrespective to the bone remodeling 
stage, hence, cancer-bone metastasis/interactions are though to be ‘‘in- dependent 
of bone remodeling stages’’. Under resorption conditions cancer cells induce 
differentiation of osteoclasts and bone resorption and inclusion of alendronate 
(ALN) inhibited cancer-induced bone resorption at the osteoclast differentiation 
level. However, alendronate treated bones were adversely impacted as 
demonstrated by their inability to respond to stimulation for new bone formation. 
These data indicated that the bone stem/progenitor cells appeared non-vital after 
alendronate exposure. Similarly, in the formation model system the new bone 
formation was also limited.  Mass spectrometric analysis of the media from 
cancer-bone organ cultures in the absence and presence of ALN was consistent 
with the organ culture results. The mineral-bound ALN impacts the bone organs 
by limiting transformation of mesenchymal stem cells to osteoblasts and leads to 
diminish endosteal cell population and degenerated osteocytes within the 
mineralized bone matrix.  
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INTRODUCTION 
 
BONE 
     Bone is a dense connective tissue that provide support, protect internal organs 
of the body, produces blood cells and stores minerals. Formed mostly of calcium 
hydroxyapatite that accounts for its rigidity. Bone microstructure is patterned to 
provide maximal strength with minimal mass, as determined by the physiological 
needs. Bone structure consists of outer hard layer known as the cortical or 
compact layer, which is characterized with minimal spaces in between providing 
it’s hard appearance, and accounts for 80 % of total bone mass. While the interior 
layer consists of trabecular or cancellous bone rich with blood vessels and marrow 
spaces network accounting for only 20 % of the total mass. The basic unit of the 
compact bone is called osteon also known as haversian system. They are 
cylindrical in structure and are usually around 2 mm in length, but can reach up to 
8 mm, and 0.2 mm in diameter. Each unit composed of central tube called the 
havarsian canal, which contains blood vessels and nerves. These canals are 
surrounded by alternate layers of lamellae, concentric rings of strong matrix 
consisted of minerals and collagen fibers. In-between the lamellae, small spaces 
are occupied by the bone cells, osteocytes called lacunae, which are linked 
together by minute channels called canaliculi providing routes where nutrient and 
waste products can be exchanged among the cells. Like compact bone, spongy 
bone contains osteocytes housed in lacunae, but they are not arranged in 
concentric circles. Instead, the lacunae and osteocytes are found in a lattice-like 
network of matrix spikes called trabeculae. The trabeculae may appear to be a 
! !!
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random network, but each trabecula forms along lines of stress to provide strength 
to the bone. The spaces of the trabeculated network provide balance to the dense 
and heavy compact bone by making bones lighter so that muscles can move them 
more easily. In addition, the spaces in some spongy bones contain red marrow, 
protected by the trabeculae, where hematopoiesis occurs. This important structure 
provides multiple functions, ranged between mechanical aspects such as 
movement, and metabolic where all the growth factors stored.  
     On the molecular level, bone is a composite material consisting of extracellular 
matrix as a major component and cellular component accounting for the cells and 
blood vessels. The ECM has organic and inorganic parts. By weight, the inorganic 
constituent accounts for about 60 % of the tissue while the organic component 
makes up approximately 30 %. The remaining 10 % is water. Bone minerals or 
inorganic component are formed primarily by crystalline carbonated 
hydroxylapatite  (Ca10 (PO4 )6 (OH)2). First matrix is laid down by the osteoblast 
as unmineralized osteoid followed by mineralization. Osteoblast secret vesicles 
containing alkaline phosphatase which is involve in the mineralization process, 
cleaving the phosphate groups and act as the foci for calcium and phosphate 
deposition. Followed by the rupture of these vesicles, which act as a center for 
crystals to grow. The Organic components consists largely of type I collagen ~90 
% and the remaining ~10 % noncollagenous proteins. Type I Collagen is formed 
first as tropocollagen intracellular, and then converted to triple-helical molecule 
containing three polypeptide chains, each composed of approximately 1000 amino 
acids. Two of the three polypeptides are identical α1 (I) chain and the third one is 
! !!
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structurally similar, but genetically different, α2 (I) chain, cross-linked together 
by hydrogen bonding aligned together in a parallel fashion to form collagen 
fibrils, which are then grouped in bundles to produce the collagen fiber. 
Noncollagenous proteins are the growth factors such as glycosaminoglycan, 
osteocalcin, osteonectin, bone sialo protein, osteopontin and cell attachment factor 
and cytokines. Although these present in very small quantities in bone, they 
significantly contribute to its biologic function and believed to play an important 
role in bone matrix mineralization as well as in the regulation of osteoclast and 
osteoblast function. 
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Figure 1. Structure of cortical and cancellous bone. 
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Figure 1. Cross-section of compact bone and spongy bone. Compact bone is 
arranged in concentric layers around the havarsian canals containing the blood 
vessels, forming structural units called osteons. Cancellous bone has a sponge-like 
appearance with numerous large spaces and is found in the marrow space 
(medullary cavity) of a bone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! !!
! ! !! 6!
Bone Cells  
 
     Four distinct types of cells are present in bone tissue, each with their own 
crucial function. Osteoblasts, osteocytes, bone lining cell and osteoclasts are 
responsible for the proper development and maintenance of the skeleton, minerals 
regulation in the blood and as well as the body. They differ in their locations, 
osteoblast, osteoclast and bone lining cell can be found on the surface of the bone, 
while osteocytes are found deep in the bone matrix Figure 2. Beside location 
differences they also have different origins. Development of osteoblast, 
osteocytes and bone lining cells occur from multipotent stem cells, which 
differentiate into different mesenchymal phenotypes such as cartilage, bone, fat 
and muscle. While osteoclast originates from the monocyte/ macrophage linage 
which fuse to make multinucleated giant cells [1, 2]. 
     Osteoblasts (OBs) are mononucleated bone forming cells, involved in both 
intramembranous and endochondrial bone formation [3, 4]. They are derived from 
osteoprogenitor stem cells that are located in the bone marrow through a multi-
steps differentiation pathway. Osteoblast shape varied upon its activation, it 
becomes oval in shape when it’s active and turns to flat shape during inactivation 
phase. Osteoblast secretes extracellular proteins such as Type I collagen, 
osteopontin, osteocalcin, and bone sialoprotein forming bone matrix. They 
robustly generate alkaline phosphatase, an enzyme that is important in the 
mineralization process of bone. Hormones such as prostaglandins, which act on 
the bone, are manufactured by osteoblast.  
      
! !!
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     Osteocytes are trapped osteoblast in lacunae isolated in the bone matrix 
interconnected by slender channels called canuliculi. They are the most abundant 
cells in the bone. They communicate via long cytoplasmic extensions creating a 
network used to exchange of nutrients and waste through gap junctions. They are 
involved in the routine bone turnover through mechanosensory mechanism on 
active OB; help regulate bone responses to stress and mechanical load, matrix 
maintenance and calcium homeostasis. 
     Bone lining cells are essentially inactive osteoblasts. They cover the entire 
available bone surface and function as a barrier for certain ions. 
    Osteoclasts (OCs) are giant multinucleated cells formed by the fusion of cells 
of the monocyte-macrophage cell line [5]. They are responsible for bone 
resorption. These giant cells are larger in size, containing 15-20 oval shaped 
nuclei located at bone surface in pits or Howship’s Lacunae. Characterized by the 
presence of foamy cytoplasm due to the high concentration of vacuoles and 
vesicles filled with acid phosphatase, less amount of rough endoplasmic reticulum 
and high contents of golgi organelles and mitochondria. Osteoclasts highly 
express tartrate resistant acid phosphatase (TRAP) and cathepsin K. Activated 
OCs form a specialized cell membrane, (ruffled border) which facilitates matrix 
removal and increases surface area interface for bone resorption. Upon activation, 
OC releases hydrogen ions that cause dissolution of the mineralized bone matrix. 
Organic matrix is digested by the release of cathepsin K and matrix 
metalloprotieses (MMP) from lyzozome. TNF (Tumor necrosis factor)-related 
cytokine, RANKL (Receptor activator of NFκB ligand) and the polypeptide 
! !!
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growth factor CSF-1 (colony stimulating factor-1) are essential factors in 
osteoclastogenesis [6, 7].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!!!!!!
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Figure 2. Bone cells Origins and location 
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Figure 2. Bone Cells Origin and Location 
The origins and locations of bone cells[8].  
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Bone Formation !
     There are two processes for bone formation during the embryonic 
development, intramembranous ossification and endochondral ossification. 
Formation of Flat bones of the skull, maxilla, mandible and clavicle occur by 
intramembranous ossification where osteoid is laid down by the osteoblast, which 
differentiated from mesenchymal cells. Mineralization of the osteoid occurs few 
days later forming immature woven bone, where collagen fibers are arranged 
haphazardly corresponding for its mechanical weakness. Thickened woven collar 
becomes eventually replaced with mature lamellar bone. However, formation of 
long bones and the healing of bone fracture [9,! 10] occur by endochondral 
ossification, which involves initial differentiation of mesenchymal cell into 
chondrocytes forming hyaline cartilage matrix model followed by mineralization 
of cartilage and later resorption and replacement by osteoblastic bone formation. 
Bone Resorption: !
     Dissolution of the inorganic fraction of the bone matrix is mediated by 
acidification of the bone surface in contact with the osteoclast whereas organic 
components are digested by lysosomal enzyme. Once Osteoclast cell body is 
polarized, and activated in response to the action of RANK by its ligand, it 
undergoes internal structural changes through the rearrangements of the actin 
cytoskeleton and formation of a tight junction between the bone surface and basal 
membrane to form a sealed compartment Figure 3. The fingerlike processes 
"ruffled border" act to increase the surface area of the cell, facilitates the delivery 
of digestive enzymes and create an acidic environment to permit the osteoclast to 
! !!
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degrade bone. Attachment to the bone matrix achieved by the recognition and 
adherence of integrin receptors, such as αvβ3, to specific amino acid motif (Arg-
Gly-Asp) in bone matrix proteins, such as osteopontin and bone sialoproteins 
creating a sealed compartment. OCs release hydrogen ions by the action of 
carbonic anhydrase through the ruffled border into the resorptive cavity, 
acidifying and aiding in the dissolution of the mineralized bone matrix (i.e.; 
hydroxyapatite), which includes calcium and phosphate ions. Furthermore, 
several hydrolytic enzymes and acid phosphatase are released to the acidic 
microenvironment through the ruffled border. Lysosome proteases such as 
cathepsin, matrix metalloprotieses and collagenase digest the organic components 
of the matrix. Of these hydrolytic enzymes, cathepsin K that mainly expressed in 
osteoclasts is of most importance. In the resorptive pit, cathepsin K is released 
from the ruffled border of active OCs, and its mainly involved in the degradation 
of type I collagen. Resorption byproducts are removed by OC endocytosis process 
and further degraded by reactive oxygen species (ROS). OCs detach after the 
completion of the resorption process and migrate to a new site leaving “resorptive 
lacuna” whereby OBs will then come and replace the resorbed bone.  
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Figure 3. Osteoclast resorption mechanism 
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Figure 3. Osteoclast bone resorption scheme. Recognition and attachment of OC 
integrin’s to specific amino acids in bone matrix leading to a resorptive pit 
formation, which is sealed off from the adjacent bone. Hydrogen ions are also 
released through the actions of carbonic anhydrase and vacuolar ATPase proton 
pumps. Acidification of the resorption lacuna due to secretion of H+ ions by 
osteoclasts leads to spontaneous demineralization of the bone. Proteolytic 
enzymes (e.g.cathepsin K) are released from lysosomes in the osteoclast to 
degrade the collagen matrix and bone resorption process occurs [11]. 
 
 
 
 
 
 
 
 
 
 
 
 
 !
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Resorption Regulation:  !
     Osteoclastogenesis and OC activity are mediated through osteoblastic cells 
interaction with mononuclear hematopoietic OC precursors [12]. OB expressed 
proteins, such as Osteoprotegerin (OPG) and receptor activator of NFkB ligand 
(RANKL) which are the molecular mediators of this regulation. Activation of OC 
starts when RANKL binds to the osteoclast precursor [13, 14]. While 
Osteoprotegerin (OPG) also known as osteoclastogenesis inhibitory factor 
(OCIF), is a soluble glycoprotein that regulates excessive bone resorption by 
acting as a soluble decoy receptor for RANKL [15], and therefore neutralizes its 
interaction with RANK, inhibiting osteoclast formation, activation, and survival 
in vitro [13, 14]. The extent of bone resorption is controlled by both OPG and 
RANKL balance, such as an increase in OPG level will prevent bone resorption, 
while reduction on OPG will lead to excessive resorption. In addition, other 
cytokines, such as interleukins 1,3,6,11 and tumor necrosis factor α and β cause 
stimulation of resorption, while interleukin 1 receptor doesn’t. Hormones like 
PTH and vitamin D3 increases resorption by stimulation of OC, but calcitonin 
oppose their effects [16]. 
The synthesis and secretion of M-CSF by osteoblasts was increased with PTH, 
TNF-α and 1, 25 dihydroxyvitamin D3 treatment [17, 18]. The same factors 
(PTH, TNF-α and 1, 25 dihydroxyvitamin D3), in addition to inflammatory 
factors (IL-1 and PGE2) and dexamethasone were shown to increase RANKL 
levels as well [7, 19, 20]. On the other hand factors like estrogen and TGF-β 
resulted in lowering RANKL levels [19]. 
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Figure 4. Regulation of Bone Resorption. 
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Figure 4. Regulation of Bone Resorption. Osteoblast lineage cells express 
RANKL which binds to RANK receptors on the surface of pre-osteoclasts  and 
mature osteoclasts, stimulating the differentiation, activity and survival of OC 
which lead to increase the resorption of  bone. OPG, which is a ‘decoy receptor’, 
produced by the OBs, inhibit bone resorption by binding to RANKL and 
preventing it’s binding to RANK receptors. The rate of resorption is determined 
by the balance of RANKL and OPG [21].  
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Bone Modeling and Remodeling 
 
  
    Bone constantly is adapting its own structure. After the formation process, bone 
grows and changes in shape by the modeling process, where OB form bone 
without prior bone resorption, which increase the bone mass and strength. Bone 
remodeling functions is to renew bone in response to various stimuli and mineral 
homeostasis. It involves sequential bone resorption followed by formation at the 
same spatial location. On the surface of trabecular and cortical bone, osteoclasts 
start to generate trenches or tunnels of bone [19]. Osteoblasts subsequently fill in 
these trenches by laying down new bone matrix in them. Thus fine balance 
between bone formation and bone resorption is required for bone maintenance. 
Bone remodeling is stringently regulated by communication 
between bone component cells such as osteoclasts, osteoblasts and osteocytes. 
This process is highly controlled by both local and systemic growth factors. 
Hormones and systemic factors play a role in regulating bone remodeling by 
modulating the production of growth factors and cytokines from bone cells [22, 
23]. Recent studies suggest that at least in response to mechanical forces, 
osteocytes regulate the recruitment of osteoclasts to sites of bone resorption by 
inducing the expression of RANKL by osteoblastic cells in the local micro-
environment [20]. An imbalance of this process is often linked to 
various bone diseases. Osteoporosis is a disease that occurs when OC resorption 
exceeds OB bone formation. Bone strength and integrity depend on maintaining a 
fine balance between bone resorption by OC and bone formation by OB. Aging 
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process or disease caused this sensitive balance to shift toward the osteoclastic 
bone resorption over bone formation rendering fragile bone prone to fracture. 
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Cancer bone metastasis 
       Bone is a highly vascularized organ and a rich storehouse of growth factors. 
It’s considered to be the third most preferred site for cancer metastasis by 
different types of primary tumors [24, 25]. Almost 75% of patients with breast or 
prostate cancer develop bone metastasis with oseolytic or osteosclerotic lesions, 
respectively [26, 27]. Active bone remodeling releases the growth factors, 
providing a specific microenvironment which foster cancer cell to metastasize. In 
addition tumor cells secret adhesive factors that bind them to stromal cells and 
bone matrix which facilitates their growth in bone environment [18]. More than 
100 years ago, Page described the concept of cancer metastasis as the seed and 
soil hypothesis as the most acceptable theory. It’s a multistep process, where the 
tumor cells interact with the host microenvironment. Certain intrinsic requisite in 
the tumor cells are necessary for the development of secondary lesion. These 
requirements involve the production of proteolytic enzymes to facilitate cellular 
intravasation, extravasation, and bone matrix degradation. Increase or decrease 
the expression of cell adhesion molecules (CAM) is mandatory to detach cancer 
cells from its primary site. In addition, cell motility and migration through the 
circulation is an important requirement for metastasis. Escaping from the host 
immune system is essential for tumor survival. Metastasis starts with a decrease in 
specific CAMs that interrupt cell-to-cell adhesion leading to initiation of local 
invasion and eventually in the development of metastasis. Tumor cells first 
detached from the adjacent cell in the primary organ, invading the tumor 
capillaries and then reach the circulation. The mechanism involved for invading 
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the capillaries is most probably a similar mechanism for that used for the tumor 
cells to exit the circulation. When tumor cells are attached to the basement 
membrane, they start secreting protoeses in order to disrupt the basement 
membrane and begin to migrate through it. Production of proteolytic enzymes is 
either locally by the tumor cells or by the host cells. Tumor cells secrete type-IV 
collagenase for the degradation process [28]. Also, host cells such as fibroblasts 
and stromal cells found to express metalloproteinase gene [29]. Reports had 
shown that Active bone remodeling could release multiple factors with 
chemotactic potential, providing a specific microenvironment which foster cancer 
cell to metastasize. As a consequence of bone remodeling and bone resorption, 
fragments of type-1 collagen, and osteocalcin have shown to cause migration of 
tumor cells [30, 31]. Both the resorbing and the remodeling conditioned media 
stimulate cancer cell  migration through the chemotactic activity of rat and human 
tumor cells [32, 33]. One of the key roles of cancer cell metastasis is the 
attachment of cells to other tumor cells, and the extracellular structures. Cell 
adhesion molecules (CAMS) such as laminin and E-cadherin are critical elements 
for the invasion processes. These molecules regulate and determine the ability of 
tumor cell to invade and proliferate through facilitating the attachment of the 
tumor cell to the host cells and the extracellular matrix [34]. Interestingly, 
depending on the stage of metastasis and the site of metastasis, cancer cells may 
express either decreased or increased levels of CAMs. For example, E-cadherin 
expression varied between metastatic breast and ovarian carcinomas [35]. In 
addition, environmental and culture conditions can regulate its expression [36]. 
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Intigrins are one of the most abundant CAMs, responsible for cell-cell and cell-
matrix interactions [37]. Metastatic bone lesions lead to disruption in the bone 
remodeling process causing bone destruction or bone formation. The osteolytic or 
osteoblastic phenotypes are due to the action of tumor-produced factors to 
stimulate either osteoclast or osteoblast activity and alter normal bone 
remodeling. In Metastatic prostate cancer, both osteoblastic and osteoclastic 
factors are released interfering with the turnover of bone. Initially osteolytic phase 
is necessary for osteoblastic phase to occur, where cancer cells release 
osteoclastic factors such as RANKL (receptor activator of NFκB ligand), PTH 
(Parathyroid hormone) and DKK-1 (Wnt inhibitor).  Following that, the 
osteoblastic phase with the production of vascular endothelial growth factor and 
endothelin-1 which have osteogenic activity [38], and the release of growth 
factors stored in the bone matrix. In addition, Many studies revealed that prostate 
cancer cells secrete bone morphogenetic proteins (BMPs), and Endotheline-1 
(ET-1) [38-41].   
     Similar to prostate cancer, bone destruction in breast cancer is mediated 
through OCs stimulation by local production of the tumor peptide parathyroid 
hormone-related peptide (PTH-rP), which is enhanced by 
normal bone remodeling. Other mechanism is the production of specific 
mediators by bone or cancer cells that stimulate OCs bone resorption and bone 
destruction during cancer bone metastasis. These mediators are produced by the 
tumor cells or by host immune cells such as transforming growth factor-α, 
interleukin-1α, tumor necrosis factor, and interleukin-6. Hence Interleukin-6 
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markedly enhances the actions of PTH-rP on osteoclastic bone resorption both in 
vitro and in vivo, through increasing the numbers of OC progenitors [42]. In 
addition, bone provide a favorable soil for the growth of tumor cells, such as 
TGF-β which may alter the behavior of many tumor cells, particularly breast 
carcinoma cells, to enhance the production of PTH-rP [43]. However local 
destruction of bone by tumor cells has been proposed but remained controversial 
issue for many years. Since there is evidence that suggests the capacity of breast 
carcinoma cells to cause bone resorption in vitro. When breast carcinoma cells 
have been added to devitalized bone, they cause both mineral release and matrix 
degradation [44]. 
     Cancer bone metastasis can cause serious complication ranging from 
hypercalcaemia, severe pain and compression of the spinal cord to pathological 
fracture and mobility impairment. [18, 45].  Once cancer bone metastasis stage 
have been reached, palliative treatment is considered rather than any therapeutic 
treatment options. Treatment modalities include chemotherapy, radiotherapy, 
immunotherapy, or antibodies and surgical intervention when needed. 
Bisphosphonate has been used as an anticancer agent to prevent further bone loss 
and pain associated with cancer bone metastasis in conjunction with 
chemotherapy or hormonal therapy. 
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Figure 5. Mechanism of cancer bone metastasis 
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Figure 5. Mechanism of cancer bone metastasis. 
Cancer cells release PTHrP which is similar to parathyroid hormone in function, 
as it induces and stimulates bone resorption by the increase the release of RANKL 
facilitating cancer bone metastasis. At the same time, they release M-CSF, a 
mediator that stimulates the formation of OCs precursors and increases the 
number of neoplastic malignant cells, which result in hypercalcemia. Figure 
reproduced from [46]. 
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Bisphosphonate: 
     Bisphosphonates (BPs) are chemically stable analogues of inorganic 
pyrophosphate that resist enzymatic and chemical breakdown. Inorganic 
pyrophosphate (Ppi), is a naturally occurring form of pyrophosphate that have 
been discovered circulating the body as an endogenous water softener, preventing 
soft tissue calcification, and regulating bone mineralization [47]. Despite their 
rapid binding to the bone minerals they hydrolyze rapidly into two phosphate 
groups, which is a major obstacle in utilizing their beneficial biological effect. 
Later on, researchers discovered similar compounds that overcome this main 
disadvantage, which led to the work with the well established bisphosphonates 
that exhibit the same inhibitory effect on bone dissolution as inorganic 
pyrophosphate [48]. Bisphosphonate formerly called disphosphonate, consists of 
two phosphate groups linked by a phosphoether bonds to a central carbon atom, 
rather than an oxygen atom, forming a more stable P-C-P. While inorganic 
pyrophosphate consists of a phosphoanhydride bond linking two phosphate 
groups, forming P-O-P backbones, which become deactivated after oral 
administration by the mucosal brush border phosphatase. Replacement of oxygen 
with a carbon atom in BPs [49] resist this enzymatic hydrolysis and made them to 
become major drugs used for the treatment of bone diseases associated with 
excessive resorption.   
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Chemical structure  
 
 
     BPs comprised of two phosphate groups linked by phosphoether bonds 
through a central carbon atom. This stable P-C-P backbone is highly resistant to 
hydrolysis under acidic conditions as well as pyrophasphatase action, unlike the 
unstable P-O-P bonds in PPi, and it is essential for binding the hydroxyapatite. A 
unique biological profile can be achieved for each BP with their ability to form 
two additional covalent bonds with the presence of the carbon atom in the center 
of its structure. The binding affinity and the anti-resorptive ability are affected by 
the modification of the structure composition. Replacing the hydroxyl (–OH) by a 
methyl (–CH3) group on each of the two phosphonate groups of the backbone 
structure will affect and prevent the binding ability to hydroxy apatite [50].  
The germinal carbon atom forming additional covalent bonds with two side 
chains usually referred to as R1 and R2. Variations in these side chains produce 
the individual bisphosphonate with different binding affinity for hydroxyapatite 
and hence their uptake and persistence. Chemical properties, mode of action and 
the potency are affected by R1, the short side chain that can be enhanced with 
hydroxyl group, to increase the calcium ion binding affinity e.g. (etidronate) 
rather than a halogen atom such as chlorine as in (clodronate) [51]. R2 the longer 
side chain determines the anti-resorptive potency and the effect on OC. Increasing 
the length of the R2 side chain will alter the OC inhibition effect. This was noticed 
with a longer R2 alkyl side chain (as in OB with a (-CH2)3) instead of methyl (- 
CH3) of etidronate while retaining the –OH on the R1 side chain [52]. Increasing 
the length of alkyl side chain can enhance the potency of BPs.!The!ideal!length!of!
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the!amino?alkyl!chain!includes!four!carbon!atoms!with!the!germinal!atom!to!intensify! the! potency.! Other! modification! such! as! adding! an! amino! (?NH2)!group!to!R2!side!chain!increased!the!anti?resorptive!potency!up!to!1000?folds![53].!In!fact!BP!with!a!nitrogen!cyclic!ring!are!10,000!fold!more!potent!than!etidronate![54].! 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! !!
! ! !! 29!
Figure 6. Structure and Types of Bisphosphonate. 
!
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Figure 6. Chemical Structure of Inorganic Pyrophosphate and Bisphosphonate. 
(A) BPs are synthetic analogs of inorganic Pyrophosphate substituting the central 
oxygen atom for carbon renders the Bisphosphonate structure more stable and 
resistant to thermal, chemical and enzymatic degradation. The functional group R1 
in BPs enhances binding to hydroxyapatite, while R2 affects the anti-resorptive 
potency, and the carbon center enhances the overall chemical stability[55]. 
(B) Demonstration of different chemical structures of non-nitrogen containing and 
nitrogen containing BP [56]. Non-nitrogen containing examples of BPs are such 
as clondronate and etidronate. Nitrogen-containing examples of BPs include 
pamidronate, alendronate, ibandroate, zoledronate, minodronate, risedronate, and 
3-PEHPC (phosphonocarboxylate analogue of risedronate). 
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Classification of Bisphosphonate  !
          BPs are classified according to their mechanism of action into non-nitrogen 
containing bisphosphonates and nitrogen containing bisphosphonates (NBP), both 
groups share the general structure of P-C-P moiety. Depending on the structural 
composition of each BP they differ in their strength of binding and inhibition 
potency. The non-nitrogen containing bisphosphonates resemble pyrophosphate 
because of their relatively short side chains (eg, clodronate and etidronate) and 
don’t contain any amino group. The mechanism of action of non-nitrogen 
containing BPs based on their metabolism into non-hydrolysable toxic analogues 
of adenosine triphosphate (ATP) by the action of Aminoacyl-tRNA synthetase 
enzyme. Normally the enzyme catalyzed the reaction between the amine 
containing group and ATP releasing pyrophosphate, while when non-nitrogen 
containing BPs are incorporated in such a reaction, it replaces the pyrophosphate. 
Accumulation of the cytotoxic metabolites in the OC will inhibit the ATP-
dependent intracellular enzymes [56, 57]. One of the affected mitochondrial 
enzymes is Adenine nucleotide translocase on the mitochondrial membrane.  The 
key function of adenine nucleotide translocase is to export ATP out of the 
mitochondrial while bringing ADP inside the cell. Interruption of this enzyme will 
affect the mitochondrial permeability and activate caspase, which leads to cell 
apoptosis [58, 59]. 
The second type is the nitrogen containing bisphosphonates (NBP); these are 
generally more potent and characterized by the presence of amine group (-NH2) in 
R2 side chain. The position of the amino group varied in each NBP, it can be 
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located in the terminus end as in alendronate, or incorporated within a 
heterocyclic ring as in risedronate. Due to the structural differences between the 
NBP and non-nitrogen containing BPs, the former interfere with mevalonate 
pathway which is critical for OCs. NBP inhibit a key enzyme, farnesyl 
pyrophosphate synthase and geranylgeranyl in the mevalonate/cholestrol pathway 
[60], thereby preventing the biosynthesis of isoprenoid compounds that are 
essential for the posttranslational modification of small guanosine triphosphate 
(GTP)-binding proteins such as Rab, Rho, and Rac, which are important signaling 
factors that regulate normal function of OC as proliferation, differentiation, 
maturation. Also membrane ruffling, cytoskeletal arrangement and vesicle 
transportation will be disrupted [61-64]. Alterations in these vital processes will 
lead to drop in OC function and increase apoptosis [65]. 
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Figure 7. Bisphosphonate Mechanism of Action 
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Figure 7. Bisphosphonate Mechanism of Action. 
Two separate mechanisms of action depending on the type of BP occur. In case of 
non-nitrogen containing BP (simple BP), BP becomes non-hydrolysable cytotoxic 
ATP analog that leads to osteoclast apoptosis. As for nitrogen containing BPs, 
inhibition of a key enzyme in the mevalonate pathway causes alterations in 
protein modifications necessary for osteoclast function and survival [66]. 
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Effects of Bisphosphonate at the cellular level 
 
Effect on Osteoclast 
 
         Bisphosphonates have high affinity for hydroxyapatite bone mineral, 
therefore they are targeted to areas with high bone turnover, where osteoclastic 
bone resorption occur. The direct effect on osteoclasts is the most likely rout by 
which these drugs inhibit resorption. 
During bone resorption, high acidic pH cause dissolution of the hydroxyapatite 
bone minerals, exposing the free unbound bisphosphonates and bring them in 
close contact with OC. Sato et al. confirmed OC internalization of bisphosphonate 
in vivo [67-69], using radiolabeled and fluorescently labeled alendronate [70]. 
Other studies showed that BPs in concentrations of >10-7 M, affect OC cell 
recruitment, differentiation, and apoptosis in studies conducted using mouse, rat, 
and rabbit OC in vitro and in vivo [71]. Bisphosphonate can cause more subtle 
changes that affect the OC ability to resorb bone such as lack of the ruffled 
border. In addition disruption of the OC cytoskeleton has been shown to occur 
[72].  
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Figure 8. Effect of BP on Osteoclast. 
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Figure 8. Effect of BP on Osteoclast. As!seen!in!the!figure,!initially!BPs!are!bound!to!bone!mineral.! !As!osteoclast!resorption!takes!place,!osteoclast!uptake!the!BP![73].!!!!!
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Effect on Osteoblast 
 
           Despite the well-documented inhibitory effect of BPs on OC both in vivo 
and in vitro, the effect on OB function have been less well studied and remain 
controversial. Some in vivo studies have shown that neither OB differentiation nor 
bone formation or matrix mineralization was affected in patients receiving yearly 
BP infusion regardless to reduced bone turnover [74-76]. In contrast, Tobias et al. 
and Iwata et al. both reported inhibitory effects on OB function and 
mineralization rate [77, 78]. 
      Data from Different in vitro experimental systems involving mesenchymal 
stem cells, ‘osteoblast-like’ cell lines, and primary osteoblasts were also 
conflicting. For example intermittent long-term treatment with pamidronate and 
alendronate in nM concentrations inhibited bone formation by mouse calvarial 
osteoblasts [79]. Additionally, µM concentration of etidronate and alendronate 
inhibited the formation of mineralized nodules in murine bone marrow culture 
while nM concentrations stimulated them [80]. Duque and Rivas 2007, reported 
that the differentiation of human mesenchymal stem cells to osteoblast can be 
stimulated by nM concentrations of alendronate [81]. Moreover, significant 
anabolic effect in both primary human trabecular bone cell culture and the MG-63 
osteoblast- like cell line treated with alendronate and risedronate attaining peak 
levels at a concentration of 10-8 M, have been reported. These effects were 
established by increased cell number, and alkaline phosphatase activity, including 
enhanced gene expression of BMP-2, Type I collagen and osteocalcin [82]. 
Mundy et al, showed that clinically used statins for cholesterol suppression, 
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sharing the same mechanism of NBP as inhibitor of the mevalonate pathway, 
stimulate BMP-2 gene expression, which increased bone formation in vitro as 
well as in vivo [83]. 
     These contrasting findings may reflect; major differences in dosing regimens 
and the adsorption of bisphosphonate onto bone surfaces in vivo. Bisphosphonates 
rapidly adsorbed onto mineralized bone surfaces from the microcirculation 
following administration in vivo [65]. Thus, the concentrations of 
bisphosphonates to which bone cells are exposed in vivo are not known. Although 
osteoblasts, including bone-lining cells, might experience lower concentrations of 
bisphosphonates than osteoclasts, they may be exposed for a longer periods of 
time. 
Clinical Implication of BP 
 
     Clinically, They are used as Anti-resorptive agents for the treatment of Paget 
disease, myeloma, cancer bone metastases, adult osteoporosis, and pediatric bone 
diseases such as osteogenesis imperfecta, because of their selective adsorption to 
mineral surfaces and internalization by bone-resorbing osteoclasts where they 
interfere with various biochemical processes. 
Anti Cancer Effect   
 
     In addition to the established role as inhibitors of osteoclast activity and bone 
resorption, bisphosphonates (BPs) also affect tumor cells. Their ability to induce 
apoptosis, reduce proliferation, and inhibit tumor cell migration and invasion has 
been demonstrated in numerous in vitro studies [84]. In addition evidence suggest 
that BP such as zoledronic acid has anti-tumor and anti-metastatic properties 
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through affecting the angiogenesis, cell invasion and adhesion [85]. Cancer-bone 
metastasis which is ‘‘bone resorption- dependent’’, became the universally 
accepted theory based on the localization of tumor cells on bone specifically, in 
addition to their effect on OC activation and differentiation [86-89]. Cancer-
induced bone resorption has a significant impact on patient survival rate and 
morbidity and has been a primary target for therapeutic intervention using 
powerful anti-resorption agents such as BPs [90-92]. 
The significance of cancer microenvironment as an important factor in tumor 
progression, metastasis and survival [84, 85, 93-96] in addition to the ability of 
BPs to alter that microenvironment by the inhibitory effect on OC bone resorption 
directly, is consistent with the desire to establish such an approach [84, 88, 95, 97, 
98]. Rapid accumulation of BP within the mineral layer of bone due its high 
affinity suggested that OC specifically exposed to the direct drug action more than 
other cells [71, 72, 99]. However the fact of the long half-life of BP and their 
preference to accumulate within the mineralized surface endanger other bone cells 
directly in contact with the bone mineral to the prolong action of the drug. Such 
occurrences of undesired side effects could be reflected by the osteonecrosis of 
the jaws and long bone fractures associated with the administration of BPs 
especially in high doses such as in cancer patients [100, 101]. 
Direct anticancer effects of nitrogen-containing BPs have been reported in 
preclinical studies in vitro and in vivo with inconclusive results and uncertain 
clinical relevance [27, 102-104]. Clinical trails analysis using BP alone or 
adjuvant to chemotherapy or hormonal therapy revealed inconsistent results [93-
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95, 105]. Several observational studies found that at doses used for osteoporosis, a 
protective effect have been noticed [106]. However, recent clinical trails were 
contrary to these studies and neither alendronate nor zoledronic acid reduced the 
risk of breast cancer [107]. Likewise, 36 trails using adjuvant bisphosphonate data 
analysis showed no effect on local recurrence or contralateral breast cancer 
incidence .The anatomical location of osteocytes within a cocoon of mineralized 
bone matrix and those of the bone periosteal/ endosteal osteoblasts and 
mesenchymal stem cells in direct contact with the mineral phase suggests their 
highly susceptible nature to drug action including BPs.  
Pharmacokinetics 
!
     BPs characterized by their low bioavailability ranging between 1 to 10 %, 
when taken orally due to the low lipophilicity and high negative charge. Oral 
administration of BP with meals affect the absorption of BP significantly 
especially with diary products and iron supplement due to the presence of calcium 
and iron, leading to decreased uptake itself or converting them into non-
absorbable form [108].  BPs adsorption begins in the stomach and small intestine 
where it passively diffused into the body through the paracellular pathway. BPs 
rapidly become deposited in the mineral layer of bone 20-80%, the remainder free 
unbounded BP is excreted by the urine. Extraosseous deposition in organs like 
liver and spleen can occur with certain type of BP e.g Pamidronate. The rate of 
BP deposition is significantly proportion to the dose administered. The half-life of 
circulating BP in plasma is short, ranging between 0.5-2 hours. The uptake of BPs 
by bone is faster and comparable to those of calcium and phosphate. BPs 
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deposited rapidly in areas of both bone formation and bone destruction. After 
deposition of BP in the skeleton, it can be released by the physiochemical 
mechanism or buried in the bone and liberated only when this bone layer becomes 
resorbed, which explains the long half-life of BPs and the possibility to remain in 
the body for life time. BP clearance from the body is through the kidneys and in 
renal failure, urinary excretion is decreased and peritoneal dialysis is poor, 
caution must be taken in patients with kidney disease while administering BP. 
 
Side Effects  
 
    Beside the beneficial effect of BP in treating different bone diseases such as 
osteoporosis, Paget’s disease and cancer bone metastasis, several side effects had 
been associated with their use. Dose and potency of the BP determine the severity 
of the side effects. Renal failure was associated with rapid injection of BP 
intravenously due to its retention in the kidney in a solid phase. Avoiding such 
complication can be achieved via slow infusion of BP with excess fluid over 2 
hours minimum. Other side effect is hypocalcemia in patients taking 
aminoglycoside antibiotic, which can cause a kidney damage and incompetence to 
accommodate for the inhibitory effect of bone resorption. Both drugs can’t be 
given concomitantly. Gastrointestinal tract irritation such as nausea, vomiting 
pain, diarrhea and ulceration can occur with oral administration of BP especially 
those with nitrogen containing compounds. 
BP-related osteonecrosis of jaw (BRONJ) is a serious effect that has been 
associated with patient that undergoes BP treatment [109]. In 2003-2004, cases 
with necrotic, exposed, non-healing bone of the maxillo-facial were first reported 
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in association with intravenous bisphosphonate. Patients may be considered to 
have BRONJ if all of the following 3 characteristics are present: 1) current or 
previous treatment with a bisphosphonate; 2) exposed, necrotic bone in the 
maxillofacial region that has persisted for more than 8 weeks; and 3) no history of 
radiation therapy to the jaws according to the American Association of Oral and 
Maxillofacial surgeons position paper definition in 2007. Patients under treatment 
with oral bisphosphonate therapy are at a considerably lower risk for BRONJ than 
those who take IV BP. The increased blood supply to jaw bone compared to the 
rest of the body and the faster rate of bone turnover, made BP to be highly 
concentrated in the jaws, coupled with chronic dental diseases, required 
treatments and the thin mucosa over bone, cause this condition to be manifested 
exclusively in the jaws due to it’s anatomic concentration. The exact leading 
theory is unclear, but suggests that the inhibitory effect of OC by the drug causes 
inhibition of both, bone remodeling and bone turnover. Other mechanism is 
inhibition of angiogenesis by BP. Fournier et al, have shown that BP inhibit 
angiogenesis, decrease capillary tube formation, and inhibit vascular endothelial 
growth factor and vessel sprouting, both in vitro and in a rat model. However, 
according to this theory more potent antiangiogenic drugs in clinical use today, 
such as thalidomide and statins haven’t shown to cause bone necrosis and 
exposure. Alteration of bone turnover rate and vascularity, allow micro damages 
accumulation and fractures, unrepaired [60]. Strategies in prevention the 
occurrence of BRONG in patients begins prior to treatment with BP injection, by 
thorough oral exam, removing any unsalvageable teeth, completion of all invasive 
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dental procedures, and optimal periodontal health should be achieved and should 
maintained.  However, patients with established lesion with BRONJ, treatment 
aims mostly in pain reduction, control infection of the soft and hard tissue, and 
minimize the progression or occurrence of bone necrosis. In addition, damage to 
the kidney can occur from the BP high affinity to metal ions forming insoluble 
compound [108]. 
 
 
 
 
 
 
 
 
 
!!
      
 
 !!!!!!!!!!!!!!!!!!!!
! !!
! ! !! 45!
 
 
 
AIM 
 
Hypothesis  
We hypothesize that ALN inhibits the ability of OCs to differentiate as well as 
causing loss of the bone stem/progenitor cell capacity to differentiate to bone 
forming osteoblasts. ALN doesn’t have a direct anti-cancer effect on cancer cell 
survival and cancer/bone metastasis is independent of bone remodeling stages. 
In order to test this hypothesis, the following specific aims are proposed: 
 Specific Aim1: Determine the impact of ALN on osteoclast differentiation under 
bone resorption condition and the bone microenvironment-mediated resistance of 
cancer cells to BPs treatment in a live three-dimensional cancer-bone metastasis 
model systems in the absence or the presence of:  
i) Prostate -PC3- cancer cell line  
ii) Breast -MDA-MB- 231-cancer cell line  
Specific Aim 2: Determine the impact of ALN on osteoblast, the ability of bone 
to regenerate and the bone microenvironment-mediated resistance of cancer cells 
under bone formation condition. 
- Generate and confirm osteoblastic bone formation system, by ascorbate-induced 
osteoblast differentiation and new bone formation, utilizing the three-dimensional 
cancer-bone metastasis model system in the absence or the presence of:  
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i) Prostate -PC3- Cancer cell line 
ii) Breast -MDA-MB-231-cancer cell line  
Specific Aim 3: Determine the impact of OPG on OC and OB under bone 
resorption/formation condition utilizing the “three-dimensional cancer-bone 
metastasis model” systems:  
i) Prostate -PC3- Cancer cell line  
ii) Breast -MDA-MB-231-cancer cell line  
Specific Aim 4: Effect of ALN/OPG on the healing process, OB and new bone 
formation using ex- vivo calvarial bone defect organ culture model system.  
Specific Aim 5 Define impact of ALN on cultured prostate (PC3) and breast 
(MDA-MB-231) cells under cell culture condition.  
Specific Aim 6: Determine effects of ALN on osteoclastic bone resorption, 
osteoblastic bone formation using Mass spectrometry analysis to highlight protein 
level alteration of the media in calvraial bone cultures and the mineralizing OB 
cell layers.  
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MATERIALS AND METHODS 
!
Roller tube model system for 3D neonatal mouse calvarial bone co-cultures 
with cancer cells (3D) and effect of alendronate (ALN) and Osteoprotegerin 
(OPG) 
     Under sterile conditions, Calvaria from 5-7 day old neonatal CD-1 mice 
(Charles River Laboratories, MA) were dissected to produce a trapezoid structure 
by partial cutting in the occipital lobe and the two frontal lobes, and then rinsed in 
the culture medium. Each calvarium was placed free floating in a roller tube (15 
cm ×1.6 cm, Belloc, Inc. N.J.) containing 2.0 ml of bone culture media with or 
without the respective cancer cells (2-5x 105 per tube) in suspension (Curtin et al, 
2012) and incubated under normoxia at 37 °C for 8 days. The live bone organ 
culture medium consisted of Dulbecco’s Modified Eagle Medium DMEM 
supplemented with bovine serum albumin (BSA), fraction V (5 mg/ml, Sigma 
Co.), 100 U/ml penicillin and 100 µg/ml streptomycin and 250 ng/ml 
amphotericin B (Gibco, Grand Island, NY) without containing any fetal calf 
serum (FCS) or ascorbic acid. Inclusion of the cancer cells stimulates osteoclastic 
bone resorption in the presence of above media. For the bone formation model the 
culture media was devoid of FCS but 1 mM sodium ascorbate (Sigma, Co.), 
which was shown to stimulate osteoblastic activity through collagen synthesis 
[110]. Alendronate sodium trihydrate (Sigma-Aldrich, Co) was added at a 
concentration of 30 µM.  
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Same experimental sets were carried out with the addition of Recombinant Mouse 
Osteoprotegerin/TNFRSF11B FC Chimera (R & D system) at 2 nM 
concentration. 
The approach permits studies to be performed with remodeling events dissociated 
whereby with the conditioned media from cancer cells, calvarial bone undergoes 
predominantly osteoclastic bone resorption Figure 9.  
 
 
!
 
 
 
 
 
 
 
 
 
 
! !!
! ! !! 49!
Figure 9. Roller Tube System. 
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Figure 9. The roller tube system was comprised of pyrex tubes of 15 cm with 2 
ml of culture media, one free-floating calvarial bone and cancer cells (5x105). The 
tubes with sterile stoppers were placed horizontally at an angle of 8-10o in a roller 
tube apparatus with a setting of 5 revolutions per min in a 37 °C incubator.  
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Prostate - (PC3) and breast – (MDA-MB-231) cancer cell culture  
     PC3 prostate and MDA-MB-231 breast tumor cell lines (American Type 
Culture Collection), were grown with F-12 K media and DMEM, respectively, in 
the presence of 10 % Fetal Calf Serum (FCS, Sigma-Aldrich, Co) at 37°C until 
confluent using 10 cm culture dishes and media changed every 2 days. The day of 
bone organ co-cultures with PC3 and or MDA-MB-231 cells, the cancer cells 
were rinsed with 10 ml of bone organ culture media first, harvested using trypsin 
in 10 ml of bone culture media followed by centrifugal pelleting. The collected 
cancer cells were re-suspended in 10 ml of bone organ culture media and re-
pelleted. The cancer cells were then suspended in bone organ culture media and 
total number of cells was counted using microscopic approach and 
hematocytometer. Two ml of bone culture media spiked with (5x105) of tumor 
cells were added to each roller tube to be co-cultured with a single full calvarial 
bone.  
Impact of alendronate (ALN) on bone biology, cancer- bone interactions, 
osteoclast differentiation/bone resorption model  
     The impact of alendronate on cancer-bone interaction was studied through the 
bone resorption condition using co-cultures of prostate and breast cancer cells 
with live bone calvarial organ culture.  
Under bone resorption conditions, calvarial bone organ cultures can only 
undergo rapid osteoclast differentiation and bone resorption with no 
capacity for osteoblast (OB) differentiation and bone formation. This is a 
unique system in which the absence of ascorbate (vitamin C) generates no 
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possibility for stable collagen synthesis and osteoblast differentiation. In 
the absence of added stimulants for OC differentiation such as cancer cells, 
the calvaria also has no osteoclastic activity in the parietal bone and hence, 
allows for clear interpretations of the results.  
Different experimental treatment group were applied to confirm the effect 
of ALN on calvarial bone co-culture with tumor cells.   
i) Calvarial bone co-culture with PC3 cancer cells  
Five groups, fifteen calvarial samples (n = 15) per each group were set up; 
per each one were set up; (a) Unstimulated negative control (Culture media 
only); (b) PC3 alone; (c) PC3+30 µM ALN (Fosamax, Sigma-Aldrich Co.); 
(d) PC3 for four days followed by inclusion of 30 µM ALN for another 
four days ; (e) 30 µM ALN for four days then PC3 for four days.  
ii) Calvarial bone co-culture with MDA-MB-231- cancer cells 
     Different experimental treatment group were applied to confirm the 
effect of ALN on calvarial co-culture with MDA-MB-231. Fifteen calveria 
per each group (n = 15) were set up; (a) Unstimulated negative control 
(Culture media only); (b) MDA-MB-231 alone;  (c) MDA-MB-231+30 µM 
ALN.  
The media of the live organ culture was changed every two days in the 
sterile cell culture fume hood. The medium of each treatment group was 
collected and labeled into 2ml eppendorf tube and stored under -4 degree 
Celsius, to be prepared for calcium analysis. 
Upon conclusion of the experiment, calvaria were hemi-dissected in the 
! !!
! ! !! 53!
mid sagittal suture resulted in 30 half calvaria per treatment group. Five 
half calvaria from each group were fixed in 10 % formalin, paraffin 
sectioned, and stained with hematoxylin and eosin (H&E, Boston Medical 
Center, Department of Pathology) for histological analysis. Twelve half 
calvaria from each group were prepared for tartrate-resistant acid 
phosphatase (TRAP) activity assay. The remaining thirteen half calvaria 
were stained with neutral red (NR, sigma-Co) to visualize general OCs 
activity, counterstained with 2 % silver nitrate for global assessment of 
OCs bone resorption. 
Impact of alendronate (ALN) on bone biology, cancer- bone interactions, OBs 
differentiation/bone formation model  
          To determine the impact of ALN on osteoblast, and the ability of bone to 
regenerate under bone formation condition, prostate and breast cancer cells co-
culture with live bone calvarial organ culture were stimulated with the addition of 
freshly made 150 µg/ml (1mM) Na ascorbate (Sigma-Aldrich, Co) which is an 
essential factor for stable collagen synthesis, extracellular matrix (ECM) 
formation and osteoblast differentiation [111, 112] in the absence or presence of 
cancer cells. 
i) Calvaria bone co-culture with PC3 cancer cells  
     Total of six groups, ten calvaria per group (n = 10), set as followed (a) 
Unstimulated negative control; (b) Stimulated positive control with 1mM ASC; 
(c) PC3+ ASC; (d) PC3+30 µM ALN+ASC, (e) 30 µM ALN + ASC for four days 
then PC3 for four days, (f) PC3+ ASC for four days then 30 µM ALN for another 
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four days.  
ii) Calvaria bone co-culture with MDA-MB-231- cancer cells 
      Mouse calvarial cultures stimulated with 1 mM ASC to confirm the 
effect of ALN on OB in bone formation system. Total of four groups, ten 
calvaria per each one (n = 10) set as followed:  
 (a) Unstimulated negative control; (b) Stimulated positive control 1 mM 
ASC; (C) MDA-MB-231+ ASC; (d) MDA-MB-231 + ASC + ALN 30 µM. 
Medium was changed every 2 days and the used medium was stored at 4 
°C for chemical and biochemical analysis. Upon conclusion of the 
experiment, calvaria were hemi- dissected in the mid sagittal suture. Seven 
half calvaria were prepared for alkaline phosphatase activity (ALP) instead 
of TRAP and the other seven half calvaria were fixed in 10 % formalin 
paraffin sectioned, and stained with hematoxylin and eosin (H&E, Boston 
Medical Center, Department of Pathology) for histological analysis. The 
remaining six half calvaria were prepared for NR and SN counterstain. 
Histology Observation  
         Histology of OC resorption and OB bone formation were obtained from the 
designated half calvaria of each treatment group (five half calvaria for the 
resorption system, and seven half for the formation system) after fixation in 10 % 
formalin, paraffin sectioned with three different regions and two serial sections, 
and stained with hematoxylin and eosin (H&E, Boston Medical Center, 
Department of Pathology). All digital images of H&E stained sections were 
captured under magnification of 100X, 200X with light microscope. 
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Quantitative analysis of TRAP activity 
      Tartrate-resistant acid phosphatase (TRAP) assay is a marker for osteoclast 
activity. This assay measures the rate of hydrolysis of the p-NPP substrate which 
dephosphorylated by TRAP from p–nitrophenyphosphate (p-NPP) into p-
nitrophenol (pNP), producing a bright yellow color under alkaline condition, and 
can be measured by ultraviolet and light spectrophotometer or 96 well ELISA 
plate reader at absorbance wavelength of (405 nm), as described in Curtin et 
al.2012. The enzyme was released from the cellular layer of calvaria by treatment 
with 250 µL lysis buffer consisted of 150 mM sodium chloride, 30 mM of sodium 
bicarbonate at pH 7.8, and 0.5 % Nonidet P-40. Each sample was put through 5 
freeze-thaw cycles, kept on ice for 1 hour followed by centrifugation for 30 
minutes at -4 degree Celsius to remove calvarial bone and debris. The TRAP 
enzyme activity was determined by incubation of 50 µl of each calvarial cell 
extract in duplicate with 250 µl of 0.1 M sodium acetate buffer, pH 5.0 containing 
50 mM tartric acid, 3 mM ZnCl2 and 16 mM p-nitrophenyphosphate (pNPP, 
Sigma Co.) for 30 minutes at 37 °C using 96 well microplate. 
At the end of incubation time, 10 µl of 1 M NaOH was added to each well to stop 
the reaction and absorbance at 415 nm measured. Assay was carried out in 
duplicates. 
To calculate the concentration of p-NP; Beer–Lambert law equation was used, c= 
Aλ /(ελx l); utilizing adjusted measured absorbance, molar absorptivity constant 
(ε405) of 12,500 (mol/L)-1cm-1 and a path length (l) of 1 cm. Incubation time of 30 
minutes to calculate the rate of substrate hydrolysis in units of mol/L*min which 
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then normalized for the protein content (per mg protein) of the calvarial cell 
extract, which was determined by modified method of Lowry’s microprotein 
assay using bicinchoninic acid (BCA) [113, 114]. The final enzyme activity is 
expressed in units of µmol/L*min/mg protein.  
Quantitative analysis of ALP activity 
     Alkaline phosphatase activity measures the activity of OB in bone formation 
model. ALP activity, a marker for osteoblast and bone formation, was determined 
by release of the enzyme from the calvarial bone cellular layer using the same 
lysis buffer as for TRAP assay. ALP activity was measured by incubation of 50 µl 
of cell extract in duplicates with 250 µl of 0.15 M NaCl+30 mM NaHCO3, pH 
8.0, in the presence of 16 mM p-nitrophenylphosphate (pNPP, Sigma Co.) for 30 
min at 37 °C using a 96 well microplate. After incubation, samples were read at 
absorbance wavelength of 405 nm with Genius detector as described in using 
spectrophotometer [115]. The chromogenic substrate p-NPP is utilized in the ALP 
assay in a similar matter as the TRAP assay.  
Visualization of osteoclast formation and bone resorption by neutral red 
staining and silver nitrate counter-staining, respectively, in bone resorption 
model system !!!!!On! the! last!day! of! the! experiment,! 70! μg/ml!NR! (Sigma,! Co.)!was! added!into! the!media!of! calvarial! bones! and! incubated! for!45!minutes! at!37! °C! in!roller! tubes.! The! live! OC! cells! rapidly! uptake! the! NR! stain! due! to! the!multinucleated!nature!of!the!OC!and!its!large!size,!which!allow!clear!contrast!between! the! OC! and! other! bone! cells.! Following NR observation, the same 
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calvaria were washed with PBS and fixed with 10 % formalin overnight and 
counterstained with 2 % silver Nitrate for 20 minutes to quantify the bone 
resorption areas and mineral loss. Under microscopic observation the resorbed 
regions were transparent to light. The extent of bone resorption is directly 
reflected by different level of light transparency. Under low magnification, 20X, 
regions were transparent to light and total resorption areas can be measured and 
quantified, using computer-assisted program to highlight these resorption areas 
and calculate the unit area. The unit resorption areas were then used to calculate 
the % bone loss relative to controls. Samples treated with tumor cells alone were 
fixed at 100 % and the other treatment groups were compared and calculated 
relative to this value.  Results were expressed as % bone resorption areas.!
Quantitative media calcium Release and Uptake in bone resorption and 
formation models 
     Calcium release and uptake is reflected in the media for both resorption and 
formation model systems, respectively, in bone-cancer co-cultures. The 
quantitative assessment of the calcium based on a chemical reaction between 
calcium chelating chromophoric O-Cresolphthalien complexone (Sigma-CO) 
reagent and calcium ion available in the media forming an concentrated purple 
colored complex reflected by the absorbance (Dorogi 1984), where the calcium 
concentration in the media is directly proportional to the absorbance. 
Calcium chloride standards with concentrations ranging between 0-50 nmol/10 µl 
was achieved as a standard linear curve with correlation value greater than 0.98 
using O-Cresolphthalein complexone concentration at 1.8 mg/10 ml to calculate 
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the calcium concentrations in the culture media. The calcium reagent was 
prepared in 50 mM with Sodium Bicarbonate buffer at pH of 10. Calcium assay 
was carried out in duplicates for the standards and samples by the addition of 190 
µL of calcium reagent in each well of a 96 wells plate, followed by the addition of 
10 µL of each of standard and sample into their respective well. Samples were 
agitated gently for 20-30 seconds for proper mixing/reaction. The absorbance 
values were obtained using a Berthold TriStar LB 941 plate reader at wavelength 
of 590 nm. As a background, an averaged blank standard absorbance value was 
used as and was subtracted from the averaged sample absorbance values. Values 
of averaged standard absorbance were plotted as a function of final calcium 
concentration to obtain a standard curve equation of y=mx+b. Correlation 
coefficient for standard curve were above 0.99. Corrected sample absorbance 
values were plotted to calculate the final calcium concentration. Which was 
multiplied with 0.1 to accommodate for the dilution factor and to obtain units of 
µM/ml. Normalization with calvaria dry weight for a final unit of µM/ml/mg. The 
data produced reflects the calcium released or uptake at each collection time point 
of 2,4,6, and 8 days. Using Microsoft Excel the data were plotted as a function of 
time and cumulative calcium release or uptake graphs.  
Normalization of Calcium Concentration by calvaria weight 
     At the end of each experiment, calvaria labeled for TRAP/ALP analysis were 
placed in eppendorf tube, covered by perforated parafilm, placed in a 
lyophilization flask, and stored overnight under-80 degree Celsius. Dehydration 
process of the calvaria was performed using lyophilizer (Virtis Sentry 2.0) and the 
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dry weight of calvaria were measured and used to normalize the calcium 
concentrations. 
Impact of osteoprotegerin (OPG) on bone biology, cancer- bone interactions, 
osteoclast differentiation/bone resorption model  
     OPG is a naturally occurring RANKL decoy receptor that inhibits OC 
differentiation by interfering with osteoblast-RANKL and macrophage-RANK 
interaction [15, 116]. The mechanism of action of OPG is similar to the 
humanized antibody against RANKL (Denosumab), which is clinically used for 
osteoporosis and metastatic cancers [116].  
     Different experimental treatment group were applied to confirm the effect of 
OPG. Six groups, 9 calvaria per group (n = 9) were set up; (a) Unstimulated 
negative control (Culture media only), (b) Stimulated positive control, by the 
inclusion of 10 nM PTH (residues 1-34 bovine PTH, Sigma- CO, (c) PTH+2 nM 
OPG, (d) PC3 alone, (e) PC3+2 nM OPG, (f) MDA-MB-231 alone, (g) MDA-
MB-231+2 nM OPG. Upon conclusion of the experiment, calvaria were hemi-
dissected in the mid sagittal suture. Six half calvaria from each group were fixed 
in 10 % formalin, paraffin sectioned, and stained with hematoxyline and eosin 
(H&E, Boston Medical Center, Department of Pathology) for histological 
analysis. Six half calvaria from each group were prepared for tartrate-resistant 
acid phosphatase (TRAP) activity assay. The remaining six half calvaria were 
stained with neutral red to visualize general OCs activity, counterstained with 2 % 
silver nitrate for global assessment of OC bone resorption.  
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Impact of osteoprotegerin (OPG) on bone biology, cancer- bone interactions, 
OBs differentiation/bone formation model  
     The effect of OPG on OB and bone formation was studied by utilizing live 
mouse calvarial culture, whereby stimulation of osteoblastic activity was achieved 
by the addition of ASC in the absence and presence of OPG. Different 
experimental treatment group were applied to confirm the effect of OPG. Total of  
7 groups, 8 calvaria per group (n = 8)were set up as followed; (a) Unstimulated 
negative control (Culture media only); (b) Stimulated positive control by the 
inclusion of of 150 µg/ml media ASC; (c) ASC+2 nM OPG; (d) PC3+ASC; (e) 
PC3+ASC+2 nM OPG; (f) MDA+ASC; (g) MDA+ASC+2 nM OPG. Upon 
conclusion of the experiment, calvaria were hemi-dissected in the mid sagittal 
suture. Six half calvaria from each group were fixed in 10 % formalin, paraffin 
sectioned, and stained with H & E (Boston Medical Center, Department of 
Pathology) for histological analysis. Six half calvaria were prepared for alkaline 
phosphatase activity assay (ALP).The remaining 4 half calvaria were stained with 
NR and counterstained with SN . 
Mass spectrometric analysis of the media from calvarial bone organ cultures in 
the absence and presence of PC3 cells, PTH, and ALN  
     (i) MS analysis of the media from resorption model system conditions  
5 experimental groups with 3 calvaria per group were established as follows: (a) 
Un-stimulated negative controls, cultured in the medium alone; (b) Stimulated 
positive controls cultured in the presence of 10 nM PTH with calvaria; (c) PC3 
cells cultured in medium alone without calvaria; (d) PC3+calvaria only; and (e) 
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PC3+calvaria+30 µM ALN. The cultures were carried out with DMEM media 
alternated between DMEM supplemented with BSA and without BSA alternative 
days. These culture conditions were maintained and repeated over an 11 day 
period that provided three BSA-free conditioned media per roller tube/calvaria, 
e.g., time points 4, 7 and 11 days. Collected DMEM medium without BSA were 
labeled and saved for MS analysis. For each calvaria within the group (3 
calvaria/group) in above experimental sets (a)–(e), separate pooled media from 
each of the collection time points were prepared (total 900 µl) using 100 µl 
medium from each time point representing the whole culture period of 4, 7, and 
11 days. The 3 pooled media of 900 µl, each representing individual calvaria 
within each group [a total of 15 pools for sets (a)–(e)], were then separately freeze 
dried, suspended in 0.5 ml of 50 mM NH4HCO3 and trypsin digested (5 µg) at 37 
°C overnight. Trypsin digests were freeze dried and dissolved in 200 µl of buffer 
A 0.1 % TFA (trifluoroacetic acid)/H2O followed by desalting using a C-18 
reverse-phase Micro- Spin column (The Nest Group, Inc., 45 Valley Road, 
Southborough, MA). Bound peptides were eluted using 200 µl of buffer B (80 % 
CH3CN/0.1 % TFA/H2O), freeze dried, re-suspended 100 µl of 97.4 % H2O: 2.5 
% CH3- CN:0.1 % HCO2H followed by liquid-chromatography– electrospray-
tandem-MS (LC–ESI–MS/MS) analyses for identification and semi-quantitation 
of the released bone ECM proteins. The MS/MS data generated from the analysis 
of the aliquots from the above samples were searched amongst a mouse-specific 
database for calvarial bone proteins, a rat-specific database for the primary 2D 
mineralizing rat osteoblast proteins, and a human-specific database for the PC3 
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cancer cell proteins using Uniprot (Universal Protein Resources, Version 9.0) that 
combines the data from Swiss-Prot (version 51) TreMBL (Version 34). The data 
were searched with specified dynamic modification of 16 Da mass additions for 
hydroxylation of the proline residues as these are the dominant (almost every third 
residue) amino-acids within collagen based proteins that represent major bone and 
mineralizing osteoblast ECM components [112]. 
     (ii) MS analysis of the media from formation model system conditions—A 
total of 4 experimental groups with 2 calvaria per group were set up as follows: 
(a) Stimulated positive control with 1 mM ASC cultured in the media alone; (b) 
PC3 cells alone cultured in the media only without calvaria +1 mM ASC; (c) PC3 
cells+calvaria+1 mM ASC; and (d) PC3 cells+calvaria +1 mM ASC+30 µM  
ALN. The cultures were maintained for 11-days period with medium changes and 
subsequent sample handling/processing as detailed above in (i) for the resorption 
system employed for MS analysis. Each group had 3 serum free samples, 
collected from different time points (D4, D7, D11) and saved for the Ms analysis. 
Albumin free media from the duplicate of each treatment group at different time 
points were combined (100 µl aliquots from each), with total volume of 600 µl for 
the formation treatment group.  
Quantitative evaluation of the tumor colony  on calvarial bones and cancer cell 
viability from bone resorption and formation model systems in the absence and 
presence of ALN  
     To evaluate quantitatively the tumor burden as a function of time under both 
remodeling conditions, i.e., bone resorption and bone formation, cultures of 
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cancer cells alone, and co-cultures of PC3 cells with the calvarial bone in the 
absence and presence of ALN in the roller tube were carried out as described 
above. In addition, PC3 cells were cultured without any calvarial bone in the 
presence and absence of ALN under both resorption and formation condition. 
Triplicate calvariral bones for each Experimental groups were set as the following 
; resorption system, (a) PC3 cells without calvaria as a negative control; (b) PC3 
with calvaria alone; (c) PC3 cells only with 30 µM ALN; (d) PC3 + 30 µM ALN 
with calvaria; (e) PC3 + 30 µM ALN single dose (first 2 days only) with calvaria. 
Formation system (a) PC3 cells +ASC without calvaria as a negative control; (b) 
PC3 + ASC with calvaria alone; (c) PC3 cells only+ASC+30 µM ALN; (d) 
PC3+ASC+ 30 µM ALN with calvaria;  (e) PC3+ASC+30 µM ALN single dose 
(first 2 days only) with calvaria. Equal number of PC3 cells (1.4 x 105 per each) 
was incubated in each group at 37°C for 8 days. Media collected every 2 days, 
centrifuged and the pellet was suspended in 100 µl of media with trypan blue 
followed with direct cell counting. The calvaria with tumor colony established at 
8 days were subjected to enzymatic dissociation/dispersion of tumors from the 
calvarial bone surface by incubating in new roller tubes containing 2 ml DMEM 
organ culture media and 0.1 % trypsin at 37°C for 1 h using roller tube apparatus 
with 5 revolutions per min. The 2 ml medium was removed and cells were 
pelleted in 2 ml Eppendorf tubes. The pelleted cells were re-suspended in 0.1 ml 
of fresh medium and microscopically observed and counted. Similar treatments 
were carried out for cancer cells cultured alone without calvarial bone. 
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 Cancer cells Viability in classical 2D Cell Culture Condition 
     Breast and prostate cancer cells were first cultured until reach confluent stage 
as described above. Cancer cells then re-seeded into 6 well culture plate at a 
density of (2.2 x 105) with 2 ml DMEM, to be tested against three different 
concentrations of ALN, (1, 30, 100 µM), triplicate for each group, where the 
viability of the cells determined as a function of time at five days, and ten days 
respectively.  
Immunhistological Staining of the human PC3 cells  
Paraffin sections of calvaria of the unstimulated media control and calvaria co-
cultured with PC3 cells were prepared for immunohistology. Antigen retrieval 
was achieved using heat induced epitope retrieval (HIER), at 95°C for 25 
minutes. Slides were left to cool down at 85°C for 10 minutes. For blocking; 
peroxide was added for 10 minutes, then washed with TBST (tween TBS). Protein 
blocking with background sniper (ready to use reagent, Bio Care Medical, 
California) was used for 30 minutes. Sections incubated with primary human 
cytokeratin 7 antibody (mouse monoclonal [OV-TL 12/30], Abcam, CO) [diluted 
to a ratio 1:50 in da vinci green Bio Care Medical, California] for 2 hours at room 
temperature then washed once with TBST then incubated with secondary 
antibody, mouse secondary reagent for 15 minutes. For tertiary 3 antibody, 
universal HRP polymer (ready to use, Biocare Medical, California) used for 
30minutes followed with TBST 1X wash. After that, Chromogen DAP (3, 3’-
diaminobenzidine) (Ready to use, Bio Care Medical, California) was used for 5 
minutes, producing brown precipitate, followed by 2X wash with deionized water. 
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Sections counterstained hematoxylin for 3 minutes, and were ready for mounting. 
High-resolution two-photon confocal-microscopy  
     High-resolution 2-photon confocal microscopy was performed on calvarial 
bones and those in co-cultures with PC3 cancer cells under both bone resorption 
and formation conditions in the absence and presence of different concentration of 
ALN including; 0.4 µM (0.25 µg) and 1.5 µM (1 µg) and higher 20 µM (13 µg).  
Additional variants in such studies were: (a) first perform cultures of bone in the 
absence and presence of PC3 cells under resorption or formation conditions for 8 
days and then fixed in buffered 10 % formalin for 5 days. For permeability, 
Calvaria were washed twice with 1 ml of 50 mM Tris buffer PH 7.4, and 
incubated with 0.5% triton 100 for 40 minutes at room temperature. The calvaria 
were then washed three times with 1 ml of 50 mM Tris buffer, pH 7.4, and 
suspended in Tris buffer containing 5 % bovine serum albumin (BSA) and the 
primary human cytokeratin 7 antibody (mouse monoclonal [OV-TL 12/30], 
Abcam, Co) overnight at 4°C. The next day primary antibody was removed and 
calvaria were washed three times with 1 ml of 50 mM Tris buffer followed by 
incubation with 5 µg of green-fluorescent-tagged secondary antibody raised 
against mouse IgG in goat (Alexa Fluor® 488 green dye, emission = 519 nm, 
absorption = 495 nm, Life Technology Inc) in 0.5 ml Tris buffer overnight at 4°C 
The calvaria were removed from the secondary fluorescent antibody buffer, 
washed three times with Tris buffer and left in 0.5 ml of Tris buffer. On the day of 
2-photon confocal microscopy, the calvaria were labeled with blue-fluorescent 
DAPI (4`,6-diamidino-2-phenylindole dihydrochloride, emission = 455, 
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absorbance = 345, Sigma-Aldrich, Co) at dilution of 1:1000 and 0.4 nmol of red-
fluorescent bisphosphonate (OsteoSense 680EX, Perkin-Elmer, Inc.) for 1 hour at 
room temperature. The calvaria were mounted on confocal microscope dishes 
with Vectashield mounting medium for Fluorescence (Vector Laboratories, Inc. 
Burlingame, CA 94010) and three fluorescent emissions namely green, blue, and 
red, were acquired at 200X magnification and 5 µm intervals with total coverage 
of 100 µm distance for vertical scanning observations and up to 180 µm distance 
for horizontal scanning observations using high resolution 2-photon confocal 
microscope LSM 710 model. The acquired scanning images were analyzed using 
Image J software program for generating merged fluorescent spatial orientation of 
the PC3 cells relative to bone cells and the mineralized bone matrix. The merged 
images were viewed in 3D orientation and recorded as an AVI movie providing 
continuous visualization of the cellular characteristics/identity as a function of 
different planes and relative to the mineralized bone matrix.  
Ex-vivo calvarial bone defect organ culture model system  
     Under sterile conditions, dissected calvaria as described above, were placed on 
a triangular stainless steel grid, in 6 well culture plates with DMEM culture 
medium as previously described without any fetal calf serum or ascorbic acid and 
incubated at 37°C with 5 % CO2 in a tissue culture incubator (NAPCO, 
Winchester,VA) overnight. Next day, sub critical defects were made on the 
middle of each parietal bone away from the suture area using hand held punch 
device (0.6 mm) and incubated again for 21 days. Calvaria were primed to 
undergo osteoblastic new osteoid and bone formation in the presence of Na 
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ascorbate 1 mM in order to evaluate the calvarial defect healing process in the 
presence or absence of ALN or OPG. For ALN experiments, total of 3 groups, 2 
calvaria per group were set up as followed: (a) Stimulated positive control 1mM 
of ASC; (b) 1 mM ASC+30 µM ALN single dose for the first two days only;  (c) 
1 mM ASC+30 µM ALN. Media was changed every 2-3 days for 21 days culture 
period. At day 14 and 21, one calvaria of each group was terminated and hemi-
disected into 2 halves. One half calvarium from each group was fixed in 10 % 
formalin, paraffin sectioned, and stained with H&E (Boston Medical Center, 
Department of Pathology) for histological analysis. The remaining halves from 
each group were stained with NR followed by silver nitrate stain.  
OPG experiment was set in the same manner. Total of 3 groups, 4 calvaria per 
group were set up as followed: (a) Stimulated positive control 1 mM of ASC, (b)1 
mM ASC+2 nM OPG single dose for the first two days only, (c)1 mM ASC+2 
nM OPG. Media was changed every 2-3 days for 21 days culture period. At day 
14, one calvaria of each group was terminated and hemi-dissected into 2 halves. 
One half calvarium from each group was fixed in 10 % formalin, paraffin 
sectioned, and stained with H&E (Boston Medical Center, Department of 
Pathology) for histological analysis, while the other half from each group was 
stained with NR followed by silver stain. The remaining calvaria were left to 
carry on for one more week. At day 21, each calvaria was hemi-dissected into 2 
halves, one was fixed for histology, and the other was stained with NR followed 
by silver stain.  
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Statistical analysis  
     Chemical, biochemical, and quantitative histomorphometric data are presented 
as mean ± S.D. The original data sets found to have normal distribution using the 
Shapiro–Wilks test were analyzed using parametric statistical analysis. The 
statistical significance of the differences between controls versus treatment groups 
and between different treatments was evaluated using two-tailed, paired t test with 
unequal variance. The differences between groups were considered statistically 
significant for p ≤ 0.05.  
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RESULTS 
!
 Bone Resorption Model System: Impact of alendronate (ALN) on bone biology, 
osteoclast differentiation/bone resorption, and bone microenvironment-mediated 
resistance of PC3 cancer cells to ALN treatment. 
- Qualitative histological evaluation of cancer-bone interactions, during bone 
resorption in the absence and presence of PC3 cells and ALN 
     The histological observations of H & E stained sections of calvarial bones 
cultured with PC3 in the absence and presence of ALN were obtained from five 
half calvaria for each treatment group and represented in Figure 10. The 
histological observations of the untreated control group (media alone) showed no 
OCs formation or bone resorption Figure 10 A. In the presence of PC3 cells, 
Figure 10 D the calvarial bone endosteum was colonized by the cancer cells 
generating a 3D solid tumor up to 12 multi-cell layers and simultaneous induction 
of resorptive multinucleated (MN) OC differentiation and extensive resorption. 
The histological observation of Inclusion of ALN led to complete inhibition of 
OC differentiation and bone resorption since ALN has an inhibitory effect on OC 
proliferation and differentiation Figure 10 G. In Figure 10 K, a set of calvarial 
bones were pretreated with two consecutive 30 µM ALN dose regimens followed 
by co-culturing with PC3 cells for an additional 4 days with two dose of ALN.  
While pre-treatment inhibited bone resorption, there was no effect on the PC3-
bone colonization. Co-culture of PC3 cells with bone first for 4 days in the 
absence of ALN which induce osteoclastic bone resorption followed by the 
inclusion of two dose of ALN to test the effect on mature resorptive MN–OCs 
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was observed in figure 10 N which showed some significant resorption. However, 
overall results indicate that PC3 cancer cells in a live bone microenvironment are 
capable of colonizing bone, proliferate and survive independently of osteoclastic 
bone resorption theory. 
- Visualization of global osteoclastic activity and bone resorption by neutral red 
staining and silver nitrate staining in the bone resorption model 
     Neutral red staining of the calvarial bones co-cultured with PC3 in presence or 
absence of ALN are represented in Figure 10. Each group is represented with 
100X magnification images. Figure 10 B illustrates unstimulated media control 
NR staining; did not demonstrate formation of macrophage or OC calvarial bones 
assume a stage of dormancy, while upon co-culture of PC3 only with calvarial 
bone, the bone responds with rapid numerous newly formed multinucleated OCs  
that were readily observable and indicative of massive bone resorption areas 
Figure 10 E . However, inclusion of ALN with PC3 didn’t show any 
multinucleated OCs Figure 10 H. Figure 10 L represents initial incubation of 
ALN then co-cultures of PC3 cells group, which show no evidence of 
multinucleated osteoclasts. Figure 10 O, represents group first co-culture with 
PC3 only for 4 days followed by ALN treatment for 4 days where some 
superficial resorption lacunae and remnants/ghosts of OCs lacking NR stained 
nuclei. Furthermore Counterstaining of NR calvaria with silver nitrate was 
obtained in order to get more details and to support the previous observations. The 
extent of bone resorption is directly reflected by different level of light 
transparency. Figure 10 C showed media lack any bone resorption activity 
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reflecting dense bone. While Figure 10 F represent PC3 only group with extensive 
transparency reflecting dissolved bone with widespread massive bone resorption 
area However, treatment with ALN Figure 10 I illustrated slight light 
transparency due to minimal bone resorption. ALN pretreatment for four days 
followed with PC3 for four days showed slight light transparency reflecting 
minimal atypical bone resorption areas Figure 10 M. Initial Co-cultures of PC3 
cells only for 4 days followed by the addition of ALN for 4 days group was 
similar to PC3 only group with extensive light transparency reflecting extensive 
bone resorption Figure 10 P. All the results were consistent with previous NR 
observation. Magnifications were taken: H & E 200X, NR 100X and silver 
staining 25X. 
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Figure. 10. Microscopic observations Co-cultures of mouse calvarial bones 
with PC3 and cancer cells under the bone resorption model condition in the 
absence and presence of alendronate (ALN). 
 
! !!
! ! !! 73!
Figure. 10. Microscopic observations Co-cultures of mouse calvarial bones 
with PC3 and cancer cells under the bone resorption model condition in the 
absence and presence of alendronate (ALN). 
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Figure 10. Co-cultures of mouse calvarial bones with PC3 cancer cells under the 
bone resorption model condition in the absence and presence of alendronate 
(ALN). Figure 10, untreated media control, (A) H & E sections of the parietal 
bone region with no osteoclastic bone resorption, (B) NR stained calvaria with no 
ultinucleated OCs, and (C) silver nitrate counterstained calvaria with little light 
transparency reflecting dense bone and absence of bone resorption. Calvaria co-
cultured with PC3 induced bone resorption, (D) H & E sections of the parietal 
bone region with pronounced osteoclastic bone resorption, and was colonized by 
the cancer cells generating a 3D solid tumor up to 12 multi-cell layers (E) NR 
stained calvaria showing numerous multinucleated osteoclasts (MNOC), and (F) 
silver nitrate counterstained calvaria showing extensive transparency reflecting 
dissolved bone with widespread bone resorption area (RA). Calvaria co-cultured 
with PC3 with the inclusion of ALN (G) H & E sections of the parietal bone 
region remained intact due to the inhibitory effect of ALN, PC3 cells are 
colonizing the endosteal surface of bone unaffected by ALN, (H) NR stained 
calvaria showing no multinucleated osteoclasts (MNOC), and (I) silver nitrate 
counterstained calvaria showing slight light transparency reflecting very minimal 
bone resorption. Pretreatment of the calvaria with ALN for 4 days followed by co-
cultured with PC3, (K) H & E sections of the parietal bone region with few 
osteoclastic bone resorption areas , (L) NR stained calvaria showing no MNOC, 
and (M) silver nitrate counterstained calvaria reflecting dense bone and absence 
of resorption. Figure 10 (N), Calvaria co-cultured with PC3 initially followed 
with inclusion of ALN after four days, H & E sections of the parietal bone region 
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with osteoclastic bone resorption, (O) NR stained calvaria showing remnant of 
MNOC, and (P) silver nitrate counterstained calvaria showing various light 
transparency reflecting several bone RA. Magnifications were taken: H & E 200X, 
NR 100X and silver staining 25X . 
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- Quantitative analysis for calcium release and TRAP activity in the absence 
and presence of PC3 cells and ALN 
     The Calcium release of each media collection over the 8 day culture 
period were determined for each treatment group; (a) Unstimulated 
negative control (Culture media only); (b) PC3 alone; (c) PC3+30 μM 
ALN; (d) 30 μM ALN for four days then PC3 for four days (e) PC3 for 
four days then 30 μM ALN for another four days and represented in Figure 
11. Over the 8 day culture period, total cumulative calcium release for each 
calvarial and TRAP activities were determined for different treatment 
groups. PC3 alone showed significant calcium release confirming the PC3 
activation of OC mediated bone resorption when compared to unstimulated 
controls. The addition of ALN caused 70 % inhibition in Ca release with p 
< 0.05. Pre-treatment with ALN followed by PC3 addition showed a 60 % 
decrease in calcium release and insignificant change in treatment group in 
which PC3 cells were included first followed by ALN, Figure 11 A. 
Significant reduction in TRAP activity in all treatment group compared to 
PC3 group after inclusion of ALN, p ≤ 0.0001 Figure 11 B. The results for 
the 4D PC3 + ALN shown in Figure 11 A, B, may appear inconsistent. 
However, these are consistent with the treatment order and the specific 
analysis performed. Figure 11 A represent cumulative calcium release 
measured every 2 days in the medium, whereas Figure 11 B represents 
TRAP enzyme activity of calvaria conducted at the end of 8 days culture 
period. Hence, Co-cultures of PC3 cells with bone for 4 days first in the 
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absence of ALN initiate osteoclast differentiation and bone resorption 
releasing calcium. In contrast, after addition of ALN after 4 days, the level 
of calcium release decreased. Total cumulative calcium over the 8 days, 
includes both the released calcium in the first 4 days with the reduced 
levels in the next 4 days in the presence of ALN. Quite distinct from the 
calcium release however, while there was osteoclasts in the first 4 days of 
the cultures, after the addition of ALN and 4 additional culture days, the 
already differentiated osteoclasts become impacted and there is no 
osteoclast differentiation. The analysis for TRAP activity was measured at 
the end of the 8 day culture after the impaction of OC activity by ALN 
inclusion.  
The overall observations among histology, NR, silver staining, and quantitative 
analyses were all consistent. This clearly demonstrates that both ALN will inhibit 
OC formation and decrease PC3 mediated bone resorption  
- Quantitative histomorphometric analysis of calvarial bones in the resorption 
model system 
     Following microscopic examination, the same stained half calvarial bone were 
used for quantitative determination of bone resorption areas and mineral loss. 
Under low magnification 25X, regions were transparent to light and total 
resorption areas can be measured and quantified. The unit resorption areas were 
then used to calculate the % bone loss relative to control, which is PC3 group. 
Figure 12 A-E, represent SN counter stained for each treatment group, starting 
with calvaria alone A, PC3 B, PC3+ALN C, ALN 4 days followed with PC3 D, 4 
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days PC3 followed with ALN treatment E. Each calvaria represent the amount of 
total % bone resporption qunitified and measured. 
Figure 12 F represents total % resorption area, where significant reduction up to 
65 % in resorption area was noticed after the inclusion of ALN compared to PC3 
only group.  
 
 
 
 
 
 
 
 
 
 
 
!
 
! !!
! ! !! 79!
Figure. 11. Cumulative calcium release, Quantitative TRAP activity under 
different culture conditions. 
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Figure 11. A- quantitative calcium analysis of media collected from media 
control, PC3 only, PC3 + ALN, PC3 + ALN, 4 days ALN only followed by PC3 
and 4 days PC3 only followed by ALN; cultured calvaria. Comparison between 
media control and PC3 control shows a substantial amount of calcium release, 
reflecting extensive bone resorption. Comparison between PC3 and PC3 + ALN 
showed significant reduction in bone resorption up to 60 % reduction in the 
amount of calcium release. Pretreatment with ALN 4 days followed with co-
culture with PC3 showed significant reduction in Ca release reflecting the effect 
of ALN on OC mediated bone resorption. Initial co-culture with PC3 only for 4 
days followed by inclusion of ALN reflect insignificant change in Ca release 
when compared to PC3 only group.  Figure 11 B, quantitative TRAP activity of 
media collected from treatment group as described above. Substantial increase in 
TRAP activity comparing media control and PC3 only group. Inclusion of ALN 
with PC3 show around 65 % reduction in TRAP activity compared with PC3 only 
reflecting a decrease in osteoclastic activity with the presence of ALN. Similar 
results found with both ALN 4 days followed with PC3 group and co-cultured of 
PC3 initially followed with ALN group where significant reduction in TRAP 
activity was shown. Student’s t test indicated that these differences in calcium 
release/bone resorption in response to different treatments were statistically 
significant with p values noted within the Figure. 
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Figure. 12. Quantitative global % bone resorption under different culture 
conditions. 
 
 
!
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Figure 12. Global % osteoclastic bone resorption determined by 
histomorphometric analysis of the silver stained whole calvarial bones. Examples 
of calvaria in each treatment group stained with NR and counter stained with 
silver nitrate where the digital images (25X magnification) were transformed to 
black and white images and different shades of these depending on the degree of 
resorption. The arrows show either black or dark gray areas where there was no 
resorption, or white and light gray areas where resorption occurred. The digital 
intensities of the white and light gray areas were used to calculate % resorption 
areas. (A) Media alone (control). (B) PC3 alone. (C) PC3 + ALN. (D) Pre-treated 
with ALN first for 4 days followed by inclusion of PC3 cells. (E) Co-cultured 
with PC3 first followed by addition of ALN.  (F) The calculated % bone 
resorption areas relative to PC3 show clear and substantial reduction in bone 
resorption as a result of inclusion of ALN up to 65 %. The two sample Student’s t 
test indicated that these differences in bone resorption in response to different 
treatments were statistically significant with p values noted within the Figure. 
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Our results with PC3 prostate cancer cells were replicated with the MDA-MB-231 
breast cancer cells co- cultures with bone organs in the absence and presence of 
ALN.  
Bone Resorption Model System: Impact of alendronate (ALN) on bone biology, 
osteoclast differentiation/bone resorption, and bone microenvironment-mediated 
resistance of MDA- MB-231 cancer cells to ALN treatment.   
- Qualitative histological evaluation of cancer-bone interactions, during bone 
resorption in the absence and presence of MDA-MB-231 cells and ALN  
     The histological observation of H & E sections obtained from seven half 
calvaria of each treatment groups are elaborated in Figure 13 (A-B). (A) MDA-
MB-231 cells colonizing the endosteal side of the bone, where at many areas it 
was either completely dissolved or significantly resorbed which is consistent with 
our previous data with PC3. (B) MDA-MB-231+ALN showed minimal 
osteoclastic bone resorption compared to MDA-MB-231 alone due to the impact 
of ALN on OC bone reorption without any impact on the tumor growth. 
- Visualization of global osteoclastic activity and bone resorption by neutral red 
staining and silver nitrate staining in the bone resorption model 
     NR staining was done on thirteen half calvaria as described earlier. For MDA-
MB-231 only group, the impact of the tumor cells on the parital bone was clearly 
visible with numerous newly formed multinucleated resorptive OC, Figure 13 C. 
However inclusion of ALN with MDA-MB-231 didn’t show multinucleated OCs 
Figure 13 D. Counterstaining with silver nitrate are represented in Figure 13 E-F. 
(E) MDA-MB-231 only showed multiple wide areas of light transparency 
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reflecting massive resorption. (F) MDA-MB-231+ALN showed no light 
transparency reflecting lack of bone resorption, due to the inhibitory effect of 
ALN on OCs.  
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Figure. 13. Microscopic observations Co-cultures of mouse calvarial bones 
with MDA-MB-231 cancer cells under the bone resorption model condition 
in the absence and presence of alendronate (ALN). 
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Figure 13. Microscopic observations of Co-cultures of mouse calvarial bones 
with MDA-MB-231 cancer cells under the bone resorption model condition in the 
absence and presence of alendronate (ALN).  Figure 13 (A) represent H & E 
sections of the parietal bone region of the calvaria co-culture with MDA-MB-23 - 
with pronounced osteoclastic bone resorption with massive amount of destruction 
and dissolved bone. Tumor cells colonized the endosteal part of the bone.(C) NR 
stained calvaria showing numerous multinucleated osteoclasts (MNOC), and (E) 
silver nitrate counterstained calvaria showing extensive transparency reflecting 
extensive bone resorption. (RA). Figure 13, (B) calvaria co-cultured with MDA-
MB-231with the inclusion of ALN H & E sections of the parietal bone region 
without any OC activity or bone resorption confirming the effect of ALN on OC 
mediated resoption, and tumor cells colonization to bone undisruptive to the ALN 
effect. (D) NR stained calvaria showing no multinucleated osteoclasts (MNOC), 
and (F) silver nitrate counterstained calvaria showing dense bone without any 
transparency to light. 
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- Quantitative analysis for calcium release and TRAP activity in the absence 
and presence of MDA-MB-231 cells and ALN 
     The calcium release of each media collection over the 8-day culture period was 
analyzed. Comparing MDA-MB-231 alone with unstimulated media control 
revealed significant increase in calcium release confirming the MDA-MB-231 
activation of OC mediated bone resorption Figure 14 A. However, Comparison 
between MDA-MB-231 and MDA-MB-231+ ALN showed significant reduction 
in calcium release, reflecting inhibition of bone resorption. Quantitative TRAP 
enzyme activities for the groups were obtained from 10 calvaria per group, Figure 
14 B. There was a significant increase in the TRAP activity of MDA-MB-231 
group compared with MDA-MB-231+ALN and unstimulated media control. 
- Quantitative histomorphometric analysis of calvarial bones in the resorption 
model system  
     Total percentage of bone loss area was represented in Figure 15. The addition 
of ALN results in significantly lower percentage of resorption area up to 50% 
compared with calvaria co-cultured with MDA-MB-231-cells alone and p value 
equal to 0.006. 
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Figure. 14. Cumulative calcium release, Quantitative TRAP activity under 
different culture conditions. 
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Figure 14. A Quantitative calcium analysis of media collected from media 
control, MDA-MB-231only, MDA-MB-231+ ALN, cultured calvaria. 
Comparison between media control and MDA-MB-231only shows an extensive 
amount of calcium release related to tumor cells stimulation to OCs, reflecting 
wide bone resorption areas. Comparison between MDA-MB-231only and MDA-
MB-231 + ALN showed significant reduction in calcium release. Figure 14 B, 
quantitative TRAP activity of media collected from treatment group as described 
above. Substantial increase in TRAP activity comparing media control and MDA-
MB-231only group. Inclusion of ALN with MDA-MB-231 showed significant 
drop in TRAP activity. 
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Figure. 15. Quantitative global % bone resorption of calvaria co-cultured 
with MDA-MB-231 in the presence and absence of ALN. 
!!!
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Figure 15. Histomorphometric analysis of % bone resorption area of calvaria co-
cultured with MDA-MB-231 with and without the addition of ALN. MDA-MB-
231 only group was set to 100 % and both media control and MDA-MB-231+ 
ALN groups were compared to it. Simultaneous inclusion of ALN with calvaria 
co-cultured with MDA-MB-231 resulted in significant inhibition of bone 
resorption area with p value of 0.006 
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- Mass spectrometric (MS) analysis of the media derived from calvarial organ 
cultures in the absence and presence of PTH, PC3 cancer cells, and ALN under 
Bone Resorption Condition 
     Advance details on the impact of ALN on OC differentiation/resorption and 
the bone response to the presence PC3 and PTH were acquired through the 
analysis of the medium collected from controls and experimental cultures by 
liquid-chromatography-tandem-mass-spectrometry (LC–MS/ MS). Media were 
obtained from the following treatment groups; (a) Control calvaria alone, (b) 
calvaria + 10 ηM PTH, (c) PC3 cell alone, (d) calvaria + PC3, (e) calvaria + PC3 
+ ALN. Minimal release of major bone matrix components via osteoclastic bone 
resorption in samples obtained from calvaria alone and calvaria + PC3 + ALN as 
compared with samples from calvaria + PC3 and calvaria +PTH, Figure. Five 
distinct collagen chains were clearly identified with their corresponding multiple 
peptides that represented collagen type I α-1 and α-2 chains, collagen type III α-1 
chain, collagen type ν α-1 and α-3 chains and fibronectin, with collagen type I as 
the most abundant component Table 1. Cultures of Calvaria + PTH (19 peptides) 
and calvaria + PC3 (16 peptides) reflected the highest levels of major bone matrix 
proteins indicating significant bone resorption and the suppression of this in the 
presence of ALN. The release of major matrix proteins and semi-quantitative 
levels of the degree of bone resorption were defined by the number of peptides 
identified for each of these proteins within the media of a given experimental 
group Figure 16. Both groups; of calvaria+PTH and calvaria+PC3 were 
associated with the most abundent levels of bone matrix protiens representing 
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significant bone resorption while inhibition  
 of bone resorption in calvaria+PC3+ALN cultures was demonstrated by lack of 
bone matrix protein identification. 
The MS/MS analysis identified vimentin in the media of PC3 cells alone without 
calvaria in the roller tubes which is a cell surface protein ‘‘intermediate filament’, 
indicating the their degeneration in the organ culture medium lacking FCS and 
live calvarial bone. LC–MS/MS analysis also identified calvarial bone derived 
matrix metalloproteinase 3 (MMP-3, also known as stromelysin), Table 1. While 
MMP-3 is capable of bone matrix degradation including collagens, it also plays a 
critical role in the cascade of pro-enzyme activation of other MMPs during bone 
resorption. Calvaria alone (control) also showed 7 distinct collagen type I alpha 2 
peptides, which reflect the naturally occurring resorption process in the suture 
areas. Results support our previous data that ALN stops the resorption, and inhibit 
OC which in turn prevent collagen release and being identified in MS analysis. 
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Table 1. Major extracellular matrix proteins in media of cultures mouse calvaria 
in the absence and presence of PC3 cell, PTH and) and 30 µM ALN using 
Resorption model system using roller tube model. 
!
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Figure. 16. Identification and semi-quantification by LC–MS/MS of the bone 
ECM components in the culture media. 
!
!
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Figure 16. Identification and semi-quantification by LC–MS/MS of the bone 
ECM components in the culture media. Total peptide ion abundance from liquid-
chromatography-tandem-mass-spectrometry (LC-MS/MS) analysis of media from 
calvarial organ cultures in the absence and presence of PTH, PC3 cells, and ALN.  
(a) calvaria alone, (b) calvaria + PTH, (c) PC3 cell alone, (d) calvaria + PC3, (e) 
calvaria + PC3 + ALN. Identification and semi-quantification of the major bone 
ECM components released into the culture media under conditions (a) – (e). 
Under resorption condition, as expected the most abundant proteins released into 
the media were collagen type I α-1 and α-2 subunits, collagen type III α -1 and 
fibronectin. In control calvaria, group (a) there were baseline level of collagen 
type I α-1 and α-2 subunits and fibronectin identified with minimal collagen type 
III α -1.  As expected in groups (b) and (d) where resorption inducing agents were 
present, e.g. PTH and PC3 cells, there were substantial level of collagen type I α-
1 and α-2 subunits, and collagen type III α -1 released into the media typical of 
active bone resorption phenomenon.  Inclusion of ALN in group (e) abolished any 
release of bone ECM components and this was below the baseline levels of 
control calvaria, suggesting impact on osteoblast/mesenchymal basal cell activity.  
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Bone Resorption Model System: Impact of osteoprotegerin (OPG) on bone 
biology, osteoclast differentiation/bone resorption, and bone microenvironment-
mediated resistance of cancer cells to OPG treatment 
     Previous observations with ALN led us to investigate non- bisphosphonate 
based inhibition of bone resorption with a different mechanism of action than 
ALN. OPG is a naturally occurring RANKL decoy receptor that inhibits OC 
differentiation by interfering with osteoblast-RANKL and macrophage-RANK 
interaction [15], similar to Denosumab (humanized antibody against RANKL) 
mechanism of action used for osteoporosis and metastatic cancers [116].  
- Qualitative histological evaluation of cancer-bone interactions, during bone 
resorption in the absence and presence of cancer cells and OPG     
     The histological observation of H & E stained sections of calvarial bones co-
cultured with tumor cells in the absence and presence of OPG were obtained from 
six half calvaria and are represented in Figure 17. Each group is represented with 
200X magnification images. Figure. 17 Panel 1A and 1D illustrate the histological 
observations of PTH only and PTH+OPG groups. PTH only shows significant 
amount of osteoclastic activity with numerous resorption areas, while inclusion of 
OPG showed inhibition of osteoclastic differentiation and bone resorption 
effectively. PC3 only and MDA-MB-231 only groups are demonstrated in Figure 
17 Panel 2A, 3A respectively. Both show substantial increase of differentiated 
multinucleated active osteoclasts and significant bone resorption with 
colonization of the calvarial bones by tumors cells generating a 3D solid tumor. 
The inclusion of 2 nM OPG showed no significant of OC activity or bone 
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resorption, Figure 17 Panel 2D, 3D. However, colonization of the tumor cells to 
the bone was not affected despite the lack of MNOcs similarly to our observations 
with ALN. 
 - Visualization of global osteoclastic activity and bone resorption by neutral red 
staining and silver nitrate staining in the bone resorption model  
      Calvarial bones stimulated with PTH in the presence or absence of OPG, NR 
staining presented in Figure 17 Panel 1B and 1E represent NR staining of the PTH 
only demonstrated numerous active multinucleated OCs, while PTH + OPG group 
show only cell membrane remnants of early developed OCs without any nulclie. 
Distinct NR stained multinucleated osteoclasts were clearly visible in both PC3 
only and MDA-MB-231 only Figures 17 Panel 2B, 3B. Inclusion of OPG showed 
no evidence of multinucleated OCs Figures 17 Panel 2E, 3E representing 
PC3+OPG and MDA-MB-231+OPG groups respectively. NR stained calvarial 
bones were counterstained with silver nitrate to visualize global bone resorption. 
Calvaria treated with PTH only Figure 17 Panel 1C show extensive light 
transparency reflecting wide resorption areas. Similarly, both PC3 and MDA-MB-
231 only groups showed substantial areas with light transparency reflecting 
extensive bone resorption with dissolution of the bone Figures 17 Panel 2C, 3C. 
However, with OPG treated groups there was minimal light transparency 
indicating no or limited bone resorption Figures 17 Panel 1F, 2F, 3F. These 
results were consistent with NR staining observation.  
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Figure. 17. Panel 1. Co-cultures of mouse calvarial bones with PTH in the 
bone resorption model in the absence and presence of osteoprotegrin (OPG). 
!
 
! !!
! ! !! 100!
Figure. 17. Panel 2. Co-cultures of mouse calvarial bones with PC3 cells in 
the bone resorption model in the absence and presence of osteoprotegrin 
(OPG). 
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Figure. 17. Panel 3. Co-cultures of mouse calvarial bones with MDA-MB-231 
cells in the bone resorption model in the absence and presence of 
osteoprotegrin (OPG). 
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Figures 17. Co-cultures of mouse calvarial bones with PC3 cells and MDA-MB-
231 in the bone resorption model in the absence and presence of osteoprotegrin 
(OPG). Panel 1. Calvaria cultured in the presence of 10 nM PTH only: (A) H & E 
sections of the parietal bone showing osteoclastic bone resorption, (B) NR stained 
calvaria showing numerous multinucleated osteoclasts, (C) NR + silver nitrate 
counter stained calvaria showing extensive bone resorption areas. Calvaria 
cultured in the presence of 10 nM PTH + 2 nM OPG: (D) H & E sections of the 
parietal bone showing minimal bone resorption, (E) NR stained calvaria showing 
no multinucleated osteoclasts, (F) NR + silver nitrate counter stained calvaria 
showing very little light transparency reflecting minimal bone resorption. Panel 2. 
Co-cultures of calvaria + PC3 cells: (A) H & E sections of the parietal bone 
showing pronounced osteoclastic bone resorption, (B) NR stained calvaria 
showing numerous active multinucleated osteoclasts (MNOC), (C) NR + silver 
nitrate counterstained calvaria showing extensive light transparency reflecting 
dissolved bone and wide resorption area (RA). Co-cultures of calvaria with PC3 
in the presence of 2 nM OPG: (D) H & E sections of the parietal bone showing no 
significant bone resorption, (E) NR stained calvaria showing no multinucleated 
osteoclasts, (F) NR+silver nitrate counter stained calvaria showing slight light 
transparency reflecting minimal bone resorption. Panel 3.  Co-cultures of calvaria 
+ MDA-MB-231 cells: (A) H & E sections of the parietal bone showing extensive 
osteoclastic bone resorption, (B) NR stained calvaria showing abundent active 
multinucleated osteoclasts (MNOC), (C) NR + silver nitrate counterstained 
calvaria showing wide area of light transparency reflecting the extent of bone 
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resorption (RA). Co-cultures of calvaria with MDA-MB-231 in the presence of 2 
nM OPG: (D) H & E sections of the parietal bone showing inhibition of bone 
resorption, (E) NR stained calvaria showing no multinucleated osteoclasts, (F) 
NR+silver nitrate counter stained calvaria showing minimal light transparency 
reflecting insignificant bone resorption. H&E 200X, NR 100X, SN 25X. 
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- Quantitative analysis for calcium release and TRAP activity in the absence 
and presence of cancer cells and OPG 
     Total cumulative calcium release for each calvarial over total of 8 days culture 
period and TRAP activity were determined from six half calvaria and are 
presented in Figure 18 A and B. Cumulative calcium release represented in Figure 
18 A:  PTH, PC3, and MDA-MB-231 only groups caused significant increase in 
the release of calcium when compared to unstimulated media control consistent 
with our previous data confirming the activation of OC mediated bone reorption. 
However, Inclusion of OPG led to decrease the level of calcium release 
significantly in all of the three groups due to its inhibitory effect. Similar to 
calcium release, there was marked reduction in the TRAP activity after the 
inclusion of OPG in all treatment groups reflecting the inhibitory effect of OPG 
on OC mediated resorption Figure 18 B. 
- Quantitative histomorphometric analysis of calvarial bones in the resorption 
model system in the absence and presence of OPG  
     Quantitative measurement of percentage bone and mineral loss is represented 
in Figure 19. The same six half calvari used for NR staining and counterstained 
with SN used to quantify the percentage of bone resorption at 25X magnification, 
digital images were created with different shades ranging from the darkest black 
to the lightest white, reflecting the degree of resorption. Calculation of the % of 
bone resorption was done depends on these intensities of each group relative to 
the PTH only group set as 100 %. PTH only and PC3 only groups showed 
extensive percentage of bone loss compared to unstimulated media control. 
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However this percentage was dropped to more than 75 % after inclusion of OPG 
in all groups. Consistent results were found with MDA-MB -231 group, since 
OPG cause significant reduction in the percentage of total bone reorption and 
mineral loss as clearly shown in Figure 19 with p < 0.01. 
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Figure. 18. Cumulative calcium release and quantitative TRAP activity, in 
calvarial bone resorption model. 
 
!
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Figure 18. Cumulative calcium release and quantitative TRAP activity in 
calvarial bone resorption model. (A) Cumulative calcium release into media from 
calvarial cultures: Controls, (calvaria alone), showed minimal calcium release into 
the media; calvaria + PTH, calvaria + PC3, calvaria +MDA-MB-231, led to 
substantial calcium release which were significantly reduced in the presence of 
OPG.  The two sample Student’s t test indicated that these differences in calcium 
release/bone resorption in response to different treatments were statistically 
significant with p values noted within the Figure. (B), Quantitative TRAP enzyme 
activity in calvarial bones cultured under different conditions which followed 
essentially the same pattern as in (A) above for calcium release. The two sample 
Student’s test indicated that TRAP activity in response to different treatment 
conditions is different and statistically significant with p values as noted within 
the figure.  
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Figure. 19. Global quantitative degree of bone resorption in calvarial bone 
resorption model. 
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Figure 19. Global quantitative degree of bone resorption in calvarial bone 
resorption model: Global % osteoclastic bone resorption determined by 
histomorphometric analysis of the silver stained whole calvarial bones. The 
calvarial bones in each of the treatment groups stained with NR and counter 
stained with silver nitrate were used to generate the digital images (at 25X 
magnification), transformed to black and white images and different shades of 
these depending on the degree of resorption. The digital intensities of the white 
and light gray areas were used to calculate % resorption areas relative to PTH as 
been 100 %. The calculated % bone resorption areas were mirror image of the 
calcium and TRAP activities observed in Figure18 (A) and (B). The two sample 
Student’s t test indicated that these differences in bone resorption in response to 
different treatments were statistically significant with p values noted within the 
Figure. 
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Bone Formation Model System: Impact of ALN on bone mesenchymal stem cells, 
osteoblasts and bone microenvironment-mediated resistance of PC3 cancer cells 
to ALN in bone formation model systems  
 - Histological observation of the effect of ALN on OBs formation and new bone 
formation and Qualitative analysis for global bone resorption and osteoclastic 
activity by neutral red staining, silver nitrate counter staining 
     The histological observations of H & E stained sections of calvarial bones co-
cultured with ASC or ASC and PC3 in the absence and presence of ALN were 
obtained from seven half calvaeria per each group are represented in Figure 20. 
  (A) H & E section of the parietal bone region with new osteoid and bone 
formation was observed in ASC control group. (B) NR stained calvaria  showing 
no multinucleated osteoclasts; (C) NR + silver nitrate counterstained calvaria 
showing lack of bone resorption reflecting dense bone. (D) PC3 + ASC group 
showed OB differentiation and new osteoid formation instead of bone resorption. 
(E) NR stained calvaria similar to ASC control group didn’t show any 
multinucleated osteoclasts (MNOC); (F) NR + silver nitrate counterstained 
calvaria showing lack of any bone resorption reflecting dense bone. However 
exposure to ALN led to incapacity of bone to undergo OB differentiation and new 
osteoid formation, in all treatment groups, where ALN was simultaneously added 
with the ASC, or added first as pretreatment, or 4 days following co-culturing of 
the calvaria with PC3 + ASC as presented in Figure 20 Panel 1,2  (G-K-N) 
respectively. PC3 cells still showing resilient to the effect of ALN, colonizing the 
bone and proliferating, forming a 3D tumor. Moreover, a distinct observation was 
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noted in the histological section of ALN treated group highlighted with the blue 
circle in Figure 20 Panel 1, 2 (G, N) where the endosteal layer appeared with 
deteriorated cellularity and normal collagen fibers.  
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Figure. 20. Panel 1. Bone formation model using mouse calvarial bone organ 
cultures in the absence and presence of ALN and sodium ascorbate. 
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Figure. 20. Panel 2. Bone formation model using mouse calvarial bone organ 
cultures in the absence and presence of ALN and sodium ascorbate. 
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Figure 20. Bone formation model using mouse calvarial bone organ cultures in 
the absence and presence of ALN and sodium ascorbate. Panel 1. (A) Calvaria + 
ASC (controls), H & E sections of the parietal bone region of calvaria cultured in 
the presence of Na ascorbate showing significant amounts of new osteoid and 
differentiated osteoblasts; (B) NR stained calvaria showing no resorption or 
multinucleated osteoclasts; (C) NR + silver nitrate counterstained calvaria 
showing lack of bone resorption reflecting dense bone. Co-cultures of calvaria + 
ASC + PC3: (D), H & E sections of the parietal bone showing significant level of 
new osteoid formation, osteoblast differentiation, and colonization of the 
endosteal bone surface by PC3 cells; (E) NR stained calvaria showing no 
resorption or multinucleated osteoclasts (MNOC); (F) NR + silver nitrate 
counterstained calvaria showing lack of any bone resorption reflecting dense 
bone. Co-cultures of calvaria + ASC with PC3 in the presence of 30 µM ALN: 
(G), H & E sections of the parietal bone showing no new osteoid formation or 
osteoblast differentiation, bone appeared very fragile, and significant colonization 
of the endosteal bone surface by the PC3 cells. (I) NR stained calvaria showing no 
multinucleated osteoclasts, (H) NR+silver nitrate counter stained calvaria 
showing no clear osteoclastic bone resorption areas. 
 Panel 2.  Calvaria + ASC co-cultured with PC3 initially for four days then in the 
presence of ALN for an additional 4 days: (A), H & E sections of the parietal 
bone showing no new osteoid formation or osteoblast differentiation, while 
significant colonization of the endosteal bone surface by the PC3 cells continued. 
(B) NR stained calvaria showing no multinucleated osteoclasts (MNOC). (C) NR 
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+ silver nitrate counterstained calvaria showing no osteoclastic bone resorption 
areas. Calvaria + ASC cultured in the presence of ALN for four days first, then 
co-cultured with PC3 for an additional 4 days: (D), H & E sections of the parietal 
bone showing no new osteoid formation or osteoblast differentiation, while 
significant colonization of the endosteal bone surface by the PC3 cells continued. 
(E) NR stained calvaria showing no multinucleated osteoclasts, and (F) NR+silver 
nitrate counter stained calvaria showing no bone resorption area. The blue oval 
circle highlights clearly the endosteal cell layer of bone devoid of cells and with 
the appearance of collagen matrix alone. H&E 200X, NR 100X, and SN 25X.  
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- Quantitative analysis of changes in media calcium concentration and ALP 
activity in the absence and presence of PC3 cells and ALN in the ASC 
stimulated bone formation model  
Calcium uptake or release of each media over 8 days culture period were analyzed 
for each treatment group and presented in Figure 21. ASC only group showed 
substantial amount of calcium uptake reflecting bone formation and 
mineralization when compared to media unstimulated negative control. PC3 + 
ASC showed significant reduction in calcium release when compared with PC3 
alone, p = 0.003. This reduction in calcium release accompanied with ASC 
became more pronounced within the inclusion of ALN and presented, as calcium 
uptake but wasn’t significant enough to form bone as we observed from the 
histological section. Initial ALN + ASC followed with PC3 treatment group also 
showed calcium uptake, while PC3+ASC followed by ALN showed similar 
calcium release as the PC3+ASC group. ALP is an OB marker, released by 
osteogenic precursor cells as an early sign of osteoblastic differentiation. ALP 
activity was reduced by 50 % in different PC3 treatment groups in the presence of 
ALN as compared with ASC controls. 
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Figure. 21. Cumulative Calcium change and quantitative ALP activity, in 
calvarial bone resorption model. 
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Figure 21. Cumulative calcium release and quantitative TRAP activity, in 
calvarial bone formation model. (A) Cumulative calcium change in the media of 
cultures with different treatment conditions. Calvaria + ASC showed significant 
calcium uptake compared to unstimulated media control and to PC3 only group. 
Calvaria co-cultured with PC3 and stimulated by ASC showed significant 
decrease in calcium release compared to PC3 only group. Inclusion of both ALN 
with ASC with calvaria co-cultured with PC3 showed some calcium uptake but 
wasn’t enough to form osteoid. Similar result with calcium uptake was found in 
calvaria pretreated with ALN in the presence with of ASC followed by co-
cultured with PC3 after 4 days. In calvaria co-cultured with PC3 for 4 days 
followed by ALN inclusion calcium release was similar to PC3 + ASC group. 
(B) ALP enzyme activity of calvarial bone exposed to different culture conditions.  
There was significant reduction in ALP activity in different treatment groups 
when compared to ASC control only group. 
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Bone Formation Model System: Impact of ALN on bone mesenchymal stem cells, 
osteoblasts and bone microenvironment-mediated resistance of MDA-MB-231 
cancer cells to ALN in bone formation model systems  
- Histological observation of the effect of ALN on OBs formation and new bone 
formation  
     Histology of each treatment groups was obtained from seven calvaria as 
described above. Slight bone resorption was demonstrated in both MDA+ASC, 
and MDA+ASC+ALN treatment groups compared to MDA alone, without any 
clear new osteoblast differentiation or new osteoid formation, which one would 
expect, as MDA-MB-231 is an osteolytic cell line and is capable of suppressing 
osteoblast differentiation and new bone formation even in the presence of ASC, 
Figure 22. 
- Quantitative analysis of changes in media calcium concentration and ALP 
activity in the absence and presence of MDA-MB-231 cells and ALN in the ASC 
stimulated bone formation model  
     Calcium uptake or release of each media over 8 days culture period were 
analyzed for each treatment group Figure 23 A. ASC only group showed 
substantial amount of calcium uptake reflecting bone formation when compared 
to media unstimulated negative control. Inclusion of ASC with or without the 
ALN led to further reduction in calcium release in both MDA-MB-231+ASC and 
MDA-MB-23 +ASC+ALN groups. ALP activity in all treatment groups was 
consistent with the cumulative calcium change above, since there was marked 
reduction in the ALP activity with significant p value when comparing the MDA-
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MB-231+ASC groups in the presence or absence of ALN to the ASC only group 
Figure 23 B.  
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Figure. 22. Bone formation model using mouse calvarial bone organ cultures 
in the absence and presence of ALN and sodium ascorbate. 
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Figure 22. Calvaria co-cultured with MDA-MB-231 breast cancer cells for 8 
days. Co-cultures of calvaria + ASC + MDA-MB-231: H & E sections of the 
parietal bone showing colonization of the endosteal bone surface by MDA-MB-
231, and minimal bone resorption compared to MDA-MB-231 only group. Co-
cultures of calvaria + ASC with MDA-MB-231 in the presence of 30 µM ALN; H 
& E sections of the parietal bone showing no new osteoid formation or osteoblast 
differentiation, and significant colonization of the endosteal bone surface by the 
MDA-MB-231cells. 
 
 
 
 
 
 
 
 
 
!!
! !!
! ! !! 123!
Figure. 23. Cumulative calcium change and quantitative ALP activity, in 
calvarial bone formation model. 
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Figure 23. Cumulative calcium change and quantitative ALP activity, in calvarial 
bone formation model. (A) Cumulative calcium change in the media of cultures 
with different treatment conditions. Calvaria + ASC showed significant calcium 
uptake compared to unstimulated media control. Calvaria co-cultured with MDA-
MB-231 and stimulated by ASC showed significant decrease in calcium release. 
Inclusion of both ALN and ASC with calvaria co-cultured with MDA-MB-231 
similarly showed less calcium release but not uptake. (B) ALP enzyme activity of 
calvarial bone exposed to different culture conditions. There was significant 
reduction in ALP activity in different treatment groups when compared to ASC 
control only group. 
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- Mass spectrometric (MS) analysis of the media derived from calvarial organ 
cultures in the absence and presence of PTH, PC3 cancer cells, and ALN under 
Bone Formation Condition. 
     MS analysis of the medium from PC3-bone co-cultures under bone formation 
conditions in the absence and presence of ALN revealed the impact of ALN on 
OB differentiation/new osteoid formation clearly confirming our previous results 
by the absence of the major bone matrix components such as collagen type I α-1 
and α-2 chains and fibronectin that are normally synthesized by OBs, Figure 24. 
Seven distinct peptides of collagen type I α 1 were identified in ASC group with 
seven peptides of collagen type I α 2. Similarly, in samples derived from PC3 
with calvaria + 1mM ASC treated cultures showed collagen type I α2  (6 distinct 
peptides), collagen type I α1 (9 distinct peptides) Table 2. 
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Table 2. Major extracellular matrix proteins in media of cultures mouse calvaria 
in the absence and presence of PC3 cell and ascorbate (ASC) and 30 µM ALN 
using Formation model system using roller tube model. 
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Figure. 24. Identification and semi-quantification by LC–MS/MS of the bone 
ECM components in the culture media under bone formation condition. 
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Figure 24. Identification and semi-quantification of the major bone ECM 
components released into the culture media under different culture conditions.  
The media from PC3 cells cultured alone in the absence of calvarial bone in roller 
tubes showed no observable proteins when the same amount of the used media 
was analyzed as those containing calvarial bones. The media from Calvaria + 
ASC and calvaria + ASC + PC3 showed similar levels of collagen type I α-1 and 
α-2 subunits in the bone formation model conditions and these were the same 
basal levels observed in the bone resorption model for calvaria cultured alone. 
Importantly, inclusion of ALN led to the same effect as in the resorption model 
where the basal osteoblast/mesenchymal cell activity ceased to operate and no 
detectable collagen type I α-1 and α-2 subunits were observable.  
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Bone Formation Model System: Impact of osteoprotegerin (OPG) on bone 
mesenchymal stem cells, osteoblasts and bone microenvironment-mediated 
resistance of cancer cells to OPG treatment   
     The impact of ALN on bone mesenchymal cells and lack of effects on PC3-
bone colonization/interactions prompt us to investigate the impact on cancer cell 
and bone biology under bone formation conditions using OPG which has a 
different mechanism of action than ALN. 
- Histological observation of the effect of OPG on OBs formation and new bone 
formation 
     The histological observation of H & E stained sections of calvarial bones 
cultured in the absence and presence of ASC or OPG are represented in Figure 25. 
Each group is represented wit 200X magnification images. ASC only group show 
significant amount of new bone formation. ASC+OPG also showed significant 
formation of osteoid and OB activity. PC3 + ASC + OPG show some OB activity. 
PC3+ASC show less resorption areas differentiated OB and Osteoid formation as 
we mentioned above. Both MDA+ASC and MDA + ASC + OPG showed fewer 
osteoclastic resorption areas without any bone formation. Results showed that 
tumor cells colonization and survival were not affected by the presence of OPG 
while osteoclast differentiation and bone resorption was inhibited, similar to ALN 
results. However under bone formation conditions, OPG did not adversely impact 
the bone mesenchymal cells and normal OB differentiation/ new osteoid 
formation contrary to ALN, which adversely affected the OB differentiation. 
Consistent with the above results and conclusions, absence of bone resorption or 
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presence of active bone formation had no impact on the cancer-bone 
colonization/interactions or cancer cell survival. 
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Figure. 25. Bone formation model using mouse calvarial bone organ cultures 
in the absence and presence of OPG and sodium ascorbate. 
 
 
 
! !!
! ! !! 132!
Figure 25. Bone formation model using mouse calvarial bone organ cultures in 
the absence and presence of ALN and sodium ascorbate. (A) calvaria + ASC 
(controls), H & E sections of the parietal bone region of calvaria cultured in the 
presence of Na ascorbate showing differentiated OB with new osteoid formation.; 
(B) Co-cultures of calvaria + ASC + OPG showing clear new osteoid/bone 
formation and differentiated osteoblasts; (C) Co-cultures of calvaria + ASC + PC3 
and (D) Co-cultures of calvaria + ASC + PC3 + OPG highlighting both new bone 
formation and significant level of bone colonization by the PC3 in the absence of 
any bone resorption. (E) Co-cultures of calvaria + ASC + MDA-MB-231 showed 
less resorption area but no evidence of osteoid formation; and (d) Co-cultures of 
calvaria + ASC + MDA-MB-231 + OPG, showed less OC resorption compared to 
MDA-MB-231 only group. MDA-MB-231 tumor cells colonizing the endosteal 
surface of the bone in both treatment groups. 
 
 
 
 
 
 !
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- Quantitative analysis of changes in media calcium concentration and ALP 
activity in the absence and presence of cancer cells and OPG in the ASC 
stimulated bone formation model  
     After the 8 day culture period, cumulative calcium change of each media and 
ALP activity were determined and presented in Figure 26 A and B. Calcium 
uptake was significant among both ASC groups (ASC control and ASC + OPG). 
Both PC3 + ASC and MDA-MB-231 + ASC groups, show calcium release as we 
previously described. However, Inclusion of OPG with PC3 + ASC showed 
significant uptake of calcium compared to PC3+ASC, while insignificant uptake 
in MDA-231 + ASC + OPG compared to MDA + ASC without any bone 
formation as expected. ALP activities were consistent with calcium data Figure 26 
B. Insignificant difference between ASC only and ASC+OPG groups. The 
addition of ASC with PC3+OPG increased the ALP activity significantly 
compared to PC3+ASC only. ALP activity for the MDA-MB-231 groups showed 
insignificant differences. 
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Figure. 26. Cumulative calcium change in the media and ALP enzyme 
activity in the calvarial bones in the presence or absence of OPG under bone 
formation model . 
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Figure 26. Cumulative calcium change in the media and ALP enzyme activity in 
the calvarial bones in the presence or abcsence of OPG under bone formation 
model. (A) ACS control group there was significant calcium uptake confirming 
the OB stimulation and new bone formation, inclusion of OGP+ ASC showed 
similar results in calcium uptake. Calvari stimultated for bone formation co-
cultured with PC3 cells showed calcium uptake, where inclusion of OPG with 
calvaria co-cultures with PC3 showed significant calcium uptake. MDA-MB-231 
cells co-cultured with calvaria in the presence of ASC showed calcium release. 
While no significant change in calcium release with the inclusion of OPG +ASC 
in the presence of MDA-MB-231.  (B) Represents ALP activity in previous 
treatment groups. No significant change in ALP activity between ASC only group 
and ASC+OPG group. Similar results found with MDA-MB-231+ASC group and 
MDA-MB-231+ASC+OPG. In PC3+ASC+OPG, there was significant increase in 
ALP activity compared to PC3 + ASC group. These results are consistent with 
calcium change in the media. 
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Cancer cell viability from bone resorption  and formation model systems in the 
absence and presence of ALN  
     Based on our extensive studies and important observations described above, 
we further assessed the cancer cell viability by direct cell count in calvarial co 
cultutred with and without bone in the absence and presence of ALN under both 
bone resorption and formation conditions.  
     Resorption system cell count results are represented in Figure 27 A, where 
media count was combined with its corresponding tube count and plotted as a 
percentage of live and dead cells relative to the PC3 cells alone without calvaria. 
It is obvious that the bone microenvironment is a critical factor for the survival 
and the proliferation of the cancer cells, more prostate cancer cells are presented 
with calvaria compared with the control PC3 cells alone group without calvarial 
bone, which were non-viable by the end of the experiment. ALN impact the tumor 
cells without calvaria, while ALN effect on cells with the bone microenvironment 
was different than the previous group (the media alone) and cause only a slight 
reduction on the number of live cell compared to the control. Interestingly that 
both single and continual dose of ALN has similar effect on cancer cells with 
bone, and that ALN impact is on bone and had no direct effect on tumor cells in 
the presence of bone microinvironment where ALN will directly be stored in the 
bone. Formation system cell count results are represented in Figure 27 B. 
Addition of ASC to cancer media cells only without calvaria impact the tumor 
cells and cause more dead cells. While ASC with PC3 and bone had an opposite 
effect and maintained the level of live cells compared to the control. ALN + ASC 
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with cancer cells only without calvaria also impacted the tumor cells similar to 
ALN effect on cells alone in the resorption system. ALN and ASC with tumor 
cells and calvarial bone both single dose or multiple doses decreased the number 
of live cells compared to the control, and with no difference among the two 
groups. This experiment provide a clear evidence that tumor cells behave 
completely different according to the surrounding environment, and what is 
observed when tumor cells are alone is not applicable when tumor cell co-cultured 
with bone. Bone microenvironment surrounding the tumor cells is closely 
representing the in vivo situation of cancer bone metastasis, and it is a critical 
factor for the survival of the tumor cells. In addition ALN impact on tumor cells is 
mostly dependent on the presence of bone or not.  
        Direct cell counting showed instability of the PC3 cells in the absence of live 
calvarial bone. Within 2 days of culture period 50 % of the PC3 cells were non-
viable, and by the end of 8 days culture period there were no apparent PC3 cell 
remaining or attached to the roller tube surface, whereas co-cultures with calvarial 
bone allowed the PC3 cell to survive, colonize despite the presence of ALN. 
These observations dictate the essential key survival of the PC3 cells, 
colonization, and viability is dependent on the live bone and unaffected by the 
presence of ALN. 
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Figure. 27. Cancer cell viability from bone resorption  and formation model 
systems in the absence and presence of ALN. 
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Figure 27. Cancer cell viability from bone resorption and formation model 
systems in the absence and presence of ALN. (A) Resorption system direct cell 
count showed PC3 cells alone group without calvarial bone, were non-viable by 
the end of the experiment, since the live and dead cells were equal amounts.  In 
co-cultures of PC3 cells and calvaria, live cells count was significantly higher 
than the number of dead cells. ALN impact the tumor cells without calvaria, while 
ALN effect on cells with the bone microenvironment was different than the 
previous group (the media alone) and cause only a slight reduction on the number 
of live cell compared to the control. Both single and multiple dose of ALN had 
similar impact on tumor cells. (B) Formation system direct cell count, similar to 
resorption system PC3 cell alone with ASC in the absence of calvaria were non-
viable by the end of the experiment. PC3 cells co-cultured with calvaria and ASC 
had maintained the number of live cells. Inclusion of ASC and ALN with PC3 
only without calvarial bone had impacted the tumor cells. However PC3 cells 
with calvarial bone + ASC and ALN single and multiple dose didn’t affect the 
number of live cells compared with PC3 co-cultured with calvarial bone and ASC 
group. 
 
 
 !!
! !!
! ! !! 140!
Effect of ALN on PC3 cancer and MDA-MB-231 cells in 2D classical cell 
culture conditions  
     The viability of the PC3 and MDA-MB-231 cancer cells was tested by direct 
cell count in the presence of different ALN concentrations as a function of time. 
At confluence, cancer cells were treated with different concentration of ALN (1, 
30 and 100 µM) Figure 28 Panel 1. PC3 Cell counting for the first 5 days showed 
~50 % survival even with the lowest concentration of 1 µM ALN, and at 10 days 
count, cells were predominantly detached or dead with the same concentration, 
revealing the effect ALN being both concentration and time dependence, Figure 
28 Panel 2 A, B. MDA-MB-231 cells treated with 1 µM ALN weren’t affected as 
PC3 cells, instead they showed more resistant to ALN, however, exposure to a 
higher concentration of ALN over 10 days impacted the cells viability, Figure 28 
Panel 2 C, D. Overall, the 2D cell cultures data of PC3 cells were very different 
than those observed in 3D live bone-microenvironment co-cultures where in 2D 
cultures PC3 cells were more sensitive to ALN treatment. We conclude that the 
3D live bone provides bone microenvironment-mediated resistance of PC3 cells 
to ALN treatment at the expense of critically impacting the bone mesenchymal 
stem cells and osteocytes/osteoblast due to ALN being rapidly scavenged from 
the media by the mineralized bone matrix. 
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Figure. 28. 2D-cell cultures of PC3 and MDA-MB-231 absence and presence 
of different concentrations of ALN. 
Panel 1  
 
Panel 2  
 
 
PC3 alone  PC3 +30 µM ALN   PC3 +100 µM ALN   
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Figure 28. 2D-cell cultures of PC3 and MDA-MB-231 in the absence and 
presence of different concentrations of ALN. Panel 1: Confluent PC3 cells treated 
with different concentrations of ALN for 5 days showing their sensitivity levels. 
Panel 2: Cell viability experiments with PC3 cells and MDA-MB-231 at different 
concentrations and time of exposure to ALN. Panel 2 (A)-(B) PC3 cells exposed 
to 1 µM, 30 µM, 100 µM ALN for 5 days and 10 days revealing the impact of 
ALN being both concentration and time dependence such that at low dose of 1 
µM for 5 days >50 % of the cells survive but with the same dose for 10 days they 
are unable to survive. Panel 2 (C)-(D) MDA-MB-231 cells are more resistant to 
the effect of ALN with low concentration, the impact of ALN is more clear on the 
viability of the cells at higher concentration. 
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Immunhistological Staining of the human PC3 cells to distinguish tumor cells 
from the mouse bone cells in the cancer-bone interaction observations 
     Our previous results were further supported using Cytokeratin 7 expression. A 
set of histological section derived from organ culture, one represented media 
control without any tumor cells, and other is from calvaria co-cultured with PC3 
cells were used for the immunohistology. Cytokeratin 7 expression was detectable 
in PC3 only group Figure 29, while the control, didn’t show any staining. 
Localization of these PC3 cells were on the endosteal surface of the bone that was 
consistent with the previous published data (42), revealing remarkable specificity 
of cancer cell colonization and growth predominantly on the endocranial side of 
the bone. 
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Figure. 29. Immunogistological staining using Cytokeratin 7 expression 
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Figure 29. Immunogistological staining using Cytokeratin 7 expression. (C-D) 
calvaria co-cultured with PC3 was positive to Cytokeratin 7 with brown staining 
in the endosteal surface of the bone. Magnification 100X 200X . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! !!
! ! !! 146!
High resolution 2-photon confocal microscopy  for three-dimensional 
visualization of cancer-bone interactions  
     To further confirm the impact of ALN on bone biology we used specific 
fluorescent-labels to differentiate between the mineralized bone, bone cells and 
the PC3 tumor cells. The mineralized bone labeled by red –fluorescent BP, the 
bone cells with the blue-fluorescent DAPI for cell nuclei and PC3 cells with 
green-fluorescent human cytokeratin-7. In the bone resorption model, co-cultures 
of PC3-bone for 8 days in the absence of ALN, fixed in formalin, followed by 
fluorescent labeling, demonstrated OC clear resorption area with mineral loss 
obvious in vertical and horizontal recordings Figure 30 A-G, where BP labeled 
with red-fluorescent highlighted the mineralized bone, isolated small oval blue 
nuclei represent the endosteal bone cells, while the large nuclei surrounded with 
green fluorescence in the cytoplasm represent the tumor cells Figure 30 A. The 
endosteal cell layer separate the tumor cells from mineralized bone surface 
without any tumor cells in the endosteal layer or in direct contact with the bone. 
However, co-cultures of PC3-bone under bone formation conditions for 8 days in 
the absence of ALN, shown in Figure 31 A-F. Similar to the resorption model, 
endosteal cell layer occupied the space between the tumor cells and mineralized 
bone surface, without any tumor cells in the endosteal cell layer that was 
noticeable in both vertical Figure 31 A-B, and horizontal C-F recording. A 3D- 
composite for bone formation was created from continual recordings over a depth 
of 175 µm at 5 µm intervals with 200X magnification, starting from the 
endosteum and moving towards the periosteum to create the horizontal recording. 
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The topographical distribution of the PC3 tumors persist the same under both 
resorption and formation condition.  
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Figure. 30. 2-Photon high-resolution confocal 3D microscopy of the calvarial 
bones co-cultured with PC3 cells in the absence of ALN under bone 
resorption conditions. 
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Figure 30. 2-Photon high-resolution confocal 3D microscopy of the calvarial 
bones co-cultured with PC3 cells under bone resorption conditions. Confocal 
microscope recordings of the calvarial bone co-cultured with PC3 cells under 
“bone resorption” conditions in a roller tube in the absence of ALN, fixed in 
formalin, followed by labelling with (OsteoSense) red-fluerescent BP, human 
cytokeratin-7 green-fluorescent and DAPI blue. (A) Vertical/edge confocal 
recording with visible light transmittance merged with red-fluorescent BP 
showing the mineralized bone matrix (red) with resorption area (white rectangular 
box), and (b) vertical confocal recording composite of mineral-bound red-
fluorescent BP, green human cytokeratin-7 fluorescence of tumor cells on the 
endosteal bone cell surface and blue nuclear stain DAPI distinguishing the tumor 
cells with large circular blue nuclei surrounded by green cytoplasm and the 
smaller isolated oval blue bone cell nuclei observable both in the endosteum and 
periosteum. The tumor cells are distinctly separated from the mineralized bone 
matrix by the endosteal cell layer. (C) A horizontal confocal recording with 
visible light transmittance merged with red-fluorescent BP showing the 
mineralized bone matrix (red) with distinct complete loss of mineral phase by the 
osteoclastic resorption activity with typical resorption front.  (D) The same view 
as in (C) with blue DAPI fluorescence merged with red-fluorescent BP showing 
the transparency of the resorption region lacking any mineral with only the small 
blue bone cell nuclei. (E) A 3D-orientation, ~90o rotated side/edge view, of the 
horizontal confocal recordings of calvarial bone with PC3 tumors recorded from 
the tumor surface of the endosteal side and moving towards the mineralized bone 
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matrix. The 3D-composite was generated from continual recordings over a depth 
of 175 µm with 600 slices using 20X magnification. (F) A face view of the 
horizontal 3D-composite recording from endocranial side of the 3D-orientaion in 
(E) showing PC3 cell on the surface of endosteum and the mineralized bone 
behind with resorption areas (RB). (G) Closer view of PC3 cells. 
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Figure. 31. 2-Photon high-resolution confocal 3D microscopy of the calvarial 
bones co-cultured with PC3 cells in the absence of ALN under bone 
formation condition. 
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Figure 31. 2-Photon high-resolution confocal 3D microscopy of the calvarial 
bones co-cultured with PC3 cells under bone formation condition. Confocal 
microscope recordings of the calvarial bone co-cultured with PC3 cells under 
“bone formation” conditions in a roller tube in the absence of ALN, fixed in 
formalin, followed by labelling with red-fluerescent BP (OsteoSense), green-
fluorescent human cytokeratin-7 and DAPI.  (A) Vertical/edge confocal recording 
with visible light transmittance merged with red-fluorescent BP showing the 
mineralized bone matrix (red), and (B) vertical confocal recording composite of 
mineral-bound red-fluorescent BP, green human cytokeratin-7 fluorescence of 
tumor cells on the endosteal bone cell surface and blue nuclear stain DAPI 
distinguishing the tumor cells with large circular blue nuclei surrounded by green 
cytoplasm and the smaller isolated oval blue bone cell nuclei observable both in 
the endosteum and periosteum. In the formation model the area between the white 
dotted lines represent the new osteoid which has not yet mineralized and lacking 
red-BP label. The tumor cells are distinctly separated from the mineralized bone 
matrix by the endosteal cell layer and the new osteoid. (C) A 3D-orientation, ~30o 
rotated partial side view, of the horizontal confocal recordings of calvarial bone 
with PC3 tumors beginning with the tumor surface from the endosteal side and 
moving towards the mineralized bone matrix. The 3D-composite was generated 
from continual recordings over a depth of 175 µm with 450 slices using 20x 
magnification. (D) A side view, 90o rotation, of the 3D-orientaion in (C) showing 
the ~60 µm thick PC3 tumor cells (green) on the surface of the bone endosteum 
(blue) and the red mineralized bone matrix. (E) A face view from endocranial side 
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of the 3D-orientaion in (C) showing dense PC3 cell colony with evidence of 
mineralization labeled with red-fluorescent BP. (F) A face view from endocranial 
side of the 3D-orientaion in (C) at a depth of ~120 µm beyond the surface of the 
PC3 cells towards the mineralized bone showing the blue endosteal bone cells 
with the mineralized bone surface in the background. 
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     PC3-bone co-cultures in the presence of low ~0.4 µM or 1.5 µM (250 or 1 µg, 
respectively) and higher 20 µM (13 µg) ALN doses, still colonized bone, with 
deterioration in the endosteal bone cells contacting the mineralized bone. In the 
bone formation model the deterioration was more prominent confirming our 
initial histological observation Figure 20 Panel 1 G and Panel 2 N. Our data 
showed that tumor cells could behave differently depending on the bone 
remodeling stage despite the presence or absence of ALN. Under both formation 
and resorption condition, tumor cells were oval to round in shape Figure 32 Panel 
1 E. Throughout the full depth of the tumor; cells retained their constant 
morphology under bone resorption condition regardless to the presence or absence 
of ALN. Nevertheless under bone formation condition specifically beyond 20 µm 
interior of the tumor colony, PC3 cells become more spread and elongated in 
shape and their cellular processes extended to interconnect with each other Figure 
32, Panel 2 E. These distinct morphological adaptations in the two bone 
remodeling stages were independent of ALN.  
PC3-bone co-cultures were first grown in the absence of ALN, fixed and labelled 
with fluorescent BP to visualize the mineralized bone matrix. These co-cultures 
showed well-defined mineralized bone matrix with perfectly preserved 
osteocytes, numerous canaliculi and blue DAPI labeled nuclei, Figure 32, Panel 1 
B and Panel 2 B. However, when the live calvaria were first cultured in the 
presence of low or high doses of ALN and fixed, followed by red-fluorescent BP 
labelling and DAPI more dramatic changes within the mineralized bone matrix 
occurred.  In such cultures, loss of both the nuclei of the osteocyte, canaliculi 
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processes and showed degeneration of their mineral cocoon and mineralized bone 
matrix, Figure 32, Panel 1 D and Panel 2 D.  
The impact of mineral-bound ALN on osteocytes was unexpected as this was 
observed at clinically relevant dose levels. The loss of osteocytes by treatment 
with low doses of either 250 ng or 1 µg BP concentrations per 12 mg calvarial 
bone was surprising, as these are comparable to the bioavailable cumulative dose 
of ~200 ng/ 12 mg human trabecular bone from daily clinical oral dose of ALN 
over 1 year, or ~1.0 µg/12 mg trabecular bone over 5 years in patients treated for 
osteoporosis.  
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Figure. 32.  Panel 1 Resorption System. 2-Photon high-resolution confocal 3D 
microscopy recordings of the calvarial bones co-cultured with PC3 cells 
under bone resorption and bone formation conditions in the absence and 
presence of ALN. 
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Figure. 32.  Panel 2 Formation System. 2-Photon high-resolution confocal 3D 
microscopy recordings of the calvarial bones co-cultured with PC3 cells 
under bone resorption and bone formation  conditions in the absence and 
presence of ALN . 
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Figure 32. 2-Photon high-resolution confocal 3D microscopy recordings of the 
calvarial bones co-cultured with PC3 cells under bone resorption and bone 
formation conditions in the absence and presence of ALN. Panel 1 (A, B) live 
calvarial bone cultured in the absence of ALN, fixed in formalin, followed by 
labelling with red-fluerescent BP (OsteoSense), green-fluorescent human 
cytokeratin-7 and DAPI; (A) 90o side view of 3D-orientation from the horizontal 
confocal recordings. Panel 1 (B) horizontal view showing details of the distinct 
mineralized bone (red-fluorescence) with defined osteocytes, their blue nuclei and 
interconnectivity amongst osteocytes with their canaliculi. Panel 1 (C-D) 
represents calvaria co-cultures with PC3 cells in the presence of ALN under bone 
resorption condition; (C) represents 90o of 3D- orientation from horizontal 
recordings starting from the endosteal side clearly show absence of significant 
portion of bone endosteal cells between tumor cells and mineralized bone in the 
presence of ALN. Panel 1 (D) Details of the mineralized bone matrix showing 
less defined mineralized bone (red-fluorescence) with general deterioration of the 
matrix mineral, loss of osteocyte nuclei and their canaliculi, and less defined 
mineral cacoon of osteocytes. Panel 1 (E) PC3 cells with define round to oval in 
shape in resorption model. Panel 2 A, B live calvarial bone cultured in the 
absence of ALN, fixed in formalin, followed by labelling with red-fluerescent BP 
(OsteoSense), green-fluorescent human cytokeratin-7 and DAPI under bone 
formation condition;  (A) 90 o side view of 3D-orientation from the horizontal 
confocal recordings. Panel 2 (B) horizontal view showing mineralized bone (red-
fluorescence) with unaltered osteocytes, their blue nuclei and canaliculi. Panel 2 
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(C-D) represents calvaria co-cultures with PC3 cells in the presence of ALN 
under bone formation condition; (C) 3D- orientation from horizontal recordings 
where major loss in the endosteal cell layer is noticeable comparing Panel 2A 
with 2C in the presence of ALN. Panel 2 (D) mineralized bone with matrix 
mineral deterioration loss of canaliculi and nuclei of the osteocytes. Green arrows 
represented the osteocyte nuclei in blue, where yellow arrows pointed to the 
canaliculi. Panel 2 (E), PC3 tumor cells on the bone surface in the formation 
model with significant morphological adaptation with significant elongation and 
extended intercellular processes. 
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 Effect of ALN/OPG on the healing process, OB and new bone formation using 
ex-vivo calvarial bone defect organ culture model system  
i) Alendronate –ALN  
     Calvarial bone defect is a suitable model to evaluate the influence of ALN on 
OBs/ mesenchymal /stem/progenitor cells and bone regeneration. We utilized an 
ex-vivo calvarial bone defect to observe new bone formation and OB stimulation. 
Subcritical size defects (0.6 mm) was selected in which complete bone 
regeneration is expected without the contribution of added factors to test whether 
the inclusion of ALN will interrupt this spontaneous healing process.  
- Neutral Red staining and Silver Nitrate counter stain 
     After the 21 day culture period, calvaria were stained with NR followed by 
fixation and counterstaining with silver nitrate to visualize the defect closure and 
amount of minerlaization. Stimulated positive control with 1 mM of ASC 
represented in Figure 33 Panel 1 A-B clearly showed complete closure of the 
defect, while single dose addition of ALN group showed few cellular proliferation 
Figure 33 Panel 2 A-B. Figure 33 Panel 3 A-B, showed the treatment group of 1 
mM ASC + 30 µM ALN, where the defect hole is still obvious with retarded 
healing. Sliver nitrate counterstain Figure 33 Panels 1C, 2C, 3C, were consistent 
with NR effect. Hence the ASC control group shows less light transparency 
through the center. ALN group clearly was transparent to the light. 
- Osteoblasts and bone formation in the absence and presence of ALN observed 
histologically  
     The histological observations of H & E stained sections of calvarial bones 
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cultured over a 21 day period for groups: (a) Stimulated positive control with 
1mM of ASC (b) 1 mM ASC+ 30 µM ALN single dose for the first two days 
only, (c) 1 mM ASC + 30 µM ALN are shown in Figure 33. In the ASC control, 
complete cellular bridging is obvious Panel 1 D-E, whereas ALN treated never 
‘caught up’ with the ASC control and did not show any cellular proliferation 
Panel 2 D-E. New bone formation was clearly observable in the ASC control 
group, with significant osteoblastic activity as evidenced by large amounts of new 
osteoid formation among the rest of the calvarial bone. Contrary to this, calvaria 
exposed to 30 µM ALN at single dose or repeat dosage every 2 days showed no 
potential for OBs differentiation and new osteoid formation.  
     We have developed and used an ex-vivo mouse calvarial, which contain all the 
necessary responsive essential cellular and bone microenvironment components 
and closely simulate the in vivo bone biology. Data clearly revealed significant 
blunting effect of initial healing process and cellular proliferation in the pretreated 
and multiple ALN doses calvaria. This impact could be due to a direct toxic effect 
or unknown physicochemical interaction between the matrix embedded 
bisphosphonate and the first responding bone cells. It is noteworthy that single 
ALN dose was enough to produce a similar effect to the multiple ALN treated 
calvaria, and impacted bone mesenchymal/ stem/ fibroblast OB cells adversely 
with no recovery to the their normal mode of action. These results are consistent 
with previously published data that reported direct effects of bisphosphonates on 
non-resorbing cells, including osteoblasts in culture, also internalization of BP by 
OB has been previously reported [77]. This may indicate a direct effect on 
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osteoblast activity and suppression of bone formation independently of bone 
resorption.  
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Figure. 33. Effect of ALN on the healing process, OB and new bone 
formation using ex-vivo calvarial bone defect organ culture model system.  
!!!!
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Figure 33. Effect of ALN on the healing process, OB and new bone formation 
using ex-vivo calvarial bone defect organ culture model system. NR staining and 
counter stained with SN of Stimulated positive control (with 1 mM of ASC) are 
represented in Panel 1 A-C show complete closure of the defect. H&E 
histological section of ASC control showed complete bridging of the cells over 
the defect area Panel 1 D-E. Calvaria treated with Single dose of ALN group NR 
staining showed few attempts of cellular proliferation Panel 2 A-B. SN 
counterstain showed light transparency Panel 2 C. Multiple dose of ALN group 
Panel 3 A-B NR staining showed more dramatic changes without any cellular 
proliferation. H&E histological section of group treated with single dose or 
multiple doses of ALN are represented in Panel 2 D-E, where the defect edges are 
clear without any cellular bridging. Magnification 25X, 100X.  
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ii) Osteoprotogrin -OPG  
     Similar set of experiments were carried out using OPG instead of the ALN to 
test the impact of OPG on the healing process, OBs and progenitor cells that pose 
different mechanism of action than ALN. 
- Neutral Red staining and Silver Nitrate counter stain  
     NR stained calvaria of each treated group (a) Stimulated positive control 1 mM 
of ASC, (b) 1 mM ASC + 2 nM OPG single dose for the first two days only, (c) 1 
mM ASC+2 nM OPG, are represented in Figure 34 Panel 1,2,3. All three treated 
groups showed similar degree of cell migration and defect closure. Contrary to 
ALN, our data showed that OPG doesn’t impact the healing process nor OB 
differentiation or cellular proliferation with both single and repeated dose of 
exposure. 
 
 
 
 
 
 
 !!!!
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Figure. 34. Effect of OPG on the healing process, OB and new bone 
formation using ex-vivo calvarial bone defect organ culture model system.  
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Figure 34. Effect of OPG on the healing process, OB and new bone formation 
using ex-vivo calvarial bone defect organ culture model system. All three 
treatment groups, ASC stimulated positive control, OPG inclusion for single dose 
or multiple dose s showed equal level of complete defect closure with NR staining 
Panels 1,2,3- A. Counterstain with SN also was consistent with NR results where 
the defect was closed completely without any light transparency Panels 1,2,3- B 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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DISCUSSION !
    Bone is a dynamic highly vascularized and rich in growth factors, which 
provide specific microenvironment to foster cancer cell metastasis. 
Bisphosphonates (BPs) have been clinically used to prevent cancer-bone 
metastasis and cancer-induced bone pathologies relying on the theory that 
metastasis is resorption-dependent. BPs have been used to treat excessive bone 
loss which manifests as osteoporosis of the bone through their effect on 
osteoclasts (OCs), however the impact of BPs on osteoblasts (OBs), bone stem 
cells, cancer cells and cancer cell interactions with bone remained controversial. 
The present study focused on bone-mediated resistance of cancer cells to BP 
therapy including Alendronate (ALN) and its impact on osteocytes/osteoblasts 
and mesenchymal stem cells by various versatile methods to expand the vision on 
these area specifically, which are difficult to achieve by previous existing in vivo 
or in vitro models. We have developed and utilized the unique model system of 
live bone organ cultures where the two naturally occurring processes of bone 
remodeling can be dissociated viz., osteoclastic bone resorption or osteoblastic 
bone formation only for the first time which enabled clear observations of the 
impact of added factors/drugs on the bone biology and cancer cells under 
controlled conditions. In clinical cancer patients the bone resorption is post-cancer 
colonization and not a pre-requisite for cancer-bone metastasis/colonization which 
has been the accepted theory for the past 40 years.  
    Bone provides an exceptional microenvironment, which is an oasis for cancer 
cell colonization and drug therapy resistance of which many facets are not well 
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understood. Based on the bone anatomical location and the concept that cancer-
bone metastasis and cancer survival were bone resorption-dependent, BPs have 
been clinically used in an attempt to prevent cancer-bone metastasis and cancer-
induced bone pathologies. However, both clinical and scientific definitions of the 
fundamental phenotypic responses of cancer and bone cells to BP exposure in a 
live bone microenvironment to date remain unclear.  Whilst it is well known that 
bone resorption can be effectively interrupted by BPs, the critical impact on bone 
mesenchymal/stem cells, cancer cells, and cancer-bone interactions within the live 
bone microenvironment remain still an uncharted territory. The present study 
detailed multiple new insights into the nature of cancer-bone interactions, bone-
mediated resistance of cancer cells to BP therapy such as ALN (Trade name 
Fosamax) and the deceitful impact of ALN on osteocytes/osteoblasts and 
mesenchymal stem cells. Firstly, we have demonstrated bone 
resorption/formation-independence using an ex-vivo live cancer-bone interactive 
models under bone resorption conditions where exposure of live bone to cancer 
cells in a roller tube leads to rapid cancer-bone colonization with subsequent 
activation of the dormant bone cells to generate osteoclast (OC) 
differentiation/bone resorption. Hence, the observed bone resorption is post-
cancer colonization and not a pre-requisite for cancer-bone 
metastasis/colonization. The possibility that the cancer cells first induce OC 
differentiation/bone resorption followed by cancer-bone colonization can be 
excluded as co-cultures in the presence of ALN with bone undergoing no OC 
differentiation/bone resorption cancer cells still colonize the bone. Consistent with 
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these observations, the use of a naturally occurring RANKL decoy receptor 
osteoprotegerin (OPG) with a different mechanism of action also provided the 
same outcomes.  Secondly, in the bone formation model in which the bone was 
activated to undergo osteoblast (OB) differentiation/new osteoid formation in the 
absence and presence of ALN and OPG, in all cases despite the absence of any 
osteoclastic bone resorption, the cancer cells continued to colonize the bone and 
developed 3D tumor. Thirdly, the unprecedented biological qualities of bone 
which bequeaths this organ a target for cancer-bone metastasis was revealed by 
the lack of survival capacity of PC3 cells alone in the bone organ culture media 
and their achievement of remarkable survival tactics in the presence of live bone. 
Our studies led to the compelling conclusions that tumor cells do not require 
specific “bone resorption or formation remodeling stages per se” for cancer-bone 
metastasis/colonization or survival. Whilst others have suggested that tumors 
colonize bone due to their ability to: (a) use “osteoblastic niche” [117-120], and 
(b) use bone resorption to gain access to a wealth of growth factors/cytokines for 
survival [27, 86-89].  
     The mechanism of amine-containing BP inhibition of bone resorption has been 
universally accepted to be through internalization of BP by mature multinucleated 
(MN)-OCs. Clearly this does occur when multinucleated resorptive osteoclasts are 
present however our work using live bones under resorption conditions and 
simultaneous addition of ALN and PTH or cancer cells also dictates that 
inhibition of bone resorption is achieved at the OC differentiation stage. A 
mechanism of drug action that has been elusive and not considered to date until 
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the present study due to the hidden impact of BPs on osteocytes/osteoblasts that 
required ability to reveal multicellular interrelationship in a live bone environment 
with clarity. The bone formation models augmented the above results from the 
resorption model where both the sequential and simultaneous treatment regimens 
with ALN and ascorbate led to incapacity of the calvarial bones to generate 
osteoblastic bone formation. Under bone formation conditions ALN elicits 
degeneration of osteocytes and mesenchymal stem cells when calvarial bones are 
stimulated to undergo OB differentiation and the observed inhibition of bone 
resorption by ALN is through its effects on OBs/osteocytes/mesenchymal stem 
cells. These results were supported by the high-resolution 2-photon confocal 
microscopy 3D images which highlighted the distinct topographical distribution 
of ALN within the mineralized bone matrix with the endosteal cell layer acting as 
a barrier between the tumor cells and the mineralized bone matrix. The regulation 
of OC function by ALN at differentiation level reflects the impaired functions of 
OBs/osteocytes, which are responsible for the local synthesis of RANKL and CSF 
essential for the differentiation of macrophages to bone resorbing OCs. The use of 
OPG with different mechanism of action via direct complexation with RANKL 
showed no adverse impact on OB differentiation and new osteoid formation.  In 
ex-vivo live bone organ culture models with no drug delivery limitations the 
cancer cells were completely resistant to ALN drug action due to its rapid 
removal by the mineral-phase. Clearly, such occurrence is directly applicable to 
both in vivo pre-clinical animal studies and human clinical scenario. This 
phenomenon can be referred to as a classic case of bone microenvironment-
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mediated resistance of cancers to BP drug therapy through preservation of tumors 
by bone at the expense of bone integrity. The pharmacokinetics of BPs in a 
clinical setting clearly support this since systemic BPs become mineral bound 
within hours of introduction and their very low “dissociation constants” with the 
mineral phase preclude their potential direct therapeutic actions against cancer 
cells even with high and frequent repeat doses. However, the immediate residents 
of the bone mineral are the osteocytes trapped within a cocoon of mineral and the 
bone endosteal/periosteal cells in direct contact with the mineralized bone surface. 
This unique bone architecture and the location of tumors on the endosteal cell 
surface isolate them from the mineral-ALN composite thus limiting their 
exposure. These studies generate a persuasive conclusion, which excludes the 
potential direct anti-cancer action of BP therapy in a live bone microenvironment 
that can be expected even at doses far exceeding the maximum dose possible for 
human use. The properties of the live ex-vivo 3D bone microenvironment that 
closely mimic the in vivo condition are not replicated in in vitro studies using 2D 
conventional cell cultures where tumor cells behave totally different towards 
general drug action including ALN. In the 2D cell cultures non-mineral 
containing confluent PC3 and OB cells were sensitive to ALN treatment at low 
and high doses in a time-dependent manner and had minimal survival capacity if 
ALN was included at the seeding stage. The role of mineral phase was 
investigated using mineralized OB cell cultures which did not change the 
sensitivity of OBs to ALN due to generation of a high density ALN-mineral 
composite directly in contact with OBs, a phenomenon consistent with our live 
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bone microenvironment observations. The pre-clinical animal models using 
zoledronic acid or dimethyl-pamidronate for cancer-bone metastasis showed 
varying and conflicting outcomes with respect to tumor burden even at extreme 
doses [121-123]. Similarly, high dose application in cancer patients led to 
confounded outcomes of clinical studies with some reporting benefits and others 
demonstrating no significant advantage [27, 94, 95, 105-107, 124-126]. Based on 
these and our results there are major conceptual interrogative issues that arise 
regarding the direct anticancer drug action of BPs: (i) if it is as clear as shown 
here that ALN has no effect on PC3 cells in the models used, it is unclear how 
conflicting results rather than consistent negative result were obtained in various 
pre-clinical and clinical studies, and (ii) if BPs/ALN worked as direct anticancer 
drug, it is also unclear how conflicting results rather than consistent positive 
results were obtained in various pre-clinical and clinical studies. The answers to 
such paradoxical events are related to the “inconsistencies” in: (a) normalized 
dose usage, (b) length of time for outcome analysis because of the time-
dependence of BP impact, and (c) analytical methods used for evaluating drug 
action. Our studies revealed that the clinically used low or high BP doses can 
generate high density mineral-BP composites capable of impacting 
OBs/osteocytes and mesenchymal stem cells as a function of time and cumulative 
dose. This latter phenomenon is correlative with the clinical development of 
“osteonecrosis of Jaw (ONJ)”: (a) using i.v. delivery of pamidronate in cancer 
patients with average minimum cumulative dose of 2,220 mg and mean event 
time of 2.8 years, and (b) oral delivery of ALN and residronate for osteoporosis 
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with bioavailable cumulative dose of 150 mg and mean event time of 4.6 years   
[127]. Our calculations from the above cumulative doses for ONJ development 
for ALN/residronate and pamidronate translates to ~1 µg/12 mg and ~15 µg/12 
mg human trabecular bone, respectively, consistent with our findings using ALN 
dose range between ~1.0 µg - 52 µg/12 mg calvarial bone. 
     The above studies and findings were further explored and supported by using 
ex-vivo calvarial bone defect organ culture model system, where in such defect 
repair model ALN clearly revealed significant blunting effect of initial healing 
process and cellular proliferation in both the pre-treated and multiple ALN doses 
treatments, in contrast to OPG, which permitted cell migration and defect closure. 
These results are consistent with the impact of ALN on osteoblasts, bone 
mesenchymal/stem cells, and osteocytes as revealed in the cancer-bone interactive 
models used above. 
  Distinct from the drug resistance phenomenon detailed above was the bone-
mediated survival of PC3 cancer cells as they lacked survival in bone culture 
media in the absence of calvarial bones.  The MS/MS analysis of the media from 
such cultures confirmed their degeneration with the identification of “vimentin”, 
an intracellular/cell surface filament network protein, released into the media of 
PC3 cells cultured alone in the roller tubes which was supported by direct cell 
counts and PC3 cell viability. Similar analysis of PC3-bone co-cultures showed 
no vimentin release as they establish survival/stability state.  The identification of 
vimentin which is a marker for “epithelial to mesenchymal transition (EMT) 
[128]” in PC3 cancer cells support the clinically observed osteosclerotic outcome 
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of prostate cancer-bone metastasis reflecting their inherent mesenchymal 
phenotype characteristics. The MS/MS data from cancer-bone interactive systems 
also identified matrix metalloproteinase-3 (also known as Stromelysin) as the 
most abundant MMP synthesized and secreted by the calvarial bones in response 
to PTH and PC3 cells in the bone resorption models. This is consistent with up-
regulation of the calvarial bone MMP-3 gene expression observed in our previous 
studies as a result of PC3-bone interactions [111].  Other MMPs such as MMP-2 
and 9 have been implicated in cancer-bone metastasis, invasive phenotype, and 
cancer cell proliferation; however, those observations refer strictly to expression 
of MMP-2 and 9 by PC3 cells [129]. The discovery of MMP-3 in abundant levels 
generated by the bone in response to PC3 cancer cells has major implications 
within the context of cancer-bone metastasis and interrelationship between the 
local bone microenvironment and cancer biology. This is due to direct association 
of MMP-3 with “EMT” and “induction of genetic instability and malignant 
transformation” with increased mobility and invasiveness [130, 131]. Taken 
together these data provide a new rational understanding of the poorly delineated 
phenomena that once the cancer-bone metastasis is established: (a) this condition 
marks the terminal stage of an untreatable disease, and (b) the stage for generating 
the chemotherapy resistant phenotype and re-emergence of tumors post-
chemotherapy treatment becomes imminent.  These outcomes can be linked to the 
bone derived MMP-3 which transforms tumors within the bone microenvironment 
to a more malignant and chemotherapy resistant phenotype after bone 
colonization.  
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CONCLUSION !
     This study offers unique insights into the interplay between cancer stem cells 
and osteocytes/osteoblasts and mesenchymal stem cells using 3D live cancer-bone 
interactive model.  Our studies led to paradigm-shifting conclusions where direct 
anti-cancer effect of BPs in a bone microenvironment or in vivo is not possible 
and cancer-bone metastasis is independent of bone remodeling stage. The bone 
microenvironment-mediated survival of cancer cells to BP exposure is at the 
expense of accumulating BP within the bone mineral phase, which adversely 
impacts osteocytes and mesenchymal progenitor cells. Our discovery of abundant 
bone MMP-3 generated in response to PC3 cancer cells provide a new rational 
understanding of the phenomena of resistant cancer phenotype and re-emergence 
of tumors post-chemotherapy treatment. These occurrences are due to 
transformation of cancer cells to more malignant and invasive type within the 
bone microenvironment after the cancer-bone metastasis. This may suggest that 
the bone homing circulating cancer cells may not be a selection of a sub-
population but rather they evolve to be one once exposed and grow in the bone 
microenvironment.  Additional cancer cell types used in the present study, i.e., 
MDA-MB-231 breast cancer cells, provided similar data as those of PC3 cells, 
demonstrating that the results have general application to other cancer cells too.  
    Despite the highly deceptive nature of the biology of cancer-bone 
metastasis/interactions the present investigations at the “phenotypic” level 
culminated in a series of new insights. They have also revealed novel avenues to 
examine commonly used chemotherapeutic drug actions at a phenotypic level and 
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development of new strategies/drugs with direct clinical implications. This 
investigation has significant translational interest with new conceptual advances 
involving cancer-bone interactions and cancer cell behavior in relation to bone 
biology and critical roles played by osteocyte/osteoblast cells.  
 
 
 
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!
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Abstract Anti-resorptive bisphosphonates (BPs) have
been clinically used to prevent cancer-bone metastasis and
cancer-induced bone pathologies despite the fact that the
phenotypic response of the cancer-bone interactions to BP
exposure is ‘‘uncharted territory’’. This study offers unique
insights into the interplay between cancer stem cells and
osteocytes/osteoblasts and mesenchymal stem cells using a
three-dimensional (3D) live cancer-bone interactive model.
We provide extraordinary cryptic details of the biological
events that occur as a result of alendronate (ALN) treat-
ment using 3D live cancer-bone model systems under
specific bone remodeling stages. While cancer cells are
susceptible to BP treatment in the absence of bone, they are
totally unaffected in the presence of bone. Cancer cells
colonize live bone irrespective of whether the bone is
committed to bone resorption or formation and hence,
cancer-bone metastasis/interactions are though to be ‘‘in-
dependent of bone remodeling stages’’. In our 3D live bone
model systems, ALN inhibited bone resorption at the
osteoclast differentiation level through effects of mineral-
bound ALN on osteocytes and osteoblasts. The mineral-
bound ALN rendered bone incapable of osteoblast differ-
entiation, while cancer cells colonize the bone with striking
morphological adaptations which led to a conclusion that a
direct anti-cancer effect of BPs in a ‘‘live or in vivo’’ bone
microenvironment is implausible. The above studies were
complemented with mass spectrometric analysis of the
media from cancer-bone organ cultures in the absence and
presence of ALN. The mineral-bound ALN impacts the
bone organs by limiting transformation of mesenchymal
stem cells to osteoblasts and leads to diminished endosteal
cell population and degenerated osteocytes within the
mineralized bone matrix.
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Biomineralization
Introduction
The clinical use of bisphosphonates (BPs) as anti-resorp-
tive agents for the treatment of Paget’s disease, multiple
myeloma, cancer-induced bone resorption, and osteoporo-
sis has provided benefits in the management of these dis-
orders [1 and references therein]. However, their ‘‘direct
anticancer’’ effects and prevention of cancer-bone metas-
tasis are not clearly understood and remain inconsistent
with both in vivo preclinical studies and clinical trials that
have yielded diverse outcomes [2–7]. As our understanding
of the inherent unique characteristics of cancers continues,
an emerging, renewed concept emphasizes the significance
of the cancer microenvironment as an important factor in
tumor progression, metastasis and survival [8–13]. Most
solid tumors such as breast and prostate have a high
propensity to colonize bone that once established, results in
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a terminal and incurable disease. The biological reasons as
to why cancer cells take refuge in bone are presently
unclear. Studies based on the cellular/biological charac-
teristics of bone and cancer cells, as well as clinical and
biological observations over the past decades have begun
to shed some light on this problem. At the forefront have
been the cancer cell interactions with bone cells that may
be responsible for the evolution of chemotherapy-resis-
tance and the ability of cancer cells to take control of the
bone biology for their own survival. The specific bone
localization of cancer colony and cancer cell-induced
osteoclast (OC) differentiation/bone resorption led to the
concept that cancer-bone metastasis is ‘‘bone resorption-
dependent’’, which became the universally accepted dogma
[14–17]. The biological occurrence of cancer-induced bone
resorption has a significant impact on patient survival rate
and morbidity and has been a primary target for therapeutic
intervention using powerful anti-resorption agents such as
BPs [18–20]. The capacity of BPs to inhibit OC bone
resorption by direct drug action that modifies the cancer
microenvironment is consistent with the desire to establish
such an approach [11, 12, 16, 21, 22]. BPs have high
affinity for the bone hydroxyapatite mineral phase that
provides a selective/rapid accumulation of the drug in the
bone. This observation suggested that bone resorbing OCs
could be exposed to the drug action more specifically than
the other bone cells [23–25]. However, local BP accumu-
lation within the mineralized bone matrix with a long half-
life of elimination has the potential to expose bone cells in
direct contact with the mineral phase to prolonged drug
action. Indeed, clinical outcomes such as osteonecrosis of
the jaw and unexpected fractures of long bones due to
increased BP use in general and more specifically at high
doses in cancer patients, are testaments to the above pos-
sibilities [26, 27]. Irrespective of the frequency of these
adverse clinical outcomes, they suggest that the impact of
BPs is beyond the pure inhibitory effects on OC and bone
resorption. While the effects of BPs on OCs are well
documented, their influence on bone cells of mesenchymal
lineage such as osteoblasts, osteocytes, and stem cells have
to date remained limited and controversial [28–33]. Pre-
clinical studies in vitro and in vivo have suggested poten-
tial direct anticancer effects of nitrogen-containing BPs
with inconclusive results and uncertain clinical relevance
[5, 6, 34, 35]. Several clinical trials as well as their meta-
analysis using BPs alone or as adjuvant with chemo-/hor-
monal-therapy have also revealed inconsistencies in
achieving the desired benefits [9, 10, 12, 35, 36]. In a
recent review of clinical trials, it was found that at doses
used for osteoporosis and contrary to reports of a protective
effect seen in several observational studies [38], neither
alendronate nor zoledronic acid reduced the risk of breast
cancer [37]. Furthermore, data analysis from 36 adjuvant
bisphosphonate trials showed no effect on local recurrence
or contralateral breast cancer incidence [39]. The above
observations give rise to paradoxical issues that relate to
the ‘‘mass action theory of drugs’’ whereby BPs are rapidly
removed from the circulation by the bone mineral within
hours and the effects of the BP-mineral composite on local
bone cells intimately associated with the mineral phase.
The anatomical location of osteocytes within a cocoon of
mineralized bone matrix and those of the bone periosteal/
endosteal osteoblasts and mesenchymal stem cells in direct
contact with the mineral phase suggests their highly sus-
ceptible nature to drug action including BPs. An unfore-
seen damage to bone mesenchymal cells has several major
clinical and scientific implications that will be revealed and
elaborated in this study. We present a series of direct
experimental studies related to the hidden biological events
involving BP therapy with precarious consequences on
bone integrity using an ex vivo live ‘‘three-dimensional
(3D) cancer-bone interactive model’’. Our results under
specific bone remodeling conditions in the absence and
presence of PC3 prostate cancer cells, alendronate (ALN,
Fosamax) and RANKL decoy receptor osteoprotegerin
(OPG) generate important new insights with paradigm-
shifting conclusions.
Materials and methods
Roller tube system for neonatal mouse calvarial
bone co-cultures with cancer cells (3D) and effect
of alendronate (ALN)
Calvaria from 5 to 7 day old neonatal CD-1 mice (Charles
River Laboratories, MA) were dissected and each calvar-
ium was placed free floating in a roller tube
(15 cm 9 16 cm, Bellco, Inc., NJ) containing 2.0 ml of
bone culture media under normoxia with or without PC3
cancer cells (2 9 105 per tube) in suspension [40]. The
bone organ culture media DMEM was devoid of fetal calf
serum (FCS) at all times.
PC3 prostate and MDA-MB-231 breast cancer cell
culture
PC3 prostate and MDA-MB-231 breast tumor cell lines
(American Type Culture Collection), were grown with
F-12 K media and DMEM, respectively, in the presence of
10 % Fetal Calf Serum (FCS, Sigma-Aldrich, Co) at 37 !C
until confluent using 10 cm culture dishes and media
changed every 2 days. The day of bone organ co-cultures
with PC3 and or MDA-MB-231 cells, the cancer cells were
rinsed with 10 ml of bone organ culture media first, har-
vested using trypsin in 10 ml of bone culture media,
564 Clin Exp Metastasis (2016) 33:563–588
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followed by centrifugal pelleting. The collected cancer
cells were re-suspension in 10 ml of bone organ culture
media and re-pelleted. The cancer cells were then sus-
pended in bone organ culture media and total number of
cells was counted using microscopic approach. Two ml of
bone culture media spiked with (2 9 105) of tumor cells
were added to each roller tube to be co-cultured with a
single full calvarial bone.
Bone resorption model
For the bone resorption model, the media described above
was used in the absence or presence of the cancer cells
(2 9 105 per tube) or 10 nM parathyroid hormone (PTH,
bovine residues 1–34, Sigma-Aldrich, Co). Under bone
resorption conditions, calvarial bone organ cultures can
only undergo rapid osteoclast differentiation and bone
resorption with no capacity for osteoblast (OB) differenti-
ation and bone formation. This is a unique system in which
the absence of ascorbate (vitamin C) generates no possi-
bility for stable collagen synthesis and osteoblast differ-
entiation. In the absence of added stimulants for OC
differentiation such as cancer cells or PTH, the calvaria
also has no osteoclastic activity in the parietal bone and
hence, allows for clear interpretations of the biological
effects of added factors and drugs. A series of experiments
were carried out using clinically used bisphosphonate,
alendronate (ALN, Fosamax, Sigma-Aldrich Co.), at a
single low dose of 0.4 and 1.5 lM (250 ng and 1 lg/2 ml
media, respectively) or high dose of 20 lM (13 lg/2 ml
media) for either 4 or 8 days as well as repeat of such doses
every 2 days over 8 days. Additional experiments included
pre-treatment of calvaria with ALN first for 4 days fol-
lowed by the addition of PC3 cancer cells and of co-cul-
tures continued for an additional 4 days, or the reverse
order of treatment such as pre-incubation of the calvaria
with PC3 cells for 4 days followed by addition of ALN and
cultured for additional 4 days. Similar experiments were
performed using 2 nM osteoprotegerin (OPG, R&D Sys-
tems, Inc.) instead of ALN. Medium was changed every
2 days and bone/cell-exposed medium was then stored at
4 !C for chemical and biochemical analysis.
Bone formation model
For the bone formation model, the culture media described
above was supplemented with freshly made 150 lg/ml
(*1 mM) Na ascorbate (Sigma-Aldrich, Co) and used in
the absence or presence of PC3 cancer cells (2 9 105 per
tube), ALN and OPG. The same series of experiments
outlined above for the resorption model were repeated
using bone formation medium. The bone formation model
uses conditions in the presence of ascorbate that is an
essential factor for stable collagen synthesis, extracellular
matrix (ECM) formation and osteoblast differentiation [40,
41]. In the absence of FCS, our culture conditions favor
osteoblast differentiation and new bone formation pre-
dominantly that takes precedence over osteoclast differ-
entiation. Medium was changed every 2 days and the used
medium was stored at 4 !C for chemical and biochemical
analysis. The development of these live craniofacial bone
organ culture model systems in the absence of ‘‘fetal calf
serum’’ permitted clear observations of the impact of added
factors and drugs on bone biology under specific conditions
that prime the bone to individually respond with osteo-
clastic bone resorption or osteoblastic bone formation.
Quantitative calcium analysis of the media, tartrate
resistant acid phosphatase (TRAP), alkaline
phosphatase (ALP) activity of calvarial bones,
and histomorphometric observations in the absence
and presence of PC3 and MDA-MB-231 breast
cancer cells, PTH, ascorbate, ALN, and OPG
Medium calcium levels were analyzed using chromophoric
O-Cresolphthalein complex one (Sigma-Aldrich Co.)
reagent as described previously and normalized by the
calvaria dry weight [40, 41]. The TRAP and ALP enzyme
activity assays of calvarial bones as markers for osteoclast
and osteoblast activity, respectively, were carried out as
previously described and the final enzyme activity was
expressed in units of lmol/L-1 min-1/mg protein [40, 41].
Upon conclusion of each set of experiments at 4 or 8 days,
eight full calvaria were fixed in 10 % formalin, decalcified,
paraffin sectioned (5 lm), and stained with hematoxylin
and eosin (H&E, Boston Medical Center, Department of
Pathology core facility) for histological analysis. Eight
separate calvaria from each group were also prepared for
TRAP and ALP enzyme activity assays. An additional
eight full calvaria from each group were stained with
neutral red (NR, Sigma-Aldrich Co.) to visualize general
OCs activity, followed by counterstaining with 2 % silver
nitrate for global assessment of OC bone resorption.
Briefly, on the last day of experiment, 70 lg/ml NR
(Sigma-Aldrich Co.), was added to the media and live
calvaria were incubated for 45 min at 37 !C in roller tubes
followed by microscopic observations. The NR stained
calvaria were then washed with PBS, fixed in 10 % for-
malin overnight, and counter stained with 2 % silver nitrate
(Sigma-Aldrich Co.) for 20 min. Global histomorphomet-
ric analysis of calvarial bones for the degree of bone
resorption were recorded and the results were expressed as
% bone resorption areas for samples treated with PC3 alone
fixed at 100 % and the other treatment groups were com-
pared and calculated relative to this value. The detailed
Clin Exp Metastasis (2016) 33:563–588 565
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descriptions of the above procedures are outlined in our
previous studies [40, 41].
Quantitative evaluation of the tumor colony
on calvarial bones and cancer cell viability
from bone resorption and formation model systems
in the absence and presence of ALN
Co-cultures of calvarial bones with cancer cells in the
absence and presence of 5 lM ALN were carried out in
roller tubes using bone resorption and formation conditions
as described above. (a) In one set of experiments, the tumor
burden was evaluated quantitatively as a function of time.
From each experimental group, triplicate calvaria from the
cultures at 2, 8 and 14 days (with cumulative ALN levels
3.3, 10, and 20 lg, respectively) were obtained and vital
stained with NR for 1 h at 37 !C. The calvaria with tumor
colony established at 2, 8, and 14 days were subjected to
enzymatic dissociation/dispersion of tumors from the cal-
varial bone surface by incubating in new roller tubes
containing 2 ml DMEM organ culture media and 0.1 %
trypsin at 37 !C for 1 h using roller tube apparatus with 5
revolutions per min. The 2 ml medium was removed and
cells were pelleted in 2 ml Eppendorf tubes. The pelleted
cells were re-suspended in 0.1 ml of fresh medium and
microscopically observed and counted. (b) In a second set
of experiments, the calvarial bones with established cancer
colonies after 8 days were enzymatically treated to disso-
ciate cells from the bones and these isolated cancer cells
were re-suspended in 0.2 ml of medium. A portion (20 %)
of these cancer cells were incubated with NR for 1 h fol-
lowed by direct microscopic counting of the NR stained
vital tumor cells. The remaining 80 % of the tumor cells
without NR stain were re-seeded in 6 well culture plates
with 2 ml DMEM ? 10 % FCS and cultured under normal
2D conditions for 9 days with medium changes every
3 days to further define the viability of the calvarial bone
derived tumors. At the end of 9 days, the*70 % confluent
cells were vital stained with NR, collected after trypsin
treatment, and microscopically observed and counted.
Evaluation for the proliferation state of tumor
colony on the calvarial bones established under bone
resorption and formation conditions
The histological sections of the calvarial bones co-cultured
with PC3 cancer cells in the absence and presence of ALN
using bone resorption and formation conditions were
incubated with 50 mM Tris buffer, pH 7.4, containing
0.5 % Triton-100 for 2 h. The sections were then washed
three times with 1 ml of 50 mM Tris buffer, pH 7.4, fol-
lowed by incubation with 50 mM Tris buffer containing
5 % bovine serum albumin (BSA) and the primary human
anti-Ki67 (B126.1) (Abcam, Co) for 2 h at room temper-
ature. The sections were then washed three times with
50 mM Tris buffer followed by incubation with 1 lg of
green-fluorescent-tagged secondary antibody raised against
mouse IgG in goat (Alexa Fluor" 488 green dye, emis-
sion = 519 nm, absorption = 495 nm, Life Technology,
Inc) in Tris buffer for 2 h at room temperature. The sec-
ondary fluorescent antibody buffer was removed, histo-
logical sections were washed with Tris buffer and nuclear
fluorescence of the human cancer cells were observed
using Nikon TE2000-S fluorescent microscope.
Mass spectrometric analysis of the media
from calvarial bone organ cultures in the absence
and presence of PC3 cells, PTH, and ALN
Our calvarial bone organ culture conditions are devoid of
FCS, easily accessible, and represent a primary fluid in
direct contact with the tissue undergoing disease or phys-
iological/biochemical changes in response to cancer cells
and/or drug treatment. These conditions permitted us to
carry out mass spectrometric (MS) analysis of the medium
from the 3D-live bone cultures and cell layer of 2D min-
eralizing osteoblasts.
(i) MS analysis of the media from resorption model
system conditions—A total of 5 experimental groups with 4
calvaria per group were established as follows: (a) Un-
stimulated negative controls, cultured in the medium alone;
(b) Stimulated positive controls cultured in the presence of
10 gM PTH with calvaria; (c) PC3 cells cultured in med-
ium alone without calvaria; (d) PC3 ? calvaria only; and
(e) PC3 ? calvaria ? 20 lM ALN. The cultures were
carried out with DMEM media alternated between DMEM
supplemented with BSA and without BSA alternative days.
These culture conditions were maintained and repeated
over an 8 day period that provided four BSA-free condi-
tioned media per roller tube/calvaria, e.g., time points 2, 4,
6, and 8 days. Collected DMEM medium without BSA
were labeled and saved for MS analysis. For each calvaria
within the group (4 calvaria/group) in above experimental
sets (a)–(e), separate pooled media from each of the col-
lection time points were prepared (total 800 ll) using
100 ll medium from each time point representing the
whole culture period of 2, 4, 6, and 8 days. The 4 pooled
media of 800 ll, each representing individual calvaria
within each group [a total of 20 pools for sets (a)–(e)], were
then separately freeze dried, suspended in 0.5 ml of
50 mM NH4HCO3 and trypsin digested (5 lg) at 37 !C
overnight. Trypsin digests were freeze dried and dissolved
in 200 ll of buffer A 0.1 % TFA (trifluoroacetic acid)/H2O
followed by desalting using a C-18 reverse-phase Micro-
Spin column (The Nest Group, Inc., 45 Valley Road,
Southborough, MA). Bound peptides were eluted using
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200 ll of buffer B (80 % CH3CN/0.1 % TFA/H2O), freeze
dried, re-suspended 100 ll of 97.4 % H2O: 2.5 % CH3-
CN:0.1 % HCO2H followed by liquid-chromatography–
electrospray-tandem-MS (LC–ESI–MS/MS) analyses for
identification and semi-quantitation of the released bone
ECM proteins. The MS/MS data generated from the anal-
ysis of the aliquots from the above samples were searched
amongst a mouse-specific database for calvarial bone
proteins, a rat-specific database for the primary 2D min-
eralizing rat osteoblast proteins, and a human-specific
database for the PC3 cancer cell proteins using Uniprot
(Universal Protein Resources, Version 9.0) that combines
the data from Swiss-Prot (version 51) TreMBL (Version
34). The data were searched with specified dynamic
modification of 16 Da mass additions for hydroxylation of
the proline residues as these are the dominant (almost every
third residue) amino-acids within collagen based proteins
that represent major bone and mineralizing osteoblast ECM
components. Additional details and procedures of MS
analysis, data searches and criteria are detailed in our
previous work [41].
(ii) MS analysis of the media from formation model
system conditions—A total of 4 experimental groups with 4
calvaria per group were set up as follows: (a) Stimulated
positive control with 1 mM ASC cultured in the media
alone; (b) PC3 cells alone cultured in the media only
without calvaria ? 1 mM ASC; (c) PC3 cells ? cal-
varia ? 1 mM ASC; and (d) PC3 cells ? cal-
varia ? 1 mM ASC ? 20 lM ALN. The cultures were
maintained for 8-days period with medium changes and
subsequent sample handling/processing as detailed above
in (i) for the resorption system employed for MS analysis.
Biomineralization of cultured primary calvarial
osteoblasts in the absence and presence of ascorbate
and alendronate
Six wells culture plate (2x106 cells/well) of confluent
osteoblasts was used as each of the following treatments:
(a) medium ? 10 mM b-glycerophosphate ? 20 lg/ml
(100 lM) Na ascorbate; (b) medium ? 10 mM b-glyc-
erophosphate ? 20 lg/ml (100 lM) Na ascor-
bate ? 0.1 lM ALN; (c) medium ? 10 mM b-
glycerophosphate ? 20 lg/ml (100 lM) Na ascor-
bate ? 1 lM ALN and (d) medium ? 10 mM b-glyc-
erophosphate ? 20 lg/ml (100 lM) Na ascorbate ? 5 lM
ALN. Triplicate wells of each treatment condition were
incubated in the presence or absence of ALN as a function
of time, followed by quantitative calcium analysis to
determine the extent of mineral deposition in the cell layer.
Medium was removed and cell layers were collected in the
presence of 1 ml lysis buffer, 50 mM NH4HCO3, pH 7.8,
using a sterile cell scraper placed in Eppendorf tubes and
left on ice for 1 h. Insoluble cell debris, nucleus and the
mineralized ECM were then collected by bench top cen-
trifugation at 10,000 r.p.m. The pellet containing the ECM
and insoluble cellular components was then suspended in
0.5 ml of 0.1 M HCl and left at 4 !C overnight for disso-
lution of the Ca–P mineral. The HCl extracts were then
partially neutralized by the addition of sub-molar equiva-
lent of 1.0 M NaOH (40 ll, maintaining pH\ 4) and
centrifuged as above to pellet the insoluble ECM and cel-
lular components. Ten microliter of supernatant from each
triplicate sample treatments (a)–(d) were assayed for cal-
cium levels in duplicates as described above. The medium
calcium levels of these mineralizing primary osteoblasts
with different treatment groups were also determined to
correlate these values with calcium deposition levels. In
addition, ALP activity was measured as described above.
The insoluble ECM and cellular components (the pellet
after HCL extraction of the mineralized cell layers above)
of controls (a) and those derived from (d) were re-sus-
pended in 0.1 ml of 50 mM NH4HCO3, pH 7.8, and 10 ll
of the HCL soluble extract (partially neutralized) was
included in this suspension and subjected to trypsin (5 lg)
digestion overnight at 37 !C. Ten ll of such trypsin
digested samples above were suspended in 20 ll of 97.4 %
H2O: 2.5 % CH3CN:0.1 % HCO2H followed by LC–ESI–
MS/MS analyses to identify and semi-quantitate of the
major proteins as we recently described (41).
High-resolution two-photon confocal-microscopy
We have performed high-resolution 2-photon confocal
microscopy on calvarial bones and those in co-cultures
with PC3 cancer cells under both bone resorption and
formation conditions in the absence and presence of low
0.4 lM (0.25 lg) and 1.5 lM (1 lg) and higher 20 lM
(13 lg) ALN doses. Additional variants in such studies
were: (a) first perform cultures of bone in the absence and
presence of PC3 cells under resorption or formation con-
ditions for 8 days and then fixed in buffered 10 % formalin
for 5 days. The calvaria were washed twice with 1 ml of
50 mM Tris buffer, pH 7.4 and incubated in 0.5 ml of
50 mM Tris buffer, pH 7.4, containing 0.5 % Triton-100
for 2 h over ice. The calvaria were then washed three times
with 1 ml of 50 mM Tris buffer, pH 7.4, and suspended in
0.5 ml of the 50 mM Tris buffer containing 5 % bovine
serum albumin (BSA) and a primary human cytokeratin 7
antibody (mouse monoclonal [OV-TL 12/30], Abcam, Co)
overnight at 4 !C. The next day primary antibody was
removed and calvaria were washed three times with 1 ml
of 50 mM Tris buffer followed by incubation with 5 lg of
green-fluorescent-tagged secondary antibody raised against
mouse IgG in goat (Alexa Fluor" 488 green dye, emis-
sion = 519 nm, absorption = 495 nm, Life Technology,
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Inc) in 0.5 ml Tris buffer overnight at 4OC. The calvaria
were removed from the secondary fluorescent antibody
buffer, washed three times with Tris buffer and left in 0.5
mls of Tris buffer. On the day of 2-photon confocal
microscopy, the calvaria were labelled with blue-fluores-
cent DAPI (40,6-diamidino-2-phenylindole dihydrochlo-
ride, emission = 455, absorbance = 345, Sigma-Aldrich,
Co) at dilution of 1:1000 and 0.4 nmol of red-fluorescent
bisphosphonate (OsteoSense 680EX, Perkin-Elmer, Inc.)
for 1 h at room temperature. The calvaria were mounted on
confocal microscope dishes with Vectashield mounting
medium for Fluorescence (Vector Laboratories, Inc. Bur-
lingame, CA 94010) and three fluorescent emissions
namely green, blue, and red, were acquired at 2009
magnification and 5 lm intervals with total coverage of
100 lm distance for vertical scanning observations and up
to 180 lm distance for horizontal scanning observations
using high resolution 2-photon confocal microscope LSM
710 model. The acquired scanning images were analyzed
using Image J software program for generating merged
fluorescent spatial orientation of the PC3 cells relative to
bone cells and the mineralized bone matrix. The merged
images were viewed in 3D orientation and recorded as an
AVI movie providing continuous visualization of the cel-
lular characteristics/identity as a function of different
planes and relative to the mineralized bone matrix.
Statistical analysis
Chemical, biochemical, and quantitative histomorphometric
data are presented as mean ± S.D. The original data sets
found to have normal distribution using the Shapiro–Wilks
test were analyzed using parametric statistical analysis. The
statistical significance of the differences between controls
versus treatment groups and between different treatments
were evaluated using two-tailed, paired t test with unequal
variance. The differences between groups were considered
statistically significant for p\ 0.05.
Results
We have utilized an ex vivo live bone model system with
its multicellular periosteum/endosteum cell layers con-
taining hematopoietic and mesenchymal stem cells, min-
eralized bone matrix and its osteocytes which closely
mimic in vivo characteristics of bone [40, 41]. This model
system provided unique capabilities to study the intricate
details of cancer-bone interactions in relation to specific
bone remodeling stages in the absence and presence of
drugs under defined conditions. In the absence of fetal calf
serum (FCS), calvarial bones assume a stage of dormancy
and upon exposure to: (a) PTH or cancer cells only, the
bone responds with rapid osteoclast (OC) differentiation
and bone resorption, or (b) ascorbate only, generates a bone
response with rapid osteoblast (OB) differentiation and
osteoid formation.
Bone resorption model system
Impact of alendronate (ALN) on bone biology, osteoclast
differentiation/bone resorption, and bone
microenvironment-mediated resistance of PC3 and MDA-
MB-231 cancer cells to ALN treatment
(i) Qualitative histological, neutral red (NR), and silver
nitrate (NS) evaluation of cancer-bone interactions, during
bone resorption in the absence and presence of PC3 cells
and ALN—Fig. 1, Panel 1, illustrates the histological
observations of the untreated control group, and verified by
global neutral red (NR) and silver nitrate (SN) counter
staining with no osteoclast (OC) formation or bone
resorption in the parietal bone. In the presence of PC3 cells,
the calvarial bone endosteum was colonized by the cancer
cells generating a 3D solid tumor up to 12 multi-cell layers
and simultaneous induction of resorptive multinucleated
(MN) OC differentiation and extensive resorption, Fig. 1,
Panel 1b, and Supplemental Figure S1. The addition of
20 lM (13 lg/2 ml media) ALN led to complete inhibition
of OC differentiation and bone resorption, Fig. 1, Panel 1c.
Surprisingly, bone colonization by PC3 cells was unaf-
fected irrespective of a single or repeat dose exposure
every 2 days over the 8 day study period with cumulative
52 lg ALN. These data demonstrated that in a system with
no drug delivery limitations, PC3 cancer cells in a live
bone microenvironment are not dependent on the
cFig. 1 Co-cultures of mouse calvarial bones with PC3 and MDA-
MB-231 cancer cells under the bone resorption model condition in the
absence and presence of alendronate (ALN). Panel 1, H&E sections
of the parietal bone regions, NR, and NR/silver nitrate counter stained
calvaria: a control untreated calvaria; c co-cultures of calvaria ? PC3
cells in the presence of 20 lM ALN; d calvaria cultured in the
presence of ALN for 4 days, then co-cultured with PC3 cells;
e calvaria co-cultured with PC3 first for 4 days then with ALN; MN-
OSC multinucleated osteoclasts, RA bone resorption areas. Magnifi-
cations: H&E 9200, NR 9100, silver nitrate 925. TC tumor cells.
Panel 2, a cumulative calcium release into the media of co-cultures;
controls media (calvaria alone), PC3 only, PC3 ? ALN, 4 days PC3
only followed by ALN and 4 days ALN only followed by PC3;
b Quantitative TRAP activity under different culture conditions as
described above; c Quantitative global % bone resorption. Panel 3,
calvaria co-cultured with MDA-MB-231 breast cancer cells for
8 days: a–f H&E sections of the parietal bone regions, NR, and NR/
silver nitrate counter stained calvaria; g Cumulative calcium,
h quantitative TRAP activity and; i Quantitative global % bone
resorption. Microscopic magnifications were same as those used for
PC3 cells
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‘‘osteoclastic bone resorption’’ for bone colonization, pro-
liferation or survival. Furthermore, while a 20 lM dose
may in some cases be higher than or equivalent to the
clinically used cumulative doses (i.e., for osteoporosis
versus cancer patients), nevertheless they signify no direct
anti-cancer effect. Instead, these results revealed bone
microenvironment-mediated resistance of cancer cells to
ALN treatment. This was due to the capacity of the min-
eralized bone matrix of *12 mg live calvarial bone to
scavenge ALN, rapidly depleting free ALN for tumor
exposure. The extent of global bone resorption was defined
by silver nitrate (SN) counter staining and quantitative
histomorphometry that reflected massive bone resorption in
the presence of PC3 cells and was inhibited by ALN,
Fig. 1, Panel 1. To test the effects of pre-treatment on PC3
cell attachment to bone or colonization, a set of calvarial
bones were treated with two consecutive 13 lg ALN dose
regimens followed by co-culturing with PC3 cells for an
additional 4 days plus delivery of two additional ALN
doses. While pre-treatment inhibited bone resorption, there
was no effect on the PC3-bone colonization, Fig. 1, Panel
1d. Additional experimental variants were the use of a
single low 1.5 lM (1 lg) or high 20 lM (13 lg) dose over
the 8-day co-cultures. The data emphasize that ALN
inhibits bone resorption via direct impact on the macro-
phage differentiation to MN–OCs, Figs. 1 and 2. The effect
on mature resorptive MN–OCs was observed in co-cultures
of PC3 cells with bone first for 4 days in the absence of
ALN during a time period in which cancer-induced
osteoclastic bone resorption ensued followed by inclusion
of two doses of ALN. This maneuver showed some
superficial resorption lacunae and remnants/ghosts of OCs
which lacked NR stained nuclei, Fig. 1, Panel 1e.
(ii) Quantitative analysis for calcium release, tartrate-
resistant-acid-phosphatase (TRAP) activity, and global
histomorphometry of bone resorption in the absence and
presence of ALN—The results from histological, NR and
SN staining were supported by the quantitative changes in
medium calcium, TRAP activity, and global bone resorp-
tion areas, Fig. 1, Panel 2a–c. Comparing PC3 alone with
unstimulated controls revealed significant calcium release
confirming the PC3 activation of OC mediated bone
resorption that was inhibited by 70 % in the presence of
ALN. Pre-treatment with ALN followed by PC3 addition
showed a 60 % decrease in calcium release and insignifi-
cant change in treatment group in which PC3 cells were
included first followed by ALN, Fig. 1, Panel 2a. These
results were closely replicated by TRAP activity (ranging
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from 50 to 80 % reduction) and global bone resorption
histomorphometric data (70 % reduction), Fig; 1, Panel 2b,
c, respectively, and Supplemental Figure S2. The results
for the 4D PC3 ? ALN shown in Figs. 1, Panel 2a, 2b may
appear inconsistent. However, these are consistent with the
treatment order and the specific analysis performed. Fig-
ure 1, Panel 2a, represent cumulative calcium release
measured every 2 days in the medium, whereas Fig. 2b
represent TRAP enzyme activity of calvaria at the end of
8 days. Co-cultures of PC3 cells with bone for 4 days first
in the absence of ALN leads to osteoclast differentiation
and bone resorption releasing calcium. In contrast, when
the ALN was included after 4 days, the level of calcium
release decreased. Of note, the total cumulative calcium
over the 8 days, Fig. 1, Panel 2b, includes both the released
calcium in the first 4 days plus the reduced levels in the
next 4 days in the presence of ALN. Quite distinct from the
calcium release however, while there was osteoclasts in the
first 4 days of the cultures, after the addition of ALN and 4
additional culture days, the already differentiated
osteoclasts become impacted and there is no osteoclast
differentiation. The analysis for TRAP activity is per-
formed on such calvarial at the end of the 8 day culture.
The capacity of ALN to inhibit the differentiation of
macrophages to MN–OCs was further demonstrated in
cultures with simultaneous inclusion of 20 lM ALN and
parathyroid hormone, Fig. 2a, b. The above results estab-
lished that in a live ex vivo multicellular responsive bone
model ALN potently inhibits cancer- and PTH-induced OC
differentiation with an ultimate halt of bone resorption. The
data likely reflect a least-considered mechanism for bis-
phosphonate drug action in vivo; specifically, the effects on
osteoblast/osteocyte cells that are critical providers of both
M-CSF and RANKL, essential for macrophage differenti-
ation to MN–OCs. This was supported by co-cultures of
calvarial bones with PC3 cells and ALN under resorption
conditions for 3 days followed by a change of culture
conditions to a bone formation model at which time ALN
was replaced with ascorbate to stimulate bone to undergo
osteoblast differentiation and new osteoid formation. Such
Fig. 2 Histological and biochemical analysis in bone resorption
model in the presence of PTH and ALN and MS/MS analysis. H&E
sections of the parietal bone, NR and NR/silver nitrate stained
calvaria: a calvarial cultures ? PTH only; b calvarial cultures
? PTH ? ALN. Magnifications: H&E 9200, NR 9100, silver nitrate
925.MN-OSC multinucleated osteoclasts and TC tumor cells. Arrows
show black or dark gray areas no resorptions, or white and light gray
resorption areas (RA). Two sample Student’s t test indicated
statistical significance with p values noted within the figure;
c Identification and semi-quantification by LC–MS/MS of the bone
ECM components in the culture media (see also Table S1A)
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bone cultures pre-exposed to a single or repeat doses of
ALN were incapable of osteoblast differentiation and new
osteoid formation but exerted no detectable effect on PC3
cancer cells and bone colonization.
Our results with PC3 prostate cancer cells were repli-
cated with the MDA-MB-231 breast cancer cells in co-
cultures with bone organs in the absence and presence of
ALN. These data also revealed the colonization of the
bone by cancer cells with significant bone resorption that
is inhibited by ALN without a clear impact on the tumor
growth. The histological, biochemical and chemical
analysis of such cultures are elaborated in Fig. 1, Panel
3a–i.
(iii) Mass spectrometric (MS) analysis of the media
derived from calvarial organ cultures in the absence and
presence of PTH, PC3 cancer cells, and ALN—Based on
the above results further details of the response of bone to
the presence of PC3 cells and the impact of ALN on OC
differentiation/bone, resorption were investigated by liq-
uid-chromatography-tandem-mass-spectrometry (LC–MS/
MS) analysis of the medium harvested from controls and
experimental cultures. The LC–MS/MS peptide levels and
the identified bone matrix components through de-novo
MS/MS peptide sequences for calvaria alone and cal-
varia ? PC3 cells ? ALN reflect minimal release of
major bone matrix components via osteoclastic bone
resorption, compared to calvaria ? PTH and cal-
varia ? PC3 cells only, Fig. 2c and Supplemental Fig-
ure S3. Five distinct collagen chains were clearly
identified with their corresponding multiple peptides that
represented collagen type I a-1 and a-2 chains, collagen
type III a-1 chain, collagen type v a-1 and a-3 chains and
fibronectin, with collagen type I as the most abundant
component, Supplemental Table S1A. As expected, the
highest levels of major bone matrix proteins were found
in cultures of calvaria ? PTH and calvaria ? PC3 cells,
indicating significant bone resorption and the suppression
of this in the presence of ALN. The MS/MS analysis
identified vimentin in the media of control PC3 cells
alone in the roller tubes that is an intracellular/cell surface
bound ‘‘intermediate filament protein’’, indicating the
absence of survival capacity of these cells and their
degeneration in the organ culture medium in the absence
of FCS and live calvarial bone. This was confirmed by
direct cell count analysis that defined bone-mediated
survival of tumors. Surprisingly, LC–MS/MS analysis
also identified calvarial bone derived matrix metallopro-
teinase 3 (MMP-3, also known as stromelysin), Supple-
mental Table S1. While MMP-3 is capable of bone matrix
degradation including collagens, it also plays a critical
role in the cascade of pro-enzyme activation of other
MMPs during bone resorption.
Impact of osteoprotegerin (OPG) on bone biology, cancer-
bone interactions, osteoclast differentiation/bone
resorption
Our observations with ALN led us to investigate non-
bisphosphonate based inhibition of bone resorption with a
different mechanism of action than ALN. We have uti-
lized OPG naturally occurring RANKL decoy receptor
that inhibits OC differentiation by interfering with
osteoblast-RANKL and macrophage-RANK interaction
[42]. The mechanism of action of OPG is similar to the
humanized antibody against RANKL (Denosumab) which
is clinically used for osteoporosis and metastatic cancers
[43].
(i) Qualitative histological, neutral red (NR), and
silver nitrate (NS) evaluation of cancer-bone interactions
during bone resorption in the absence and presence of
PC3 cells, parathyroid hormone (PTH), and OPG—
Fig. 3, Panel 1a illustrates colonization of the calvarial
bones by PC3 cells generating a 3D solid tumor with
simultaneous induction of resorptive MN–OCs and
extensive bone resorption in the absence of OPG.
Addition of 2 nM OPG to such co-cultures completely
inhibits OC differentiation/bone resorption. Nevertheless,
the bone colonization by PC3 cells continued despite a
lack of MN–OCs or observable bone resorption (as
observed in the presence ALN), Fig. 3, Panel 1b. The
efficiency of OPG to inhibit the differentiation of mac-
rophages to MN–OCs in our bone model was further
demonstrated with PTH in the absence and presence of
OPG, Fig. 3, Panel 1c, d.
(ii) Quantitative analysis for calcium release, TRAP
activity, and global histomorphometry of bone resorption
in the absence and presence of PC3, PTH and OPG—The
results from histological, global NR and SN staining were
cFig. 3 Co-cultures of calvarial bones with PC3 and MDA-MB-231
cancer cells in the absence and presence of osteoprotegerin (OPG)
and PTH in the bone resorption model. Panel 1, H&E sections of the
parietal bone, NR and NR/silver nitrate stained whole calvaria;
a calvaria ? PC3 cells; b calvaria ? PC3 ? 2 nM OPG; c cal-
varia ? 10 nM PTH; d calvaria ? 10 nM PTH ? 2 nM OPG. Mag-
nifications: H&E 9200, NR 9100, silver nitrate 925. MN-OSC
multinucleated osteoclasts, RA bone resorption areas. Panel 2,
a cumulative calcium release from controls (calvaria alone) and co-
cultures of calvaria ? PC3 cells in the absence and presence of OPG;
b quantitative TRAP enzyme activity in calvarial bones under
different treatment culture conditions; c quantitative global % bone
resorption. Two sample Student’s t test indicated statistical signifi-
cance with p values noted within the figures. Panel 3, calvaria co-
cultured with MDA-MB-231 breast cancer cells for 8 days: a–f, H&E
sections of the parietal bone regions, NR, and NR/silver nitrate
counter stained calvaria; g cumulative calcium; h quantitative TRAP
activity. Microscopic magnifications were same as those used for PC3
cells
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supported by the quantitative change in medium calcium,
TRAP activity of calvarial bones, and global total bone
resorption using histomorphometry, Fig. 3, Panel 2a–c
and Supplemental Figure S2. Comparing PC3 ? calvaria
or PTH ? calvaria with those in the presence of OPG
showed *75 % reduction in calcium release, TRAP
activity, and total bone resorption area, reflecting signif-
icant inhibition of both OC differentiation and bone
resorption. The above results collectively established that
in a live ex vivo multicellular responsive bone model,
potent inhibition of cancer- and PTH-induced osteoclast
differentiation/bone resorption by OPG without effecting
cancer-bone colonization. The mechanism of action of
OPG includes the inhibition of osteoclast differentiation
via direct complexation with already synthesized RANKL
by osteoblasts/osteocytes, whereas inhibition by ALN
occurs via its impact on osteoblast/osteocyte biology and
RANKL synthesis.
The above studies with PC3 cells and OPG were also
carried out using MDA-MB-231 breast cancer cells. These
results closely resembled those obtained with PC3 cells
above, Fig. 3, Panel 3a–h.
Bone formation model
Impact of ALN on bone mesenchymal stem cells,
osteoblasts and bone microenvironment-mediated
resistance of PC3 and MDA-MB-231 cancer cells to ALN
and OPG in bone formation model systems
The critical observations above using bone resorption
systems led to our postulate that the physico-chemical
characteristics of bisphosphonates with high affinity to
bone mineral has a high potential for impacting the mes-
enchymal stem cells, osteoblasts (OBs), and osteocytes
intimately associated with the pre-existing mineralized
bone. We therefore carried out experiments under ‘‘bone
formation model conditions’’ to determine whether pre-
treatment of bone organs with ALN ? ASC prior to
addition of PC3 cells or simultaneous inclusion have an
impact on OB differentiation, new bone formation or bone
colonization. Figure 4, Panel 1a shows histological, NR
and SN data for control calvaria in the presence of ascor-
bate to stimulate OB differentiation and new osteoid for-
mation. In the presence of PC3 cells, the bone underwent
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OB differentiation as well as new osteoid formation instead
of bone resorption, Fig. 4, Panel 1b. However, those
exposed to ALN pre-treatment followed by the addition of
ascorbate or simultaneous inclusion of ALN with ascorbate
led to a surprising incapacity of bone to undergo OB dif-
ferentiation and new osteoid formation, Fig. 4, Panel 1c.
Despite this, PC3 cells still colonized the bone and pro-
liferated, forming a 3D tumor. Furthermore, the bone
endosteal cell layer showed diminished cellularity, circled
areas in Fig. 4, Panel 1c, e. Calcium analysis indicated
uptake of calcium reflecting new bone formation/mineral-
ization in ASC only groups. In contrast, PC3 ? ASC
showed a significant reduction in calcium release, whereas
addition of ALN in the remaining treatment groups led to a
either a further reduction in calcium release or frank cal-
cium uptake without new bone formation, Fig. 4, Panel 2a.
Consistent with these results, ALP activity was reduced by
*50 % in different PC3 treatment groups in the presence
of ALN as compared with ASC controls, Fig. 4, Panel 2b.
These data were supported by the MS analysis of the
medium from PC3-bone co-cultures under bone formation
conditions in the absence and presence of ALN. The
impact of ALN on OB differentiation/new osteoid forma-
tion was confirmed by the absence of the major bone
matrix components such as collagen type I a-1 and a-2
chains and fibronectin that are normally synthesized by
OBs, Supplemental Table S1B, and Fig. 4, Panel 2c.
Similar to the bone resorption models, direct cell counting
also showed instability of the PC3 cells in the absence of
live calvarial bone. PC3 cells remained floating in the
medium of which 50 % were non-viable within 2 days of
culture. At the end of 8 days, there were no observable PC3
cells remaining or attached to the roller tube surface. In
contrast, co-cultures with calvarial bones promoted PC3
cell survival, bone colonization, and viable PC3 cells on
the roller tube surface that was unaffected by the presence
of ALN. The results conclusively demonstrate the capacity
of PC3 cells to survive in the presence of live bone in
medium devoid of FCS and bone-mediated-resistance to
ALN exposure. These observations and results are also
applicable to other tumors such as MDA-MB-231 breast
cancers since experiments with these cancers cells revealed
similar results, Fig. 4, Panel 3a–d. The impact of ALN on
bone mesenchymal cells and OB differentiation under bone
formation conditions prompted us to investigate the effect
of OPG, an agent with a different mechanism of action than
ALN. In the presence of OPG and similar to ALN, there
were no effect on the PC3-bone colonization/interactions
or survival. However, and contrary to ALN under bone
formation conditions, OPG did not adversely impact the
bone mesenchymal cells and normal OB differentiation/
new osteoid formation continued, Fig. 5a–d. The same
series of experiments were also performed using MDA-
MB-231 breast cancer cells, Fig. 5e, f. Quantitative anal-
ysis for calcium and ALP activity supported the histolog-
ical observations whereby the addition of OPG with the
ASC supported OB differentiation, new osteoid formation
and calcium uptake, Fig. 5g, h.
Quantitative evaluation of the tumor colony on calvarial
bones and cancer cell viability from bone resorption
and formation model systems in the absence and presence
of ALN
Based on our extensive studies and important observations
described above, we further assessed the calvarial bone-
cancer colonization with respect to the quantitative tumor
burden and cancer cell vitality and viability. The established
bone associated tumor colonies under bone resorption and
formation conditions in the absence and presence of ALN as
a function of time, viz., at 2, 8, and 14 days, the tumor
colonies were found to be[90 % vital, Fig. 6, Panels 1, 2.
The bone associated cancer cells showed*2.5 fold increase
from day 2 to day 8 and remained constant at day 14.
Importantly, the level of tumor burden was the same for such
cultures with regard to bone resorption and formation con-
ditions with or without ALN. These results indicate a lack of
significant ALN effect on these parameters, Fig. 6, Panel 1.
The vital state of these bone derived cancer cells and the
increase in tumor burden between day 2 and day 8 of culture
is a result of the proliferation capacity of the initial bone
tumor colony that occurred within the first two days. This is
because the firstmedium change at day 2 essentially removes
all of the suspended cancer cells that were originally added to
the culture. Interestingly, the tumor burden remain about the
same between 8 and 14 days, suggesting that the most active
growth takes place between day 1 through 8 and reaches a
dynamic equilibrium of cancer load that the calvaria can
support. We have further investigated the viability of the
tumor colonies on the bone surface by re-seeding the bone
derived cancer cells established over 8 culture days in 6 well
culture plates under bone resorption and formation condi-
tions, with or without ALN. Under normal 2D culture con-
ditions, the bone derived tumor cells were fully viable and in
all cases reached *70 % confluency within 9 days. There
were no significant differences between bone derived cancer
cells from bone resorption or formation and absence or
presence of ALN in the number of cancer cells or vitality,
Fig. 6, Panel 3.
Evaluation for the proliferation state of tumor colony
on the calvarial bones established under bone resorption
and formation conditions
The results of our studies and specific conclusions were
further supported using human specific proliferation
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marker Ki67 antibody. A set of representative histological
sections reported in Figs. 1, 3, 4, and 5 derived from organ
culture experiments using 8 day cultures were evaluated
for cancer cell proliferation state. The data revealed pro-
liferating cancer cells of the bone colonies were generally
on the outer cancer cell surface layer, and not the inner
solid tumor bulk cells which were predominantly dormant
at day 8, Fig. 6, Panel 4. Importantly, these occurrences
were common to all of the different cancer-bone organ
culture conditions, as well as in the absence and presence
of ALN. These results are consistent with the quantitative
tumor burden levels observed above as a function of time,
Fig. 6, Panel 1. Although the cancer cells of the bone
colonies were all vital and viable most of the prolifera-
tion/growth on bone takes place between day 1 and day 8.
Effect of ALN on PC3 cancer and osteoblast (OB) cells
in 2D classical cell culture conditions
We evaluated the viability of the PC3 cancer and OB cells
by direct cell count in the presence of different ALN
concentrations as a function of time. At confluence, treat-
ment of PC3 cancer cells with increasing ALN concen-
trations (1, 30 and 100 lM), led to*50 % survival for the
first 5 days. In contrast, cells were predominantly detached
or dead after 10 days, Fig. 7a, c, d. Non-mineralized con-
fluent OBs were more sensitive to ALN and use of 30 lM
or higher ALN led to total loss of OBs within 5 days. At
1 lM ALN, *50 % of the OB cells were lost after 5 days
and[95 % died by day 10, Fig. 7b, e. Furthermore, if ALN
was introduced at the time of seeding, both PC3 and OB
cells exhibited minimal or no survival capacity. The critical
role of the mineral phase was investigated using OB cul-
tures undergoing biomineralization in the absence and
presence of 0.1, 1.0, and 5.0 lM ALN. At days 0, 5, 10, 15,
quantitative calcium analyses of such cell culture layers
showed significant mineral deposition between days 5 and
10. ALN-treated samples showed *2.5 fold higher cal-
cium deposition compared to control. However, while
controls continued to increase in calcium deposition
beyond 10 days, those with ALN exposure declined in a
concentration-dependent manner, Fig. 7f. These results
clearly outline the time-dependent effects of ALN and its
capacity to nucleate additional calcium accretion, a phe-
nomenon that was also observed under bone formation
conditions with calvaria ? PC3-ALN generating calcium
uptake with no new osteoid/bone formation, Fig. 4a.
Quantitative analysis for ALP activity, a marker for OBs,
followed the same pattern, with the exception that ALP
activity for all the cultures were similar up to day 10.
However, controls were elevated to[fivefold above those
exposed to ALN by day 15, Fig. 7g. The results suggest
that ALN affects both OB differentiation to a mineralizing
phenotype and their survival. The LC–MS/MS analysis of
mineralizing OB cell layers of controls and the 5 lM ALN
treated cultures showed significant reduction in the iden-
tified major ECM proteins/peptides by MS/MS after
5 days, Supplemental Figure S2 and Table S1C. Based on
the number of peptides identified, ALN treatment led to
[twofold reduction in collagen type I a-1 and a-2 sub-
units, fibronectin and vimentin, Fig. 7h. Identification of
vimentin was due to treatment of the collected mineralizing
cell layer with detergent for ALP activity measurements
that also released the intracellular/membrane bound
vimentin.
High resolution 2-photon confocal microscopy
for three-dimensional visualization of cancer-bone
interactions
We pursued the impact of ALN on bone biology and PC3
cells using high resolution 2-photon confocal microscopy.
Distinctions between the mineralized bone matrix, bone
cells and the PC3 tumor cells were achieved by specific
fluorescent-labels using red-fluorescent BP for the miner-
alized bone, green-fluorescent human cytokeratin-7 for
PC3 cells, and blue-fluorescent DAPI for cell nuclei. Fig-
ure 8, Panel 1a–f, shows co-cultures of PC3-bone under
bone formation conditions for 8 days first in the absence of
ALN, fixed in formalin, followed by labelling with the
above fluorescent moieties. The mineralized bone matrix
was highlighted with red-fluorescent BP, bone endosteal
cells as small oval isolated blue nuclei only distinct from
those of the larger nuclei surrounded by green fluorescence
in the cytoplasm of the tumor cells. Both the vertical,
Fig. 8, Panel 1a, b, and horizontal, Fig. 8, Panel 1c–f,
recordings of the calvarial bones were observed with
cFig. 4 Histological, NR, and silver nitrate staining in bone formation
model using co-cultures of calvarial bones with PC3 and MDA-MB-
231 in the absence and presence of ALN and sodium ascorbate. Panel
1, H&E sections of the parietal bone, NR and NR/silver nitrate stained
calvaria: a calvaria ? ASC (controls); b calvaria ? ASC ? PC3;
c calvaria ? ASC ? PC3 ? ALN; d calvaria ? ASC co-cultured
with PC3 for four days first then in the presence of ALN for an
additional 4 days; e calvaria ? ASC cultured in the presence of ALN
for four days first and then with PC3 for an additional 4 days. The
blue circles highlight endosteal cell layer with non-cellular collagen
matrix. Note the absence of MN-OSC and bone resorption in the
formation model. X, denotes fragile bone. Magnifications: H&E
9200, NR 9100, and silver nitrate 925. TC tumor cells, OB
differentiated osteoblasts. Panel 2, a cumulative calcium change in
media; b ALP enzyme activity of calvarial bones and; c identification
and semi-quantification of the bone ECM components in the culture
media, for co-cultures used in Panel 1 (see also Table S1B). Panel 3
calvaria co-cultured with MDA-MB-231 breast cancer cells for
8 days: a, b H&E sections of the parietal bone regions; c cumulative
calcium and; d quantitative ALP enzyme activity of calvarial bones.
Microscopic magnifications were same as those used for PC3 cells
576 Clin Exp Metastasis (2016) 33:563–588
123
Clin Exp Metastasis (2016) 33:563–588 577
123
distinct separation of the tumors from the mineralized bone
matrix by the endosteal cells with no tumors on the min-
eralized bone surface or inner endosteum cell layers. The
horizontal recordings were captured beginning from
endosteum and moving towards the periosteum. A 3D-
composite for bone formation was generated from contin-
ual recordings over a depth of 175 lm at 5 lm intervals
with 2009 magnification. In the bone resorption model,
similar vertical and horizontal recordings revealed distinct
OC resorption areas with loss of mineralized bone matrix
reflecting differences from those of bone formation con-
ditions, Fig. 8, Panel 2a–g. Despite those differences, the
topographical distribution of the PC3 tumors remained the
same as in the bone formation conditions. The PC3-bone
co-cultures in the presence of low *0.4 lM or 1.5 lM
(250 or 1 lg, respectively) and higher 20 lM (13 lg) ALN
doses, provided more details of these biological events
wherein PC3 tumors still colonized bone, while endosteal
bone cells in contact with the mineralized bone showed
deterioration. This was more pronounced in the bone for-
mation model, Fig. 9, Panel 1, confirming our initial his-
tological observations, Fig. 4. Further evaluation of the
PC3-bone colony in the absence and presence of ALN
under bone formation and resorption conditions revealed
strikingly different tumor cell behavior in the two respec-
tive bone remodeling stages. The outer surface of the tumor
colony showed a similar morphology (oval/round shape)
under both formation and resorption conditions. This
characteristic appearance remained the same for the
resorption model over the full depth of the tumor. How-
ever, in the bone formation model there were major mor-
phological adaptations with PC3 cells becoming more
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Fig. 4 continued
cFig. 5 Histological, chemical and biochemical analysis of co-
cultures of calvarial bones with PC3 and MDA-MB-231 cancer cells
using bone formation model in the absence and presence of OPG. a–
f H&E sections of the parietal bone of calvaria cultured with ASC in
the absence and presence of PC3 and MDA-MB-231 cells and OPG:
a calvaria ? ASC (controls); b calvaria ? ASC ? OPG; c cal-
varia ? ASC ? PC3; and d calvaria ? ASC ? PC3 ? OPG; e cal-
varia ? ASC ? MDA-MB-231; f calvaria ? ASC ? MDA-MB-
231 ? OPG. g Cumulative calcium change in media, and h ALP
enzyme activity of calvarial bones from used above. Two sample
Student’s t test indicated statistical significance with p values noted
within the figures. Magnifications: H&E 9200
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spread/elongated with significant extensions of their cel-
lular processes interconnecting with each other beyond
20 lm interior of the tumor colony, Fig. 9, Panel 1e and
Panel 2e. These distinct morphological adaptations in the
two bone remodeling stages were independent of ALN.
Our next observation within the mineralized bone matrix
was even more dramatic after PC3-bone co-cultures were
first grown in the absence of ALN, fixed and labelled with
fluorescent BP. These co-cultures showed well-defined
mineralized bone matrix with perfectly preserved osteo-
cytes, numerous canaliculi and blue DAPI labeled nuclei,
Fig. 9, Panel 1b and Panel 2b. However, these properties
became substantially altered if the live calvaria were first
cultured in the presence of low or high doses of ALN and
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Fig. 6 Quantitative tumor colony burden on calvarial bones, cancer
cell viability, and cancer cell proliferation state using bone resorption
and formation model systems in the absence and presence of ALN.
Panel 1, number of vital PC3 cancer cells on calvarial bones at 2, 8,
and 14 days of co-cultures using bone resorption and formation
conditions in the absence and presence of ALN. Panel 2, bone-
derived tumor cells after incubation with NR vital stain.
Magnification 9200. Panel 3, bone derived tumor cells re-seeded
and cultured in 6 well culture plates in the presence of 10 % FCS
under normal 2D culture conditions for 9 days, trypsin treated and
microscopically observed and counted. Panel 4, evaluation of cancer
cell proliferation state by human specific Ki67 antibody utilizing
histological sections of calvarial bones colonized by PC3 cells for
8 days with and without ALN
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fixed, followed by red-fluorescent BP labelling and DAPI.
In such cultures, the osteocytes lost their canaliculi pro-
cesses and nuclei, showed degeneration of their mineral
cocoon and mineralized bone matrix, Fig. 9, Panel 1d and
Panel 2d. The impact of mineral-bound ALN on osteocytes
was unexpected as this was observed at clinically relevant
dose levels. The loss of osteocytes by treatment with low
doses of either 250 ng or 1 lg BP concentrations per
12 mg calvarial bone was surprising, as these are compa-
rable to the bioavailable cumulative dose of *200 ng/
12 mg human trabecular bone from daily clinical oral dose
of ALN over 1 year, or *1.0 lg/12 mg trabecular bone
over 5 years in patients treated for osteoporosis. In com-
parison, 4 mg zoledronic administered to cancer patients
every 3–4 weeks would provide a cumulative dose of
*400 ng or *1.5 lg/12 mg human trabecular bone over
1 year or 3 years, respectively. Similarly, a single injection
of 90 mg pamidronate (closest analogue of ALN) in cancer
patients would lead to *550 ng or cumulative 6.5 lg per
12 mg human trabecular bone over a 1 year. The latter
cumulative dose translates to a single dose of *10.5 lM
equivalence of ALN in our 2 ml organ culture media.
Discussion
Bone provides an exceptional microenvironment that rep-
resents an oasis for cancer cell colonization and drug
therapy resistance of which many facets are not well
understood. Based on bone anatomical location and the
concept that cancer-bone metastasis and cancer survival
were bone resorption-dependent, bisphosphonates (BPs)
have been clinically used to prevent cancer-bone metastasis
and cancer-induced bone pathologies. However, both
clinical and scientific definitions of the fundamental phe-
notypic responses of cancer and bone cells to BP exposure
Fig. 7 2D-cell cultures of PC3 and primary rat osteoblasts (OB) in
the absence and presence of different concentrations of ALN:
a confluent PC3 cells treated with different concentrations of ALN
for 5 days; b confluent non-mineralized primary osteoblasts treated
with ALN; c cell viability of PC3 cells exposed to ALN for 5 days
and; d 10 days; e viability of primary OB cells exposed to 1 lM ALN
for 5 days and 10 days; f calcium accumulation in mineralizing OB
cell layer and; g ALP enzyme activity of OB cells in the presence of
low ALN doses as a function of time; h identification and semi-
quantitation by LC–MS/MS analysis of the ECM from mineralizing
OBs cultured in the absence and presence of 5 lM ALN for 5 days
(see also Table S1C)
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in a live bone microenvironment are unclear. Whilst it is
well known that bone resorption can be effectively inter-
rupted by BPs, the critical impact on bone mesenchymal/
stem cells, cancer cells, and cancer-bone interactions
within the live bone microenvironment are not well char-
acterized. The present study detailed multiple new insights
into the nature of cancer-bone interactions, bone-mediated
resistance of cancer cells to BP therapy including alen-
dronate (ALN, Fosamax) and the ‘‘deceitful’’ impact of
ALN on osteocytes/osteoblasts and mesenchymal stem
cells. First, we demonstrate bone resorption/formation-in-
dependence using ex vivo live cancer-bone interactive
models under bone resorption conditions where exposure
of live bone to cancer cells in a roller tube leads to rapid
cancer-bone colonization with subsequent activation of the
dormant bone cells to generate osteoclast (OC) differenti-
ation/bone resorption. Hence, the observed bone resorption
is post-cancer colonization and not a pre-requisite for
cancer-bone metastasis/colonization. The possibility that
the cancer cells first induce OC differentiation/bone
resorption followed by cancer-bone colonization can be
excluded as co-cultures in the presence of ALN with bone
without OC differentiation/bone resorption cancer cells
still colonize bone. Consistent with these observations, the
use of a naturally occurring RANKL decoy receptor
osteoprotegerin (OPG) with a different mechanism of
action also provided the same bone outcomes. Secondly, in
the bone formation model in which bone was activated to
undergo osteoblast (OB) differentiation/new osteoid for-
mation in the absence and presence of ALN and OPG and
despite the absence of any osteoclastic bone resorption, the
cancer cells continued to colonize the bone and developed
3D tumor in all cases. Thirdly, the unprecedented biolog-
ical qualities of bone that bequeaths this organ as target for
cancer-bone metastasis was revealed by the lack of survival
capacity of PC3 cells alone in the bone organ culture
medium and their achievement of remarkable survival
capacity in the presence of live bone. Our studies lead to
the compelling conclusions that tumor cells do not require
specific ‘‘bone resorption or formation remodeling stages
per se’’ for cancer-bone metastasis/colonization or cancer
cell survival. In contrast, others suggest that tumors colo-
nize bone due to their ability to: (a) use the ‘‘osteoblastic
niche’’ [44–47] or (b) use bone resorption to gain access to
a wealth of growth factors/cytokines for survival [14–17,
35].
The mechanism of amine-containing BP inhibition of
bone resorption has been universally accepted to be
through internalization of BP by mature multinucleated
(MN)-OCs. Clearly, this occurs when multinucleated
resorptive osteoclasts are present. However, our work using
live bones under resorption conditions and simultaneous
addition of ALN and PTH or cancer cells also dictates that
inhibition of bone resorption is achieved at the OC dif-
ferentiation stage. A mechanism of drug action that has
been elusive until the present study consider that the hidden
impact of BPs on osteocytes/osteoblasts are required to
clearly reveal multicellular interrelationships in a live bone
environment. The above results from our resorption model
were augmented by the bone formation models wherein
both sequential and simultaneous treatment regimens with
ALN and ascorbate resulted in the inability of calvarial
bones to generate osteoblastic bone formation. Under bone
formation conditions, ALN elicits degeneration of osteo-
cytes and mesenchymal stem cells when calvarial bones are
stimulated to undergo OB differentiation and the observed
inhibition of bone resorption by ALN is through its effects
on OBs/osteocytes/mesenchymal stem cells. These results
were supported by the high-resolution 2-photon confocal
microscopy 3D images that highlight the distinct topo-
graphical distribution of ALN within the mineralized bone
matrix with the endosteal cell layer acting as a barrier
between the tumor cells and the mineralized bone matrix.
The regulation of OC function by ALN at the level of
differentiation reflects the impaired functions of OBs/os-
teocytes that are responsible for the local synthesis of
RANKL and CSF essential for the differentiation of
bFig. 8 2-Photon high-resolution confocal 3D microscopy of the
calvarial bones co-cultured with PC3 cells under ‘‘bone formation and
resorption’’ conditions in the absence of ALN. Panel 1, confocal
microscope recordings of the bone-PC3 co-cultures under ‘‘bone
formation’’ conditions in the absence of ALN, fixed in formalin and
fluorescent labelled with BP (red), human cytokeratin-7 (green) and
DAPI (blue): a vertical/edge recording with visible light transmit-
tance merged with red-fluorescent BP and; b fluorescence composite
of mineral-bound BP, human cytokeratin-7 of tumor cells and DAPI
nuclear stain of vertical recording. The white dotted lines non-
mineralized new osteoid lacking red-BP label, see Fig. 4a, b; c Partial
side view of 3D-orientation of the PC3-bone interactions; d 90! side
view of the 3D-orientation in c showing the 60 lm thick PC3 tumor
cells (green) on bone endosteum (blue) and mineralized bone matrix
(red). e Face view from endocranial side of the 3D-orientation in c;
f Face view of the 3D-orientation in c at a depth of 120 lm beyond
the surface of the PC3 cells towards the mineralized bone showing
blue endosteal bone cells and red mineralized bone surface. Panel 2,
confocal microscope recordings of the bone-PC3 co-cultures under
‘‘bone resorption’’ conditions in the absence of ALN, fixed in
formalin and fluorescent labelled with BP (red), human cytokeratin-7
(green) and DAPI (blue): a vertical/edge recording with merged
visible light and red-fluorescent BP and; b fluorescence composite of
mineral-bound BP, human cytokeratin-7 of tumor cells and DAPI
nuclear stain; c Horizontal recording with merged visible light and
red-fluorescent BP showing the mineralized bone matrix and bone
resorption areas lacking mineral; d The same view as in c with
merged blue (DAPI) and red (BP) fluorescence; e 90! side view of
3D-orientation of the horizontal recordings; f face view of the
horizontal 3D-composite recording from endocranial side of the 3D-
orientation in e with PC3 cells on the endosteum surface and the
mineralized bone with resorbed bone (RB); g higher power view of
PC3 cells
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macrophages to bone resorbing OCs. The use of OPG with
different mechanisms of action via complex formation with
RANKL showed no adverse impact on OB differentiation
or new osteoid formation. In ex vivo live bone organ cul-
ture models without drug delivery limitations, cancer cells
were completely resistant to ALN action due to rapid drug
removal by the mineral-phase. Clearly, such occurrence is
directly applicable to both in vivo pre-clinical animal
studies and human clinical scenario. This phenomenon
represents a classic case of bone microenvironment-medi-
ated resistance of cancers to BP drug therapy in which
tumors are preserved by bone at the expense of its own
integrity. The pharmacokinetics of BPs in a clinical setting
clearly support this hypothesis since systemic BPs become
mineral bound within hours of introduction and their very
low ‘‘dissociation constants’’ with the mineral phase pre-
clude their direct therapeutic actions against cancer cells
despite high or repeated dosing. However, osteocytes
trapped within a cocoon of mineral and the bone endosteal/
periosteal cells in direct contact with the mineralized bone
surface are the immediate residents of the bone mineral.
This unique bone architecture and the location of tumors on
the endosteal cell surface isolate them from the mineral-
ALN composite, thereby limiting their exposure. These
studies generate the compelling conclusion that excludes a
potential direct anti-cancer action of BP therapy in a live
bone microenvironment that can be expected even at doses
that far exceeds the maximum dose possible for human
use. The properties of the live ex vivo 3D bone
microenvironment that closely mimic the in vivo condition
are not replicated in in vitro studies using 2D conventional
cell cultures wherein tumor cells behave in a totally dif-
ferent manner towards the action of drugs including ALN.
In the 2D cell cultures, non-mineral containing confluent
PC3 and OB cells were sensitive to ALN treatment at low
and high doses in a time-dependent manner and had
minimal survival capacity if ALN was included during the
seeding stage. The mineral phase role was investigated
using mineralized OB cell cultures that did not change the
sensitivity of OBs to ALN due to generation of a high
density ALN-mineral composite directly in contact with
OBs, a phenomenon consistent with our live bone
microenvironment observations. The pre-clinical animal
models using zoledronic acid or dimethyl-pamidronate for
cancer-bone metastasis showed varying and conflicting
outcomes with respect to tumor burden even at extreme
doses [4, 48, 49]. Similarly, high dose application in
cancer patients led to confounded outcomes of clinical
studies with some reporting benefits whereas others did
not [10, 12, 35–39, 50–52]. Based on these prior results
and the current data, there are major conceptual interrog-
ative issues that arise regarding the direct anticancer drug
action of BPs: (i) if ALN clearly has no effect on cancer
cells in the models used here, then it is unclear why
consistently negative result were not obtained in various
pre-clinical and clinical studies and; (ii) if BPs/ALN
worked as a direct anticancer drug, it is also unclear why
consistently positive results were not obtained in various
pre-clinical and clinical studies. The answers to these
questions might result from inconsistencies in: (a) nor-
malized dose usage, (b) the length of time for bone out-
come analysis due to the time-dependence of BP impact
and; (c) different analytical methods used for evaluating
drug action. Our studies reveal that clinically relevant low
or high BP doses generate high density mineral-BP com-
posites are capable of impacting OBs/osteocytes and
mesenchymal stem cells as a function of time and cumu-
lative dose. This latter phenomenon is correlative with the
clinical development of ‘‘osteonecrosis of jaw (ONJ)’’:
(a) using i.v. delivery of pamidronate in cancer patients
with average minimum cumulative dose of 2220 mg and a
mean event time of 2.8 years and; (b) oral delivery of
ALN and residronate for osteoporosis with bioavailable
cumulative dose of 150 mg and a mean event time of
4.6 years [53]. Our calculations from the above cumula-
tive doses for ONJ development for ALN/residronate and
pamidronate translates to *1 lg/12 mg and *15 lg/
12 mg human trabecular bone, respectively and is highly
consistent with our findings using an ALN dose ranging
between *1.0 lg and 52 lg/12 mg calvarial bone.
bFig. 9 2-Photon high-resolution confocal 3D microscopy recordings
of the live calvarial bone co-cultured with PC3 cells under ‘‘bone
formation and resorption’’ conditions in the absence and presence of
ALN: panel 1, a, b live calvarial bones first cultured in the absence of
ALN, fixed in formalin, and fluorescent labelled with BP, human
cytokeratin-7 and DAPI, showing mineralized bone with defined
osteocyte morphology, blue nuclei and their canaliculi. Bone-PC3
tumors 90! side view of 3D-orientation from the horizontal recordings
from periosteum side (a), and horizontal view (b); c, d calvaria ? PC3
cells co-cultured in the presence of ALN, 90! side view of 3D-
orientation from the horizontal recordings beginning from the
endosteum side and the horizontal view, respectively; d mineralized
bone with matrix mineral deterioration, loss of osteocyte nuclei and
their canaliculi. Green and yellow arrows osteocyte nuclei and
canaliculi, respectively; e PC3 cells on the endosteal cell surface with
morphological adaptation displaying elongation and extended inter-
cellular processes in bone formation model. Panel 2, a, b live
calvarial bones first cultured in the absence of ALN, fixed in formalin,
and fluorescent labelled with BP, human cytokeratin-7 and DAPI.
a Bone-PC3 tumors 90! side view of 3D-orientation from the
horizontal recordings beginning from the endosteum side and;
(B) horizontal view within mineralized bone matrix; c, d cal-
varia ? PC3 cells co-cultured in the presence of ALN; 90! side view
of 3D-orientation from the horizontal recordings beginning from the
endosteum side and the horizontal view, respectively; d mineralized
bone with matrix mineral deterioration, loss of osteocyte nuclei and
their canaliculi. Green and yellow arrows osteocyte nuclei (blue) and
canaliculi, respectively; e PC3 cells with distinct round/oval mor-
phological adaptation in the resorption model
Clin Exp Metastasis (2016) 33:563–588 585
123
The observation that PC3 cancer cells failed to survive
in culture medium in the absence of calvarial bones is
distinct from the drug resistance phenomenon detailed
above. MS/MS analysis of the medium from such cultures
identified that ‘‘vimentin’’, an intracellular/cell surface fil-
ament network protein, was released into the media of PC3
cells cultured alone in roller tubes and resulted in cell
degeneration was supported by direct cell counts and PC3
cell viability. In contrast, similar analysis of PC3-bone co-
cultures showed no vimentin release during their survival/
stability state. The identification of vimentin as a marker
for ‘‘epithelial to mesenchymal transition (EMT) [54]’’ in
PC3 cancer cells supports the clinically observed
osteosclerotic outcome of prostate cancer-bone metastasis
and reflects their inherent mesenchymal phenotype char-
acteristics. The MS/MS data from cancer-bone interactive
systems also identified matrix metalloproteinase-3 (also
known as stromelysin) as the most abundant MMP syn-
thesized and secreted by the calvarial bones in response to
PTH and PC3 cells in bone resorption models. This is
consistent with up-regulation of the calvarial bone MMP-3
gene expression observed in our previous studies as a result
of PC3-bone interactions [40]. Other MMPs such as MMP-
2 and 9 have been implicated in cancer-bone metastasis, an
invasive phenotype, and in cancer cell proliferation.
However, those observations refer strictly to the expression
of MMP-2 and 9 by PC3 cells [55]. Our discovery of
MMP-3 in abundant levels generated by bone in response
to PC3 cancer cells has major implications within the
context of cancer-bone metastasis and the interrelationship
between the local bone microenvironment and cancer
biology. This is due to direct association of MMP-3 with
‘‘EMT’’ and ‘‘induction of genetic instability and malig-
nant transformation’’ with increased mobility and inva-
siveness [56, 57]. Taken together, these data provide a new
rational for understanding the poorly delineated phenom-
ena that cancer-bone metastasis, once established marks:
(a) the terminal stage of an untreatable disease and; (b) the
stage for generating a chemotherapy-resistant phenotype
that promotes the imminent re-emergence of tumors. These
outcomes can be linked to the bone derived MMP-3 that
transforms tumors within the bone microenvironment to a
more malignant and chemotherapy resistant phenotype
after bone colonization.
Conclusion
This study offers unique insights into the interplay between
cancer stem cells and osteocytes/osteoblasts and mes-
enchymal stem cells in a live, 3D cancer-bone interactive
model. Our studies suggest paradigm-shifting conclusions.
We suggest that a direct anti-cancer effect of BPs in the
bone microenvironment or in vivo is not possible and that
cancer-bone metastasis is independent of the bone remod-
eling stage. The bone microenvironment-mediated survival
of cancer cells after BP exposure occurs at the expense of
accumulating BP within the bone mineral phase that
adversely impacts osteocytes and mesenchymal progenitor
cells. Our discovery of abundant bone MMP-3 generated in
response to PC3 cancer cells provides a new rational for
understanding chemotherapy-resistant cancer phenotypes
and the re-emergence of tumors after chemotherapy treat-
ment. These occurrences are due to transformation of
metastatic cancer cells to more malignant and invasive type
within the bone microenvironment. This may suggest that
the bone homing circulating cancer cells may not represent
a select sub-population but rather they might evolve once
exposed to the bone microenvironment. In addition to
extensive data presented herein for PC3 prostate cancer
cells, relevant data presented for MDA-MB-231 breast
cancer cells supports the general application of our findings
to other tumors. Despite the highly deceptive nature of the
biology of cancer-bone metastasis/interactions, the present
investigations at the ‘‘phenotypic’’ level culminated in a
series of new insights. These insights suggest novel ave-
nues for examining commonly used chemotherapeutic drug
actions at a phenotypic level and the development of new
strategies/drugs with direct clinical implications for
approaching metastatic bone tumors. Conceptual advances
may stimulate translational interest for cancer-bone inter-
actions and cancer cell behavior in relation to bone biology
and the critical roles played by osteocyte/osteoblast cells.
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a b s t r a c t
Egg yolk phosvitin is one of the most highly phosphorylated extracellular matrix proteins known in
nature with unique physico-chemical properties deemed to be critical during ex-vivo egg embryo
development. We have utilized our unique live mouse calvarial bone organ culture models under
conditions which dissociates the two bone remodeling stages, viz., resorption by osteoclasts and
formation by osteoblasts, to highlight important and to date unknown critical biological functions of
egg phosvitin. In our resorption model live bone cultures were grown in the absence of ascorbate and
were stimulated by parathyroid hormone (PTH) to undergo rapid osteoclast formation/differentiation
with bone resorption. In this resorption model native phosvitin potently inhibited PTH-induced
osteoclastic bone resorption with simultaneous new osteoid/bone formation in the absence of ascorbate
(vitamin C). These surprising and critical observations were extended using the bone formation model in
the absence of ascorbate and in the presence of phosvitin which supported the above results. The results
were corroborated by analyses for calcium release or uptake, tartrate-resistant acid phosphatase activity
(marker for osteoclasts), alkaline phosphatase activity (marker for osteoblasts), collagen and hydroxypro-
line composition, and histological and quantitative histomorphometric evaluations. The data revealed
that the discovered bioactivity of phosvitin mirrors that of ascorbate during collagen synthesis and the
formation of new osteoid/bone. Complementing those studies use of the synthetic collagen peptide
analog and cultured calvarial osteoblasts in conjunction with mass spectrometric analysis provided
results that augmented the bone organ culture work and confirmed the capacity of phosvitin to stimulate
differentiation of osteoblasts, collagen synthesis, hydroxyproline formation, and biomineralization. There
are striking implications and interrelationships of this affect that relates to the evolutionary inactivation
of the gene of an enzyme L-gulono-γ-lactone oxidase, which is involved in the final step of ascorbate
biosynthesis, in many vertebrate species including passeriform birds, reptiles and teleost fish whose egg
yolk contain phosvitin. These represent examples of how developing ex-vivo embryos of such species can
achieve connective tissue and skeletal system formation in the absence of ascorbate.
& 2013 Elsevier Inc. All rights reserved.
Introduction
In the past two decades there has been an emergence of
conceptual developments in the area of extracellular matrix
(ECM) component-mediated influence on cellular function and
behavior. ECM proteins have the capacity to play major roles in
general tissue morphogenesis by imposing regulatory effects on
cell growth and differentiation (Ingber, 1993; Mizuno et al., 2000;
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Decup et al., 2000; Six et al., 2002; Wang et al., 2006; Gordon et al.,
2007). Such biological processes are achieved, in general, through
what is known as “outside-in” signaling via interactions between
ECM proteins and cell surface receptors, in particular the integrins
(Hynes, 1992; Albelda and Buck, 1990; Blobel and White, 1992).
One specific field in which the ECM non-collagenous phosphopro-
teins have been extensively studied is normally mineralizing
tissues such as bone (Fisher et al., 1983; Franzen and Heinegard,
1985; Salih et al., 1996a, 1996b, 1997, 2002; Salih and Fluckiger,
2004; Glimcher et al., 1979; Boskey et al., 2008) and dentin (Veis
et al., 1972; Veis and George, 2008; He et al., 2005; Jadlowiec et al.,
2006). In addition to their involvement in biomineralization and
its regulation (Mizuno et al., 2000; Decup et al., 2000; Six et al.,
2002; Gordon et al., 2007; Salih et al., 2002; Boskey et al., 2008;
Endo and Glimcher, 1989; Hunter and Goldberg, 1993; Boskey
et al., 1993), bone ECM phosphoproteins are implicated in mod-
ulating cellular function and behavior of bone cells (Gordon et al.,
2007; Boskey et al., 2008; Stubbs III et al., 1997; Denhardt and
Noda, 1998; Chambers et al., 1986; Davies et al., 1989; Reinholt
et al., 1990; Ross et al., 1993; Helfrich et al., 1992) via promoting
cell adhesion, motility and transmembrane signaling. The cova-
lently-bound phosphate groups on these proteins have been
shown to play a direct role in the nucleation of Ca-P crystals
during biomineralization (Salih et al., 2002; Glimcher, 1989) as
well as in cell attachment (Ek-Rylander et al., 1994; Katayama
et al., 1998; Andersson et al., 2003). Other studies demonstrated
the effects on cellular activity and behavior such as osteoblast
differentiation and bone formation both in vitro and in vivo by
bone sialoprotein (BSP) (Mizuno et al., 2000; Zhou et al., 1995;
Cooper et al., 1998). The biological functions of ECM phosphopro-
teins continue to evolve with new discoveries such as the
influence of the covalently-bound phosphates on signal transduc-
tion (outside-in signaling). For instance, we have determined
selective/differential transmembrane protein tyrosine phosphory-
lation and down-stream differentially expressed genes in response
to purified BSP and its different phosphorylation states. These
observations were augmented with studies using our unique live
mouse neonatal calvarial bone organ cultures stimulated by
parathyroid hormone (PTH) to undergo osteoclastic bone resorp-
tion which was inhibited by added BSP forms (Curtin et al., 2009).
ECM phosphoproteins are not restricted only to bone and dentin
and occur in the egg yolks of birds, reptiles and fish which contain
an abundant highly phosphorylated protein known as phosvitin
(Allerton and Perlmann, 1965; Van het Schip et al, 1987). Unlike the
bone ECM phosphoproteins known to contain ∼10–15 mol of P-Ser/
P-Thr residues/mol of protein (Salih et al., 1996b, 1997, 2002; Salih
and Fluckiger, 2004), phosvitin possesses extraordinary levels of
covalently-bound phosphates with an estimated ∼120 sites of
phosphorylation (Allerton and Perlmann, 1965). Phosvitin has been
shown to have biological functions common with those of bone
phosphoproteins such as a very strong divalent metal binding
capacity, particularly iron and calcium (Grogan and Taborsky,
1986; Hegenauer et al., 1979)), as well as calcium phosphate crystal
nucleation property (Onuma, 2005). However, there are exceptional
properties of phosvitin not shared with bone phosphoproteins.
These include powerful antioxidant/reducing activities, and anti-
bacterial effects (Ishikawa et al., 2004; Katayama et al., 2006; Sattar
Khan et al., 2000). Phosvitin binds to ferric ion (Fe3+) very strongly,
whereas it forms weak complexes with the ferrous ion (Fe2+) and is
capable of converting one oxidation state to another (Taborsky,
1963). It has been shown that phosvitin can effectively inhibit
Fe2+- and Cu2+-mediated oxidation of phospholipids (Lu and Baker,
1986) and inhibits Fe2+-catalyzed hydroxyl radical (OH) production
in Fenton reaction system (Ishikawa et al., 2004). These properties
suggest that phosvitin has a unique spectrum of biological functions
during egg yolk embryo development. Furthermore, the above
chemical characteristics of phosvitin overlap with those of ascor-
bate (vitamin C) which as an antioxidant/reducing agent has major
roles in a number of importance physiological reactions such as
collagen synthesis/stability, iron metabolism and immunity (Padh,
1990). Based on the significance of collagen as the most abundant
protein and its wide distribution throughout vertebrate tissues,
organs and skeletal system, it is surprising that many species have
lost the capacity to synthesize ascorbate. These include primates
(Burns, 1957; Pauling, 1970), guinea pigs (Zilva, 1936), teleost fish
(Dabrowski, 1990), bats (Birney et al., 1976) and passeriform birds
(Chaudhuri and Chatterjee, 1969). In these species the lack of
appropriate ascorbate supplementation in their diet adversely
impacts multiple metabolic biochemical processes with eventual
development of scurvy. The inability to synthesize vitamin C is due
to a deficiency in L-gulono-γ-lactone oxidase (GLO) which is the
enzyme responsible for catalyzing the last step of ascorbate
biosynthesis (Burns, 1957).
Despite its discovery more than half a century ago, phosvitin
has not been characterized with respect to its biological functions
related to connective tissue and bone formation. This is most likely
due to the lack of an appropriate experimental model that could
be used which can reveal clearly such bioactivity with interpre-
table data and without major uncertainties or complications that
the observed effects are solely due to the added biomolecule. For
example common in vivo animal models such as mice would have
multiple metabolic problems if ascorbate were eliminated from
the diet but mice have retained the capacity to synthesize
ascorbate. It is possible to generate knock-out mice lacking the
capacity to synthesize ascorbate, however, such an approach is
also associated with the problem that the absence of ascorbate
leads to major adverse general physiological problems that could
complicate the clear interpretation of the final observed experi-
mental outcome. One of the unique chemical characteristics of
phosvitin is its powerful antioxidant/reducing agent capacity
which mirrors that of ascorbate. Importantly, ascorbate as an
antioxidant/reducing agent is an essential biomolecule during
collagen biosynthesis and hence, formation and maintenance of
connective tissue, organs and skeletal system. This led to our
postulate that phosvitin should facilitate collagen synthesis and
bone formation in the absence of ascorbate. We have utilized our
unique and well established ex-vivo live neonatal mouse calvarial
bone organ culture model systems in the absence and presence of
phosvitin to reveal its potential biological activity in connective
tissue and bone biology. Using conditions that separate the
different bone remodeling stages, viz., osteoclastic bone resorption
or osteoblastic bone formation model systems highlighted the
unique and to date unknown biological properties of phosvitin
with important scientific and evolutionary implications. We report
on our findings that give rise to critical unknown physiological
functions of phosvitin in the synthesis of stable collagen, forma-
tion of new osteoid and general connective tissue and bone
organogenesis with major scientific and evolutionary impact.
Materials and methods
Live mouse calvarial bone organ cultures and effect of native
phosvitin on bone remodeling
Calvaria from 5–7 day old neonatal CD-1 mice (Charles River
Laboratories, MA) were dissected under sterile conditions. Calvaria
were cut in the occipital lobe, and partially in the frontal lobe, to
produce a trapezoid structure and washed briefly in culture
medium. The live bone organ culture medium consisted of
Dulbecco's modified Eagle medium (DMEM) supplemented with
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bovine serum albumin (BSA), fraction V (5 mg/ml, Sigma Co.),
100 U/ml penicillin and 100 μg/ml streptomycin and 250 ng/ml
amphotericin B (Gibco, Grand Island, NY) with “no” fetal calf serum
(FCS) or ascorbate. This approach permits studies to be performed
with remodeling events dissociated whereby addition of 10 nM
parathyroid hormone (PTH) the calvarial bone undergoes predo-
minantly osteoclastic bone resorption. For bone formation the
culture media was supplemented with 1 mM sodium ascorbate
(Sigma, Co.) instead of PTH. These models were developed and
used recently in our other studies where detailed methodologies
were described (Curtin et al., 2009, 2012).
Chicken egg yolk native phosvitin was purchased from (Sigma-
Aldrich, Co.) and its purity was tested by SDS-PAGE and highly
sensitive mass spectrometric MS/MS analysis of the trypsin
digests. (a) 30 mg of native phosvitin was run using a 12% SDS-
PAGE however due to its high phosphorylation states phosvitin
cannot be visualized by Coomasie blue, but can be readily detected
using “Stains all” (Salih et al., 1996b). Native phosvitin stained a
40 kDa band (∼80%) with two other minor bands at 90 kDa (∼20%)
and 140 kDa (o2%). In gel trypsin digestion of the excised bands
corresponding to the above molecular weight bands was followed
by MS/MS analysis for identification. (b) A second sample of native
phosvitin 1 mg in 50 mM ammonium bicarbonate was digested
using 3% (w/w) trypsin!2 over 24 h followed by repeating this for
a second time. Overall, 12% trypsin was used during 48 h incuba-
tion at 37 1C, which is much higher than that commonly used
which is 2% (w/w) trypsin once overnight. This is because
phosvitin is resistant to proteolytic action due to its extensive
phosphorylation. Aliquots of the digested samples were processed
for tandem-mass-spectrometric analysis (MS/MS sequence analysis)
and the collision-induced-dissociation fragmentation sequence data
was searched against the chicken database using specified dynamic
mass modification of 80 Da on Ser/Thr residues (for phosphoryla-
tion) to identify both the phosphorylated and non-phosphorylated
peptides that may belong to phosvitin or any other protein
unrelated to phosvitin. The global search of the MS/MS sequence
data against the chicken and bird databases identified more than 76
phosphopeptides/peptides all belonging to chicken phosvitin with
no identification of peptides belonging to any other protein within
these databases. These results clearly indicated that the samples of
phosvitin used were remarkably pure.
Effect of chicken egg yolk native phosvitin in bone resorption model
The effect of native phosvitin on osteoclast formation and bone
resorption was evaluated using mouse calvarial bone organ cul-
tures stimulated by PTH to undergo rapid osteoclastic bone
resorption in the absence and presence of native phosvitin. Four
groups, 6 calvaria per group, for a total of 24 calvariumwere set up
as follows: (a) unstimulated controls (negative control); (b) bone
resorption model, stimulated by 10 nM parathyroid hormone
(residues 1–34 bovine PTH, positive control) in DMEM–BSA media;
(c) 10 nM PTH+150 nM native phosvitin (5 μg/ml in DMEM–BSA);
(d) 10 nM PTH+1 mM ascorbate (200 mg/ml); and (e) 10 nM PTH
+15 mM phospho-amino acids individually P-Ser, or P-Thr or P-Tyr.
The concentration of the phospho-amino acids was adjusted to be
15 mM in order to equate to the total number of P-Ser/P-Thr
residues that may be present per mole of native phosvitin that
has been reported in the literature, as ∼100 mol P-Ser/P-Thr/mol of
protein (Allerton and Perlmann, 1965). The concentration of
phosvitin used in the present study was based on the normally
expected physiologically relevant concentrations of bioactive
molecules in vivo as well as our other studies using ECM bone
phosphoproteins with the calvarial bone organ culture system
(Curtin et al., 2009). The calvaria were placed on stainless steel
grids such that the bone was elevated and the media formed a thin
film over the periosteal surface and incubated at 37 1C with 5% CO2
in a tissue culture incubator (NAPCO, Winchester, VA) for 10 days,
as previously described (Curtin et al., 2009). The media was
changed every 2 days and the used media was stored at 4 1C for
calcium analyses. At the end of the 10 day culture period, the six
calvaria from each treated group in (a)–(d) were bisected along the
sagittal suture to generate 12 half calvaria per treatment group.
Four half calvaria from each group (a)–(d) were fixed in 10%
formalin, embedded in paraffin, sectioned and stained with
hematoxylin and eosin (H & E) for histological observations. Four
half calvaria from each group (a)–(d) were processed for tartrate-
resistant acid phosphatase (TRAP) activity (see below) and the
remaining four from each group were used for neutral red (NR)
staining followed by silver nitrate counter-staining.
Neutral red (NR) staining to visualize osteoclast activity and silver
nitrate staining for bone resorption in response to PTH in the absence
and presence of phosvitin
NR has been used for staining of osteoclasts (Curtin et al., 2009,
2012; Sidgui et al., 1995; Braidman et al., 1990) as they take up NR
rapidly and because their large size and multinucleated nature
provide a clear contrast between themselves and other bone cells
for microscopic observations. After the 10 day culture period,
calvaria were incubated for an additional 45 min at 37 1C with NR,
70 μg/ml (Sigma, Co.). The mature multinucleated osteoclasts were
evaluated microscopically in the experimental groups (a)–(d). Fol-
lowing this, NR stained samples were washed in PBS, fixed in 10%
formalin overnight and counter stained with 2% silver nitrate
(Sigma-Aldrich, Co.) for 20 min to reveal gross mineral loss and
bone resorption areas. We have used this similar approach in our
recent work to develop and study a three-dimensional cancer–bone
metastasis model using live calvarial bones and tumor cells in a
roller tube system (Curtin et al., 2012). Other investigators have
used NR staining to visualize osteoclasts and quantitate their
numbers and have showed that the results were closely related to
those for TRAP staining of osteoclasts (Sidgui et al., 1995). Further-
more, NR stains and localizes the same osteoclasts as TRAP
(Braidman et al., 1990). It should be noted that, within the context
of our studies, where the NR staining is performed at the end of the
experiment followed by silver nitrate counter staining, the possible
undesirable effects of NR on cellular biology does not impact
our observations. After NR staining the bones are not cultured
further.
Global histomorphometric analysis of calvarial bones in resorption
model
The calvarial bones in experimental groups (a)–(d) above
stained with NR and counter stained with silver nitrate were used
at low microscopic magnification (2! ) to measure quantitative
degree of osteoclastic bone resorption. The digital recorded images
such as those in for example Fig. 1; Panels 1c, 2c, 3c and 4c were
processed and converted to black and white images such that
there were gradation between black and white background
depending on the degree of resorption. This provided shades that
ranged from “black and dark gray for no resorption areas” and
“white for complete resorption of bone with large irregular holes
and light gray for resorption areas where those regions of calvaria
became thin”. The total areas reflecting the above shades were
measured and processed for quantitation of the degree of resorp-
tion under different bone organ culture treatments.
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Tartrate resistant acid phosphatase (TRAP) activity of calvarial bone
organ cultures stimulated by PTH in the absence and presence of
phosvitin
In order to assay for TRAP activity, which is a marker for
osteoclast numbers and activity, the enzyme was released from
the cellular layer of the calvaria by treatment with 250 ml/calvar-
ium lysis buffer, (0.15 M NaCl/30 mM NaHCO3, pH 8.0, containing
0.5% Nonidet P-40), and kept on ice for 1 h with frequent agitation
followed by centrifugation to remove calvarial bone and debris,
and cell extracts were used immediately for assay. The TRAP
enzyme activity was determined by incubation of 50 μl of each
calvarial cell extract in duplicate with 250 μl of 0.1 M sodium
acetate buffer, pH 5.0, containing 50 mM tartaric acid, 3 mM ZnCl2
and 16 mM p-nitrophenylphosphate (pNPP, Sigma Co.) for 30 min
at 37 1C using a 96 well microplate. At the end of the incubation
time, 10 ml of 2 M NaOH was added to each well and absorbance at
405 nmwas measured. The hydrolysis of the substrate and amount
of p-nitrophenol (pNP) released was calculated using the extinc-
tion coefficient ε405 nm¼12,500 mol−1 l cm−1 to calculate the con-
centration in mol l−1. This information together with time of
incubation was used to calculate the rate of substrate hydrolysis
in terms of μmol l−1 min−1 and normalized for the protein content
(per mg protein) of the calvarial cell extract. The protein content of
the cell extracts was determined by a modified method of Lowry's
micro-protein assay using bicinchoninic acid (Lowry et al., 1951).
Effect of native phosvitin in bone formation model
Effect of phosvitin on osteoblastic bone formation was evalu-
ated using mouse calvarial bone organ cultures stimulated to
undergo osteoblastic new osteoid and bone formation in the
absence and presence of ascorbate and native phosvitin. Four
groups of calvarial bone organ cultures, 6 calvaria per group, for a
total of 24 calvarium were set up as follows: (a) unstimulated
controls (negative control); (b) bone formation model by inclusion
of 1 mM Na ascorbate (positive control, 200 mg/ml DMEM–BSA
media); (c) 150 nM of native phosvitin only (5 mg/ml DMEM–BSA
media), and (d) 1 mM ascorbate+150 nM native phosvitin. The
calvaria were cultured on a “grid-system” as described above for 10
days. The media was changed every 2 days and the used media
saved for calcium analysis. At the end of the 10 day culture period,
the 6 calvaria from each group, treated as in (a)–(d), were bisected
along the sagittal suture. One half of each calvaria was fixed in 10%
formalin, embedded in paraffin, sectioned and stained with H & E
Fig. 1. Bone resorption model using mouse calvarial bone organ cultures stimulated by PTH to undergo bone resorption in the absence and presence of phosvitin and Na
ascorbate. Panel 1, control untreated calvaria: (a) H & E sections of the parietal bone region with no osteoclastic bone resorption; (b) NR stained calvaria showing no
multinucleated osteoclasts (MNOC); and (c) NR+silver nitrate counter-stained calvaria showing very little light transparency consistent with mineral dense bone and
reflecting lack of bone resorption. Panel 2, calvaria stimulated with PTH to undergo osteoclastic bone resorption: (a) H & E sections of the parietal bone region showing
osteoclastic bone resorption regions; (b) NR stained calvaria showing numerous active multinucleated osteoclasts; and (c) NR+silver nitrate counter-stained calvaria showing
extensive areas with light transparency reflecting substantial bone resorption. Panel 3, calvaria stimulated by PTH to undergo osteoclastic bone resorption in the presence of
phosvitin: (a) H & E sections of the parietal bone region showing no osteoclastic bone resorption, however, there was substantial amount of new osteoid/bone formation;
(b) NR stained calvaria showing no active multinucleated osteoclasts (OSC), and (c) NR+silver nitrate counter-stained calvaria showing very little light transparency reflecting
minimal bone resorption areas (RA). Panel 4, calvaria stimulated by PTH to undergo osteoclastic bone resorption in the presence of Na ascorbate: (a) H & E sections of the
parietal bone region showing no osteoclastic bone resorption or new bone formation; (b) NR stained calvaria showing no active multinucleated osteoclasts; and (c) NR+silver
nitrate counter-stained calvaria showing very little light transparency reflecting minimal bone resorption. All magnifications were: H & E 200" , NR 200" and silver nitrate
counter stain 100" .
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for histological observations, and the second half was processed
for alkaline phosphatase (ALP) activity.
Alkaline phosphatase (ALP) activity of calvarial bone organ cultures
in the absence and presence of ascorbate and phosvitin
ALP activity, a marker for osteoblast and bone formation, was
determined by release of the enzyme from the calvarial bone
cellular layer using the same lysis buffer as for TRAP enzyme
preparation detailed above. ALP activity was measured by incuba-
tion of 50 ml of cell extract in duplicates with 250 ml of 0.15 M NaCl
+30 mM NaHCO3, pH 8.0, in the presence of 16 mM p-nitrophe-
nylphosphate (pNPP, Sigma Co.) for 30 min at 37 1C using a 96 well
microplate. The absorbance at 405 nm was measured and the rate
of hydrolysis of the substrate and amount of p-nitrophenol (pNP)
released was calculated using the extinction coefficient ε405 nm¼
12,500 mol−1 l cm−1 to calculate the concentration in mol l−1 and
the rate of hydrolysis using the incubation time in mol l−1 min−1.
The alkaline phosphatase activity in mmol l−1 min−1 was then
normalized for the protein concentration as for the TRAP acti-
vity above.
Determination of hydroxyproline and collagen analysis in the
calvarial bone organ cultures
In order to further support the chemical, biochemical and
histological analysis which demonstrated the synthesis of stable
collagen, formation of new osteoid and bone we have determined
collagen and hydroxyproline composition at a quantitative level of
the cultured calvarial bones. At the end of the culture period each
group containing 4 calvaria for groups: (i) controls with media
alone; (ii) media+150 mg/ml Na ascorbate; and (iii) media+150 nM
phosvitin, were rinsed in phosphate buffer, vacuum dried and
hydrolyzed in 0.5 ml of 6 N HCl at 110 1C for 22 h. The hydrolysates
were then subjected to amino acid analysis and collagen content
was calculated from the total hydroxylproline and total amino-acid
content as described previously (Salih et al., 1996b, 2002).
Calcium analysis of the media
Media calcium levels were determined by an Arsenazo III
microplate calcium assay. The assay reagent contained 300 mg/l
Arsenazo III in a 50 mM sodium acetate buffer pH 4.8 (Yingst and
Hoffman, 1983). 10 μl from each sample, all time points, were
assayed in duplicates with the addition of 190 μl of the Arsenazo III
reagent in a 96 well plate and absorbance measured at 620 nm.
Calcium contents were calculated from a standard curve from 0 to
70 nmol [Ca2+].
Histological and quantitative histomorphometric analysis
Histological sections for the resorption model experiments
using PTH were obtained from 4 calvaria per treatment group
with three different regions and two serial sections for each
region. A total of 20 sections from each of the treatment groups
were used to obtain representative osteoclastic bone loss. Histo-
logical sections for the bone formation model experiments were
obtained from 6 calvaria from each of the treatment groups with
similar sectioning strategy as above. A total of 30 sections from
each group were examined to adequately evaluate the predomi-
nant pattern occurring in each group. Quantitative histomorpho-
metric analysis for sets of experiments using bone formation
model were obtained from the above 30 sections. All microscopic
images were obtained as previously described (Curtin et al., 2009,
2012).
Primary osteoblasts as prolyl-hydroxylase enzyme source and
hydroxylation of synthetic collagen peptide analog
We have designed and utilized a synthetic collagen peptide
analog containing 20 amino-acids and consensus sequences with
multiple potential proline hydroxylation sites, GPPGPSGPPGPS
GPPGPSGK, (synthesized by Peptide 2 Inc., Chantilly, VA, USA).
Cultured primary calvarial osteoblasts as enzyme source
The primary 19 day embryonic rat calvarial osteoblasts were
generated as described previously (Vora et al., 2010). We have
cultured the primary osteoblasts in 10 ml of α-MEM supplemented
with non-essential amino-acids, 10% fetal calf serum and penicil-
lin/streptomycin antibiotic in 10 cm culture dishes with initial cell
density ∼1"106 cells per dish. At confluency (∼10 day culture) the
cells were cultured overnight with α-MEM media containing “no
fetal calf serum” and the cell layers of four 10 cm culture dishes
were collected.
(i) Total cell lysate preparation. The cell layers from two culture
dishes (total ∼15"106 cells) were collected using sterile cell
scraper in the presence of 1 ml lyses buffer, 50 mM NH4HCO3,
pH 7.8, containing 0.5% Nonidet-P-40, and kept on ice for 1 h. The
sample was then centrifuged at 10,000 rpm using Eppendorf
bench top centrifuge to remove cell debris and the supernatant
was kept as an enzyme source.
(ii) Microsomal fraction containing endoplasmic reticulum (ER)
+Golgi preparation. The cell layers from two culture dishes (total
∼10"106 cells) were collected using sterile cell scraper in the
presence of 1 ml of 50 mM NH4HCO3, pH 7.8, buffer with “no”
Nonidet-P-40. The sample was then centrifuged at 10,000 rpm using
Eppendorf bench top centrifuge to remove nucleus and cell mem-
brane. The supernatant containing microsomal fractions was then
subjected high speed centrifugation at 100,000g to collect the ER
+Golgi fraction. The pellet was then suspended in 200 ml of 50 mM
NH4HCO3, pH 7.8 containing 0.5% Nonidet-P-40 and kept as an ER
+Golgi enzyme source as described previously, (Salih et al., 1996a). The
two osteoblast enzyme sources, (i) and (ii), were then used to evaluate
the prolyl-hydroxylation of the synthetic collagen peptide analog in
the absence and presence of ascorbate, phosvitin, Fe+2 and Fe+3 and 2-
ketoglutarate. Reaction conditions with total volume of 100 ml
containing 50 ml of total cell lysate or 20 ml of microsomal fraction
enzyme source: (a) negative control-1 containing no Fe+2 and Fe+3,
50 mg peptide+0.3 mM 2-ketoglutarate+enzyme source (i) or (ii)
+50mM NH4HCO3, pH 7.8; (b) negative control-2 containing no
enzyme source, 50 mg peptide+0.3 mM 2-ketoglutarate+100 mM
ferrous chloride (Fe+2)+50mM NH4HCO3, pH 7.8; (c) negative con-
trol-3 with Fe+3, 50 mg peptide+0.3 mM 2-ketoglutarate+100 mM
ferric chloride (Fe+3)+enzyme source (i) or (ii)+50mM NH4HCO3,
pH 7.8; (d) positive control with ferrous chloride (Fe+2), 50 mg peptide
+0.3 mM 2-ketoglutarate+100 mM ferrous chloride (Fe+2)+enzyme
source (i) or (ii)+50mM NH4HCO3, pH 7.8; (e) test reaction with
ascorbate, 50 mg peptide+0.3 mM 2-ketoglutarate+100 mM ferric
chloride (Fe+3)+enzyme source (i) or (ii)+1mM Na ascorbate+50
mM NH4HCO3, pH 7.8; (f) test reaction with phosvitin, 50 mg peptide
+0.3 mM 2-ketoglutarate+100 mM ferric chloride (Fe+3)+enzyme
source (i) or (ii)+∼0.4 mM phosvitin+50mM NH4HCO3, pH 7.8. The
reactions were allowed to proceed for 1 h at 37 1C, followed by
aliquots of 10 ml from each reaction condition (a)–(f) subjected to
LC–MS/MS analysis to define proline hydroxylation and the precise
site(s) of hydroxylation within the peptide.
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Mass spectrometric analysis for the prolyl-hydroxylation of the
synthetic collagen peptide analog
Nano-flow liquid-chromatography–electrospray-ionization–tadem
mass spectrometric (LC–ESI–MS/MS) analyses were carried out using
an LTQ-linear ion trap mass spectrometer (Thermo Electron, San Jose,
CA). The reaction samples of 10 ml each from (a) to (f) above were
suspended in 20 ml of 97.4% H2O:2.5% CH3CN:0.1% HCO2H followed by
LC–ESI–MS/MS analyses using an on-line auto-sampler (Micro AS,
Thermo-Finnigan, CA) with auto-injections of 3 ml onto an in-line
fused silica micro-capillary column, (75 mm!10 cm), packed in-
house with C18 resin (Micron Bio-resource, Inc. Auburn, CA) and
developed at a flow rate of 250 nl/min. Peptides were separated by a
55 min elution comprising of multi-step-linear gradient using solvent
A, H2O/2.5% CH3CN/0.1% HCO2H, and solvent B, CH3CN/0.1% HCO2H.
The gradient steps were from 100% solvent A to 8% solvent B in 5 min,
to 15% solvent B in 10 min, to 25% solvent B in 10 min, to 50% solvent
B in 20 min, and to 95% solvent B in 10 min using a Surveyor MS
Pump Plus (ThermoFinnigan, CA). The eluted peptides were directly
nano-electrosprayed and the MS/MS data were generated using data-
dependent acquisition with a MS survey scan range between 390 and
2000m/z. This data-dependent acquisition begins with the LC separa-
tion which generates a total ion chromatogram in a survey scan
followed by selection of specific ions for collision induced dissociation
(CID, MS/MS) in descending order of signal intensity. Each survey scan
(MS) was followed by sequential selection of five peptides for CID, at
35% normalized collision energy, with dynamic exclusion parameters,
repeat count 1, repeat duration 30 s and exclusion duration 20 s. This
process was continuously alternated between MS scan and five
tandem MS throughout the nano-LC chromatography.
MS/MS data search for identification of prolyl-hydroxylation and
location of the hydroxylated proline residue within the synthetic
collagen peptide analog
Since our designed synthetic collagen peptide has unique sequence
with repeats of GPP, PPG, GPS, and PSG we have generated a custom
database containing multiple unrelated proteins and inserted the
synthetic peptide sequence, GPPGPSGPPGPSGPPGPSGK, into that
database. This permitted rapid search of the MS/MS data generated
from the analysis of above reaction aliquots by usual Bioworks 3.3.1
software and SEQUEST search engine (Eng et al., 1994). The DTA files
were generated with the following settings: precursor-ion tolerance of
1.5 amu, fragment ion tolerance of 1.0 amu, and automated calculated
charged states +1, +2, and +3. The searches were performed with
parameters: half trypsin since we have only one trypsin recognized
residue within the peptide, and +16 Da (mass addition) modifications
of proline residues which are expected to occur if proline hydroxyla-
tion occurred. We have also specified up to 5 potential hydroxylations
on the peptide because there are multiple potential proline residues
within the peptide that may possibly become hydroxylated.
The database search results were filtered using the criteria:
∆Cn≥0.1; probability≤0.1; for and XCorr≥1.8, 2.2, 3.75 for Z¼+1, +2,
and +3. In addition to the search parameters and criteria used, the
identified peptide sequences assessed manually by examining
each of the identified peptide MS/MS spectra for the quality and
the confidence through the y and b ion fragment series. In such
evaluation the number of y and b ion fragments, their consecutive
occurrence in a series and representation of “high-intensity” ion-
fragments were used as bases for acceptance.
Biomineralization of cultured primary osteoblasts in the absence and
presence of ascorbate and phosvitin
The primary rat osteoblasts were cultured in six well (3.5 cm
each well) culture plates until confluent as described above. One
culture plate (six wells, 2!106 cells/well) of confluent osteoblasts
was used for each of the following treatments: (a) media alone;
(b) media+10 mM β-glycerolphosphate; (c) media+10 mM β-gly-
cerophosphate+20 mg/ml (100 mM) Na ascorbate; and (d) media
+10 mM β-glycerophosphate+20 mg/ml (0.7 mM) phosvitin. These
cultures were incubated for 5 days followed by (i) triplicate wells
of each treatment were used for fixing with 10% formalin over-
night followed by exposure to 2% silver nitrate for 30–60 min to
visualize Ca-P deposition microscopically, and (ii) triplicate wells
of each treatment were processed for quantitative calcium analysis
to determine extent of mineral deposition in the cell layer. For
quantitative calcium analysis in (ii) the media was removed and
the cell layer was collected in the presence of 0.5 ml of 50 mM
NH4HCO3 using sterile cell scraper and placed in Eppendorf tubes
and left on ice for 1 h for cells to burst in this “hypotonic” buffer.
The insoluble cell debris, nucleus and the mineralized ECM was
then collected by bench top centrifugation at 10,000 rpm. The
pellet containing the ECM and insoluble cellular components was
then suspended in 0.5 ml of 0.1 M HCl and left at 4 1C overnight for
dissolution of the Ca-P mineral. The HCl extracts were then
partially neutralized by addition of sub-molar equivalent of 1.0 M
NaOH (40 ml, keeping still the pHo4) and centrifuged as above to
pellet the insoluble ECM and cellular components. 10 ml of super-
natant from each triplicate sample treatments (a)–(d) were assayed
for calcium levels in duplicates as described above using Arsenazo III
reagent calcium assay. The media calcium levels of these mineraliz-
ing primary osteoblasts treated as in (a)–(d) above was also
determined in order to correlate with calcium deposition levels.
Synthesis of hydroxyproline containing collagens and critical proteins
involved in osteoblast differentiation by cultured osteoblasts in the
absence and presence of β-glycerolphosphate, ascorbate and
phosvitin
The insoluble ECM and cellular components (the pellet after HCl
extraction of the mineralized cell layers above) was re-suspended in
0.1 ml of 50 mM NH4HCO3, pH 7.8, and 10 ml of the HCl soluble extract
(partially neutralized) was included in this suspension and subjected
to trypsin (5 mg) digestion overnight at 37 1C. 10 ml of such trypsin
digested samples derived from each of the culture conditions (a)–(d)
above were suspended in 20 ml of 97.4% H2O:2.5% CH3CN:0.1% HCO2H
followed by LC–ESI–MS/MS analyses using an on-line auto-sampler
(Micro AS, Thermo-Finnigan, CA) with auto-injections of 3 ml onto an
in-line fused silica micro-capillary column, (75 mm!10 cm) as
detailed above. The MS/MS data generated from the analysis of
aliquots from the above samples were searched against the rat-
specific database, Uniprot (Universal Protein Resources, Version 9.0),
which combines the data from Swiss-Prot (version 51) TreMBL
(Version 34) and PIR using the Bioworks 3.3.1 software and SEQUEST
search engine (Eng et al., 1994). The data were searched with specified
dynamic modification of 16 Da mass additions for hydroxylation of the
proline residues and the results documented as described above.
Statistics
Data are presented as means7SD The paired Student's t-test
was used to compare groups. The differences between groups
were considered statistically significant for po0.05. It should be
noted that although there are multiple treatment sets the impor-
tant comparisons are between PTH treatment versus control
(media alone) showing PTH induced bone resorption, or PTH
treatment versus ascorbate or phosvitin to indicate effects of these
added factors on PTH-induced bone resorption. Similarly in the
bone formation model the comparison needed is negative controls
versus ascorbate or phosvitin treatment, or positive control
(+ascorbate) versus +phosvitin. Such analysis require paired
Student's t-test and not an Anova type analysis.
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Results
Histological observations of the effect of native phosvitin on
osteoclast formation and bone resorption induced by PTH
in live mouse calvarial bone resorption model
The histological observations of H & E stained sections of
calvarial bones cultured with PTH in the absence and presence
of native phosvitin are represented in Fig. 1. There was significant
osteoclastic activity and bone resorption readily observable for
those groups treated with PTH only, but not for the untreated
control and PTH+native phosvitin groups. Panel 1a in Fig. 1 shows
H & E histological section for unstimulated control calvaria with no
noticeable osteoclastic bone resorbtion. Panel 2a in Fig. 1 shows a
histological section of calvarial bone with PTH showing numerous
multinucleated osteoclasts and bone resorption. Panel 3a in Fig. 1
shows histological section of calvarial bones treated with PTH
+native phosvitin with minimal osteoclastic bone resorption
coupled with formation of substantial new osteoid and bone. This
is an unexpected event in our resorption model system, as the
culture media was devoid of ascorbate. Interestingly, our observa-
tions for the PTH+native phosvitin group are somewhat similar to
calvaria treated with PTH+ascorbate (Fig. 1; Panel 4a), suggesting
that phosvitin has the capacity to mimic functions closely related
to ascorbic acid. It is worth noting that at the end of the
experimental period there are obvious variations in the thickness
of the periosteum and the overall bone in the histological sections
in Panels 1a–4a in Fig. 1. This is due to culture starting conditions
and treatments where the original starting calvarial bone thick-
ness would be as shown in Panel 1a in Fig. 1 and in this control
experiment there is no significant change in the periosteum or the
bone over the culture period. However, when the calvaria were
cultured in the presence of different stimulatory factors such as
PTH, ascorbate and phosvitin (Fig. 1; Panels 2a, 3a, and 4a)
proliferation and differentiation of mesenchymal/stem cells com-
bined with formation of new osteoid/bone leads to much thicker
bone (old bone+new bone) and periosteum cellular layer.
Global visualization of osteoclast formation by neutral red in cultures
stimulated with PTH in the absence and presence of native phosvitin
and or ascorbate
In the present work to gain further insights into the biologic
events, we have globally visualized the osteoclasts by NR and
resorption activities with silver nitrate. Panels 1b, 2b, 3b, and 4b in
Fig. 1 show NR staining of control calvaria, PTH treated only, PTH
+native phosvitin treated and PTH+ascorbate treated, respectively.
Such a global visualization approach showed an absence of
observable osteoclasts in the control (untreated) calvaria (Fig. 1;
Panel 1b). In contrast, cultures treated with PTH alone showed
numerous and distinct NR stained multinucleated osteoclasts
(Fig. 1; Panel 2b). Importantly, the calvaria treated with both
PTH+native phosvitin and those treated with PTH+ascorbate
showed no evidence of mature multinucleated osteoclasts
(Fig. 1; Panels 3b and 4b). In order to further examine these
observations, and reveal global osteoclastic resorption activities, or
lack thereof, we have counterstained the NR stained calvaria with
silver nitrate. The negative controls showed no resorption areas
(Fig. 1; Panel 1c), whereas calvaria treated with PTH alone showed
substantial loss of bone with large resorption areas becoming
transparent to light (Fig. 1; Panel 2c). Those calvaria cultured in the
presence of PTH+native phosvitin and/or PTH+ascorbate showed
minimal or no osteoclastic bone resorption and light transparency
(Fig. 1; Panels 3c and 4c), respectively. These data were consistent
with the observations from histological sections and NR staining.
Quantitative analysis of the changes in media calcium and TRAP
activity in response to parathyroid hormone (PTH) in the absence and
presence of phosvitin and ascorbate in mouse calvarial bone organ
cultures
The total change in media calcium was determined over the 10
day culture period for groups (a) unstimulated controls,
(b) stimulated by 10 nM PTH to undergo resorption, (c) 10 nM
PTH+150 nM native phosvitin, and (d) 10 nM PTH+1 mM Na
ascorbate. Fig. 2A shows total cumulative changes in media
calcium for the groups (a)–(d) over a 10 day culture period.
Unstimulated controls showed minimal calcium release whereas
those treated with PTH only showed substantial release of calcium.
However, this release of calcium was significantly inhibited in the
presence of 150 nM phosvitin by 2.5 fold (∼60%) and this was
Fig. 2. Quantitative calcium release analysis for bone loss and TRAP enzyme
activity for osteoclast quantification in calvarial bone resorption model.
(A) Quantitative calcium analysis of media from calvarial cultures; controls (media
alone), PTH treated only, PTH+phosvitin treated, PTH+Na ascorbate treated,
phosvitin alone and ascorbate alone. The release of calcium into the media in the
presence of PTH was substantial compared to the controls. This calcium release was
significantly reduced (∼60%) in the presence of PTH+phosvitin, and even more so in
calvaria cultured in the presence of PTH+ascorbate. In the latter case there was
calcium uptake which was also observed with bone cultures treated with phosvitin
alone and ascorbate alone. The two sample Student's t test indicated that these
differences in calcium release/bone resorption in response to different treatments
were statistically significant with p values noted within the figure. (B) Quantitative
TRAP enzyme activity analysis as a measure of osteoclast numbers in calvaria
cultured under different conditions as indicated above in (A). The results are
consistent with the observed calcium levels in the media and the data in Fig. 1. The
two sample Student's t test indicated that the difference in TRAP activity in
response to PTH, PTH+phosvitin, and PTH+Na ascorbate were different and
statistically significant with p values as noted within the figure.
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statistically significant po0.001. A simultaneous inclusion of PTH
with 1 mM Na ascorbate led to complete inhibition of calcium
release with additional calcium uptake from the media despite the
presence of PTH. This latter case is similar to what would be
observed in our bone formation model in the presence of ascor-
bate and absence of PTH. The quantitative TRAP enzyme activity, a
marker for osteoclasts, was consistent with the above results
(Fig. 2B). The TRAP activity measurements clearly supported the
calcium change measurements, where both phosvitin and ascor-
bate impact significantly PTH-induced osteoclast differentiation
and bone resorption. The results for both calcium and TRAP
activity were analyzed by two tailed paired Student's t-test to
show statistical significance (p values are recorded in the legend of
Fig. 2A and B). Overall, histological, NR, and silver nitrate observa-
tions were consistent with the quantitative analysis for calcium
and TRAP activity.
Quantitative histomorphometric analysis of calvarial bones in the
resorption model system in the absence and presence of PTH,
phosvitin and ascorbate
We have utilized the silver nitrate stained calvaria at 2!
magnification to determine the quantitative global bone resorp-
tion areas. Fig. 3A shows examples of the approaches used for
global quantitation of the resorption areas whereby NR and
counter stained calvarial digital images were transformed to “black
and white” images with shades of gray in between directly
proportional to the degree of light transparency and extent of
bone loss. For example areas with complete resorption through
the whole thickness of the calvaria are completely white, those
areas where there was no resorption were black or dark gray, and
those areas that have undergone significant resorption without
penetrating through the whole calvarial thickness were light gray.
Fig. 3B shows quantitative histomorphometric analysis where the
results are expressed as % bone resorption with total unit resorp-
tion area for samples treated with PTH alone fixed as 100% and the
results for the other sets calculated relative to this. The data clearly
demonstrated that phosvitin inhibits the PTH-induced osteoclastic
bone resorption, and has the capacity to enable new osteoid and
bone formation in the absence of ascorbate.
In order to distinguish a specific phosvitin function from just a
role for organic phosphate or phosphate group, a parallel set of
experiments using PTH and phosphoamino-acids at concentra-
tions ∼equivalent to those present in phosvitin were carried out.
Fig. 4A shows quantitative calcium release and TRAP activity
measurements for these experiments with no significant effect
that was statistically relevant to PTH-induced calcium release by
any of the added phospho-amino acids. TRAP activity measure-
ments however, showed a small decrease in the presence of P-Ser
and P-Thr (Fig. 4B).
Osteoblasts and bone formation in the absence and presence of
ascorbate and native phosvitin observed histologically in calvarial
bone organ culture formation model
The histological observations of H & E stained sections of
calvarial bones cultured over a 10 day period for groups
(a) unstimulated controls, (b) stimulated by 1 mM ascorbate to
Panel 1 Media alone (control) Panel 2 + PTH
Panel 3 + PTH + Phosvitin Panel 4 + PTH + Ascorbate
No Resorption areas Resorption areas
Fig. 3. Global % osteoclastic bone resorption determined by histomorphometric analysis of the silver stained whole calvarial bones. (A) Examples of calvaria in each
treatment group stained with NR and counter stained with silver nitrate where the digital images (at 2! magnification) were transformed to black and white images and
different shades of these depending on the degree of resorption. The arrows show either black or dark gray areas where there were no resorption, or white and light gray
areas where resorption occurred. The digital intensities of the white and light gray areas were used to calculate % resorption areas. Panel 1, media alone (control); Panel 2,
PTH alone; Panel 3, PTH+phosvitin and Panel 4, PTH+ascorbate. (B) The calculated % bone resorption areas relative to PTH-induced bone resorption show clear and
substantial reduction in bone resorption as a result of inclusion of either phosvitin or ascorbate in the PTH-treated cultures,∼60% and ∼90%, respectively. The two sample
Student's t test indicated that these differences in bone resorption in response to different treatments were statistically significant with p values noted within the figure.
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undergo bone formation, and (c) 1 mM ascorbate+150 nM native
phosvitin are shown in Fig. 5. Fig. 5a shows unstimulated control
cultures where there was no clear new osteoblast differentiation
or new osteoid formation. In the presence of ascorbate, new bone
formation was clearly observable with significant osteoblastic
activity as evidenced by large amounts of new osteoid formation
(Fig. 5b). This was also obvious from the large difference in the
actual overall bone thickness when comparing Fig. 5a and b. In the
presence of phosvitin, the relative increase in osteoblast numbers/
activity and degree of new osteoid formation were more easily
detected (Fig. 5c). In the presence of phosvitin, there was a
remarkable degree of osteoblast differentiation to the extent that
it can be observed that (i) many osteoblasts just being surrounded
by their new osteoid (ECM), and (ii) clusters of differentiated
osteoblasts along the whole bone surface (Fig. 5d). In the presence
of combined ascorbate+phosvitin such occurences were even
more enhanced (Fig. 5e and f). These data were supported by
the significant levels of ALP activity, see below.
Quantitative calcium uptake and alkaline phosphatase acitivity in the
absence and presence of ascorbate and phosvitin in calvarial bone
organ culture formation model
The cumulative change in media calcium was determined over
a 10 day culture period for groups (a) unstimulated controls,
(b) 1 mM ascorbate, (c) 150 nM phosvitin+1 mM ascorbate, and
(d) 150 nM native phosvitin. Fig. 6A shows total change in media
calcium for the groups (a)–(d). These data were expressed as mmol
calcium per ml media and normalized per mg dry weight of
calvarial bones. Unstimulated controls, group (a), showed minimal
calcium uptake whereas those treated with ascorbate, group (b),
showed substantial uptake of calcium indicating enhanced osteo-
blastic activity and new bone formation. Similarly, cultures treated
with a combination of ascorbate+phosvitin, group (c), showed
calcium uptake similar to that of ascorbate alone. Those calvaria
cultured in the presence of phosvitin alone, group (d), showed
significant uptake of calcium, 10-fold above that of media alone,
but this was much lower than calvaria cultured in the presence of
ascorbate or ascorbate+phosvitin. This is clearly seen in the
histological sections where the new osteoid stained very “light
pink” reflective of young osteoid/bone ECM (Fig. 5c). The ALP
activity was consistent with the histological observations whereby
cultures treated as in (b)–(d) showed significantly higher ALP
activity compared to the control media alone (Fig. 6B).
Quantitative histomorphometric analysis of calvarial bones in the
formation model system in the absence and presence of phosvitin and
ascorbate
Quantitative histomorphometric analysis of H & E sections for
calvaria treated as in (a)–(d) above as well as those with PTH+ASC
and PTH+phosvitin showed clearly the significant new osteoid/
bone formation (Fig. 7). Fig. 7A shows examples of how measure-
ments of new osteoid/bone formation were carried out for
quantitative analysis. For this purpose the areas between the
“dotted lines” which show the new light pink osteoid/bone and
early stages of the differentiated osteoblasts surrounded by their
synthesized ECM were used. The old/original bone at the start of
the experiment can be very easily distinguished by its much
darker color characteristics. The measured areas of the total new
osteoid/bone formed for calvaria cultured in the presence of
ascorbate only was set to be 100% and all of the other experi-
mental groups with different treatments were calculated relative
to this (Fig. 7B).
Stable collagen synthesis, new osteoid and bone formation in the
presence of phosvitin
Analysis of hydroxylproline and total amino-acid content were
used to calculate the % collagen content of the total protein present
within the calvarial bone culture groups (i) media alone, (ii) media
+ascorbate, and (iii) media+phosvitin. The results indicated that
the total organic matrix in calvaria cultured in the presence of
ascorbate, group (ii), or phosvitin, group (iii), were 2–3! higher
than those of the controls, media alone group (i). The total
hydroxyproline content of the groups with ascorbate or phosvitin
were also 2–3! higher providing a calculated % collagen content
of total proteins to be 5376%, 5774%, 5875% for groups in (i),
(ii), and (iii), respectively, consistent with the observations using
the above multiple chemical, biochemical and histological analysis.
These data clearly demonstrated that in the presence of ascorbate
and or phosvitin the newly synthesized ECM is typical bone matrix
with appropriate hydroxyproline containing stable collagen synth-
esis forming the new osteoid and bone.
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Fig. 4. Quantitative calcium release analysis for bone loss and TRAP enzyme
activity for osteoclast quantification in the presence of phospho-amino-acids using
bone resorption model. (A) Quantitative calcium analysis of media from calvarial
cultures: controls, PTH treated only; PTH+P-Ser treated; PTH+P-Thr and PTH+P-Tyr
treated. The release of calcium into the media in the presence of PTH was
substantial compared to the control media alone. In the presence of PTH+phos-
pho-amino acids there was no significant difference statistically from the PTH alone
in calcium release. (B) Quantitative TRAP enzyme activity analysis as a measure of
osteoclast numbers and activity in calvaria cultured under different conditions as
indicated above in (A).
J. Liu et al. / Developmental Biology 381 (2013) 256–275264
Primary osteoblasts as prolyl-hydroxylase enzyme source and
hydroxylation of synthetic collagen peptide analog in the absence and
presence of ascorbate and phosvitin
We have utilized a designed synthetic collagen peptide analog
containing multiple consensus recognition sequences for 3- and
4-prolyl hydroxylases for proline hydroxylation and two prolyl-
hydroxylase enzyme sources were used for test tube hydroxylation
experiments. Both of the osteoblast enzyme sources were used in
test tube reaction conditions involving negative controls, positive
control and test reactions in the presence of Fe+3 and ascorbate or
phosvitin. The two osteoblast enzyme sources, total lysate and
microsomal enriched fractions, provided essentially the same
results. The complexity of the total lysate was overcome by use
of only a small amount of the reaction sample for MS/MS analysis
by design of appropriate concentrations of reaction mixture
components for clear and easy identification of the synthetic
peptide during MS analysis. The MS/MS data search provided
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Fig. 5. Bone formation model using mouse calvarial bone organ cultures in the absence and presence of phosvitin and Na ascorbate. (a) H & E sections of the parietal bone
region of calvaria cultured in media alone with no osteoblastic new formation. (b) H & E sections of the parietal bone region of calvaria cultured in the presence of Na
ascorbate showing new osteoblastic bone formation. (c) H & E sections of the parietal bone region of calvaria cultured in the presence of phosvitin alone showing significant
amounts of new osteoid and differentiated osteoblasts. (d) Higher magnification of the H & E section in (c). (e) H & E sections of the parietal bone region of calvaria cultured
in the presence of Na ascorbate+phosvitin showing significant amounts of new osteoid and differentiated osteoblasts. (f) Higher magnification of the H & E section in (e). The
new bone formation in (b), (c) and (d) as compared to the control (a) is clearly visible from the thickness of the overall bone and the new light pink osteoid surrounding the
differentiated osteoblasts. All the magnifications were at 200! except those higher magnifications; 400! , for (d) and (e).
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identification of the original peptide sequence, GPPGPSGPPGP-
SGPPGPSGK (expected mass of 1680 Da), with no evidence for
hydroxylated proline residues in any of the negative control
reactions. Fig. 8A shows an example of MS/MS fragmentation
sequence data that led to the identification of the unmodified
original peptide in the negative controls. The positive control
reactions in the presence of Fe+2 provided identification of multi-
ple hydroxylated forms of the peptide, GPPGPSGPP*GP*SGPPG
PSGK (1712 Da, 2! P–OH), GPPGPSGP*PGP*SGPPGPSGK (1712 Da,
2! P–OH), GPPGPSGPPGPSGP*PGPSGK (1696 Da, 1! P–OH), and
GPPGPSGPP*GPSGPPGPSGK (1696 Da, 1! P–OH). The asterisks (*)
denotes the location of the hydroxyproline with 16 Da mass
addition for each hydroxyl group and this applies to all of the
peptides identified below too. Fig. 8B shows an example of MS/MS
spectra that led to the identification of the hydroxylated peptides
in the positive control with Fe+2. The test reactions in the presence
of Fe+3 and ascorbate provided identification of multiple hydro-
xylated forms of the peptide, GPPGPSGPPGP*SGPPGPSGK (1696
Da, 1! P–OH), GPPGPSGP*PGP*SGPPGPSGK (1712 Da, 2! P–OH)
GPPGPSGPPGPSGPP*GP*SGK (1712 Da, 2! P–OH), and GPPGP*SGP
P*GPSGP*PGPSGK (1728 Da, 3! P–OH). An example of MS/MS
fragmentation sequence data that led to the identification of the
hydroxylated peptides in the test reaction with Fe+3 and ascorbate
is depicted in Fig. 8C. The test reactions in the presence of Fe+3 and
phosvitin provided identification of multiple hydroxylated forms
of the peptide, GPPGPSGPPGP*SGP*PGPSGK (1712 Da, 2! P–OH),
GPPGP*SGPPGP*SGP*PGPSGK (1728 Da, 3! P–OH) GPPGPSGPPG
PSGP*P*GPSGK (1712 Da, 2! P–OH), and GPPGPSGPPGP*SGPPGP
SGK (1696 Da, 1! P–OH). An example of MS/MS fragmentation
sequence data that led to the identification of the modified
hydroxylated peptides in the test reaction with Fe+3 and phosvitin
is given in Fig. 8D.
Biomineralization of cultured primary osteoblasts in the absence and
presence of ascorbate and phosvitin
To provide additional evidence for the involvement of phosvitin
in the synthesis of collagen and biomineralization we have
cultured primary calvarial osteoblast in the absence and presence
of β-glycerolphosphate, ascorbate and phosvitin. Fig. 9A shows
mineral deposition microscopically observed after cell layer of
osteoblast cultures were exposed to 2% silver nitrate with essen-
tially no Ca-P deposition in the cultures with media alone and β-
glycerolphosphate, while presence of ascorbate or phosvitin led to
substantial mineral deposition. Quantitative Ca analysis of such
cell layers and the culture media provided results consistent with
these observations. The control cultures showed minimal Ca+2
levels in the cell layers, whereas those with ascorbate or phosvitin
showed substantial Ca+2 levels, 4–5-fold, as compared to the
controls (Fig. 9B). These results were consistent with the Ca
analysis of the used media of such cultures showing clear
corresponding Ca uptake from the media (Fig. 9C). Overall, the
data obtained from osteoblast cultures were consistent with and
supported those of the calvarial bone organ culture studies.
Synthesis of hydroxyproline containing collagens and critical proteins
by cultured osteoblasts in the absence and presence of
β-glycerolphosphate, ascorbate and phosvitin
Importantly, the mineralization experiments with osteoblasts
above also provided a third and ultimate opportunity to define
under cell culture conditions synthesis of collagens, proline
hydroxylation, and early critical proteins in the absence and
presence of ascorbate and phosvitin by MS technology. Inset of
Fig. 10 shows pictorial representation of the insoluble cell layer
white pellets of the cultured osteoblasts after acid extraction and
bench top centrifugation with clear visible white pellets showing
the major quantitative ECM differences between the controls
versus those in the presence of ascorbate or phosvitin. The media
alone and β-glycerolphosphate showed similar and very small size
insoluble ECM, whereas ascorbate and phosvitin treated cultures
generated substantially larger insoluble ECM. The ECM and inso-
luble components of the cell layers were subjected to trypsin
digestion followed by LC–ESI–MS/MS analysis. This was performed
on small enough aliquots to minimize complexity and highlight
specifically the most abundant ECM and acid soluble components.
The LC–ESI–MS total base-peak ion abundance profiles were
consistent and correlated with the white pellet sizes, whereby
for controls media alone and β-glycerolphosphate the total ion
intensities were ∼5! lower than those of the corresponding
ascorbate and phosvitin. The MS/MS sequence data were searched
against the rat database and the results are summarized in Table 1
with major and significant results confirming/augmenting the
bone organ culture, synthetic collagen peptide and mineralizing
osteoblast culture studies. Four distinct collagen chains were
clearly identified with collagen type I as the major component
Fig. 6. Quantitative calcium uptake analysis for new bone formation and ALP
enzyme activity for osteoblast quantification in calvarial bone formation model.
(A) Quantitative calcium analysis of media from calvarial cultures: controls;
phosvitin treated only; phosvitin+ascorbate treated; and Na ascorbate treated
only. The uptake of calcium from the media in the presence of ascorbate and
ascorbate+phosvitin was significant and much higher than that of cultures in the
presence of phosvitin. However, the calcium uptake in the presence of phosvitin
was ∼10! higher than those of controls with media alone. The two sample
Student's t test indicated that these differences in calcium uptake/bone formation
in response to different treatments were statistically significant with p values noted
within the figure. (B) Quantitative ALP enzyme activity analysis as a measure of
osteoblast numbers in calvaria cultured under different conditions as indicated
above in (A). The results are consistent with the observed calcium uptake levels in
(A) above and the histological data in Fig. 5 The two sample Student's t test
indicated that the difference in ALP enzyme activity in response to different
treatments were statistically significant with p values noted within the figure.
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and these were present in both ascorbate and phosvitin treated
cultures but were absent in the controls. As expected ascorbate
treated cultures led to identification of collagen type I alpha 2
(17 distinct peptides with multiple hydroxyproline sites in each
peptide), collagen type I alpha 1 (3 distinct peptides with multiple
hydroxyproline sites in each peptide), collagen type III alpha 1
(7 distinct peptides with multiple hydroxyproline sites in each
peptide) and collagen type XII alpha 1 (3 distinct peptides with no
hydroxyproline sites). Similarly, in samples derived from phosvitin
treated cultures collagen type I alpha 2 (11 distinct peptides with
multiple hydroxyproline sites in each peptide), collagen type I
alpha 1 (5 distinct peptides with multiple hydroxyproline sites in
each peptide), collagen type III alpha 1 (2 distinct peptides with
multiple hydroxyproline sites in each peptide) were clearly iden-
tified. Another interesting major protein that was identified only
in ascorbate and phosvitin treated cultures was vimentin which
was not present in the controls. While collagens and fibronectin
are well known ECM components, vimentin has been defined as
intracellular/cell surface bound “intermediate filament protein”
and our identification of this protein was possibly due to cells
being lysed and insoluble components together with the ECM was
pelleted together. The significance of identifying this important
protein in only ascorbate and phosvitin treated samples is the fact
that it is a marker for “epithelial to mesenchymal transition”. One
common protein identified in all of the samples derived from the
cultured osteoblasts was fibronectin, which is important for
osteoblast differentiation and is a survival factor for the differ-
entiated osteoblasts. While semi-quantitative, from the repeat
counts and the number of distinct peptides identified there are
clear different levels of this protein in the four differently treated
samples. The highest level was observed in phosvitin and ascor-
bate treated samples, 17 distinct peptides and 11 respectively,
whereas only 4–5 peptides were identified for the samples derived
from media alone and β-glycerolphosphate treated samples. It is
noteworthy that identification of the proteins and the peptides
were through the same search conditions (+16 Da modifications
for hydroxylation of P residues) and defined within the same
search result list for each of the different treatment samples.
Importantly, while fibronectin contains multiple proline residues
none of the peptides of this protein were defined to contain
hydroxylated proline residue. For example in phosvitin treated
cultures there were 17 peptides of fibronectin identified with total
of 18 proline residues but no hydroxyprolines were defined,
whereas collagen type I alpha 2 in this same sample and search
identified 11 distinct peptides of this protein with total of 44
proline residues and 21 of these were identified as hydroxypro-
lines. Fig. 11 shows an example of the MS/MS fragmentation
sequence data with y and b ion fragments for one of the collagen
type I alpha 2 peptide with three hydroxyproline sites found in
ascorbate and phosvitin treated osteoblast cultures. The precise
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Fig. 7. Quantitative histomorphometric analyses of the H & E sections for determining % new osteoid and bone formation. (A) Examples of how measurements of new
osteoid/bone formation were carried out for quantitative analysis. The areas between the “dotted lines” which show the new light pink osteoid/bone and early stages of the
differentiated osteoblasts surrounded by their synthesized ECM were measured. The old (original starting bone) at the beginning of the experiment can be very easily
distinguished by its much darker color characteristics. (B) The calculated % new osteoid/bone formation areas relative to ascorbate alone show clear and substantial
quantitative new bone formation as measured for bone sections of calvaria cultured in the presence of ascorbate, phosvitin, PTH+phosvitin, and PTH+ascorbate. The media
alone as the control showed no new osteoid/bone formation. The two sample Student's t test indicated that calvaria cultured in the presence of phosvitin and or ascorbate
showed significant bone formation and these were substantially higher and statistically significant than the controls (media alone), with p values noted within the figure.
Statistical evaluation of the calvaria cultured in the presence of phosvitin and or ascorbate showed no difference amongst these in the presence and absence of PTH, with p
values noted within the figure.
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proline sites of hydroxylation were defined by the specific y and b
ion fragments with 16 Da mass additions on proline residues
indicated by the red arrows in Fig. 11.
Discussion
Ascorbic acid (vitamin C) is one of the nature's vital biomole-
cules serving an essential role in a number of important physio-
logical reactions such as collagen synthesis, iron metabolism and
immunity (Padh, 1990). As detailed in the introduction it is
surprising therefore, that many species have lost the capacity to
synthesize ascorbate. This defect has been estimated to have taken
place some 35–55 million years ago in humans and guinea pigs as
a result of highly mutated nonfunctional versions of GLO gene
(Nishikimi et al., 1992, 1994; Lachapelle and Drouin, 2011) and
believed to be a common occurrence for many species. It appears
that this was a result of evolutionary pressure due to the coupling
of the ability to have placental embryo development for reproduc-
tion and readily available dietary vitamin C source. In the case of
mammalian vertebrates such an occurrence was inherently timely
with no major adverse outcome. However, for those species that
retained the ex-vivo egg embryo development for reproduction,
the consequences and the adverse limitations of this is obvious.
For development of the egg embryo and general organogenesis the
absence of an ascorbate source dictates no development. Based on
our current knowledge, however, despite this the ex-vivo embryos
of birds and fish defiantly continue to grow and eventually hatch.
Fish, dinosaurs and birds were the early vertebrates to evolve pre-
dating modern vertebrates and primates between 450 and 150
million years. Ironically all of these early vertebrates were egg
laying species for reproduction and while the dinosaurs are extinct
the fish and birds are still in existence and continue to use the
same biological process for reproduction. A lack of capacity to
synthesize ascorbate by passeriform birds and teleost fish suggests
that the developing embryos of these species in ex-vivo eggs may
utilize alternative biomolecule(s) and mechanism(s) for stable
collagen synthesis during embryogenesis. The physico-chemical
properties of egg yolk phosvitin suggest its plausible candidacy
but scientific evidence in support of this has not been possible
until the present study. As discussed in the introduction this was
mainly due to lack of appropriate experimental model systems.
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Fig. 8. LC–ESI–MS/MS sequence analyses of synthetic collagen peptide analog incubated with prolyl-hydroxylase source in the absence and presence of Fe+2, Fe+3, ascorbate
and phosvitin. MS/MS spectrum of the synthetic peptide incubated under different reaction conditions. (A) A negative control conditions containing no Fe+2 and Fe+3, 50 mg
peptide+0.3 mM 2-ketoglutarate+enzyme source+50 mM NH4HCO3, pH 7.8, the series of y and b fragment ions provide the full peptide sequence GPPGPSGPPGPSGPPGPSGK
containing no hydroxyproline residue. (B) A positive control conditions containing ferrous chloride (Fe+2), 50 mg peptide+0.3 mM 2-ketoglutarate+100 mM ferrous chloride
(Fe+2)+enzyme source+50 mM NH4HCO3, pH 7.8, the series of y and b fragment ions reflect the full peptide sequence GPPGPSGPPGPSGP*PGPSGK with a single
hydroxyproline residue. (C) A test reaction with ascorbate, 50 mg peptide+0.3 mM 2-ketoglutarate+100 mM ferric chloride (Fe+3)+enzyme source+1 mM Na ascorbate
+50 mM NH4HCO3, pH 7.8, the series of y and b fragment ions reflect the full peptide sequence GPPGPSGPPGPSGPP*GPSGK with a single hydroxyproline residue. (D) A test
reaction with phosvitin, 50 mg peptide+0.3 mM 2-ketoglutarate+100 mM ferric chloride (Fe+3)+enzyme source+∼0.4 mM phosvitin+50 mM NH4HCO3, pH 7.8, the series of y
and b fragment ions reflect the full peptide sequence GPPGPSGPPGP*SGPPGPSGK with a single hydroxyproline residue indicated by a loss of mass equivalent to P+16 Da
(−113 Da) between y9 and y10 fragment ions, red arrow. In all cases the precise sites of hydroxyproline are denoted by an asterisk (*).
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For example, the most common animal model is the mouse and
interestingly they are one of the few species which evolutionarily
retained the capacity to biosynthesize ascorbate. Knock-out stu-
dies in mice with deficient ascorbate synthesis through deletion of
the GLO gene showed that collagen synthesis and the ratio of
proline:4-hydroxyproline appeared not to change significantly
(Parsons et al., 2006). The data indicated that although there
was an undesirable impact on general survival and weight gain
there was no significant effect on the synthesis of collagen. It was
suggested that either there was residual active ascorbate in
tissues/organs or collagen synthesis was independent of ascorbate
and there was perhaps another mechanism by which stable
collagen synthesis was possible (Parsons et al., 2006). Our studies,
however, using ex-vivo live neonatal mouse calvarial bone cultures
which eliminates the natural supply of ascorbate showed clearly
that in the absence of added ascorbate in such cultures there was
no new osteoid/bone formation and hence no stable collagen
synthesis (data presented herein; Curtin et al., 2012). Inclusion
of ascorbate in such cultures on the other hand proceeded with
rapid synthesis of collagen and formation of new osteoid
and bone.
Phosvitin is an abundant highly phosphorylated protein com-
ponent of egg yolk derived from the mid-portion of a full length
protein of vitellogenin II gene by post-translational proteolytic
cleavage and has been studied for almost half a century. Our most
recent studies on the topographical distribution of phosphoryla-
tion sites of phosvitins also led to the discovery of a second
phosvitin derived from vitellogenin I gene (Czernick et al., 2013).
Internalization of the egg yolk phosvitin into the oocyte via
specific cell receptor binding and subsequent endocytosis suggests
several important physiological functions for this protein during
embryogenesis of birds, reptiles and fish (MacLean and Sanders,
1983). One unique chemical property of phosvitin is its powerful
antioxidant/reducing agent capacity. This knowledge, however,
has not been linked to the fact that it is reminiscent of ascorbate
which is also an antioxidant/reducing agent that is an essential
biomolecule during the synthesis of stable collagen and hence,
formation and maintenance of connective tissue, organs and
skeletal system. In order to test our conceptual developments
detailed above we have utilized our live neonatal mouse calvarial
bone organ culture system under dissociative bone resorption and
formation conditions to reveal the unique and important biologi-
cal properties of phosvitin not shared by any other ECM phospho-
protein to date. The models we have developed have some very
critical significance since conditions used dissociates the two
remodeling stages, e.g., osteoclastic bone resorption and
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Fig. 9. Biomineralization of the primary embryonic calvarial osteoblasts in the absence and presence of β-glycerolphosphate, ascorbate and phosvitin. (A) Microscopic
observation of confluent osteoblasts cultured for 5 days in media alone, β-glycerolphosphate, β-glycerolphosphate+ascorbate, and β-glycerolphosphate+phosvitin followed
by exposure to 2% silver nitrate for 30 min. The significant density of black nodules of mineral deposits were clearly visible in cultures treated with ascorbate and phosvitin.
All magnifications were 100! . (B) Quantitative calcium levels in HCl extracts of the mineralizing osteoblast cell layers demonstrating the substantial mineral deposition in
the presence of ascorbate and phosvitin. The two sample Student's t test indicated that the differences in the levels of calcium deposition in controls (media alone or β-
glycerolphosphate) versus those cultures in the presence of β-glycerolphosphate+ascorbate or phosvitin were statistically significant with p values noted within the figure.
The calcium deposition for ascorbate versus phosvitin were, however, at similar levels and not statistically different. (C) Quantitative calcium uptake from the media of
cultures in media alone, β-glycerolphosphate, β-glycerolphosphate+ascorbate, and β-glycerolphosphate+phosvitin reflecting significant level of calcium uptake from the
media by osteoblast cell layer for cultures in the presence of ascorbate or phosvitin consistent with the calcium deposition levels in (B) above. The two sample Student's t test
indicated differences to be statistically different with p values noted within the figure.
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osteoblastic bone formation such that studies can be carried out to
target effects of added factors and drugs on individual components
as well as studies of cancer–bone interactions (Curtin et al., 2009,
2012). The resorption model was designed to permit PTH-induced
osteoclast differentiation from the resident progenitor/stem cells
in the absence of ascorbate. Under these conditions PTH induces
rapid osteoclastic bone resorption with complete suppression of
osteoblast differentiation. Interestingly, this latter phenomenon is
related to the inability of the mesenchymal/stromal cells to
differentiate to osteoblasts since in the absence of ascorbate they
cannot synthesize stable collagen which leads to lack of ECM
formation and hence no osteoblast differentiation. The models
used also “highlight critically important evidence that osteoclas-
togenesis is completely independent of ascorbate” in ex-vivo live
bone micro-
environment which is highly likely to be the case in in vivo bone
microenvironment too. This is contrary to the suggestion in the
literature that ascorbate was essential for “osteoclastogenesis” and
induced the formation of osteoclasts in a cooperative fusion with
1α,25-dihydrovitamin D3 (or PTH) in co-culture system of bone
marrow cells and clonal stromal ST2 (or CIMC-2) as mesenchymal
support cells (Otsuka et al., 2000; Ragab et al., 1998). As we have
recently highlighted in our work with cancer–bone interaction
studies (Curtin et al., 2012), there are major advantages of the live
bone organ culture models we have developed and that the co-
culture cell systems often do not provide the conditions that are
relevant to the in vivo circumstances. Under resorption conditions,
phosvitin inhibited PTH-induced osteoclast differentiation and
bone resorption as revealed by NR staining and global quantitative
histomorphometric analysis of silver stained whole calvaria which
has major advantages over typical histomorphometric analysis
using thin histological sections. There were however, some differ-
ences in the tissue's response toward the PTH+phosvitin and PTH
+ascorbate treatments. In the presence of phosvitin the osteoclas-
tic activity as well as their numbers were significantly reduced and
did not develop their typical multinucleated form. In the presence
of ascorbate on the other hand there was no significant osteoclas-
tic activity and or release of calcium instead there was uptake of
calcium. The surprising aspect of these observations was the fact
that phosvitin inhibited PTH-induced bone resorption with “simul-
taneous formation of significant amounts of new osteoid and
bone” in the absence of ascorbate. This latter case clearly provoked
a major interest within the context of this study, since our calvarial
bone resorption model is based on the use of culture media that is
devoid of ascorbate. Under such conditions it would be expected
that there will be no new stable collagen synthesis, osteoid or
bone formation because the synthesis and stability of the collagen
molecule is critically dependent upon the presence of ascorbate
for the synthesis of collagen containing hydroxylproline residues.
Such post-translational modifications occur through the action of
prolyl-hydroxylases whose catalytic activities are completely
dependent on the presence of ascorbate as an antioxidant/redu-
cing agent to regenerate ferrous (Fe+2) ion which undergoes
electronic oxidation to ferric (Fe+3) ion during the hydroxylation
step. These observations led us to further investigate this impor-
tant biologic event using our calvarial “bone formation model”. The
results from this bone formation model augmented the observa-
tions in the resorption system where chemical and biochemical,
histological and histomorphometric measurements were consis-
tent with new collagen synthesis and osteoid/bone formation. The
calcium uptake for phosvitin was lower than that of the ascorbate
alone however, in the presence of phosvitin alone there was
significant amount of differentiated osteoblasts and new osteoid
formation similar to that of ascorbate alone. These data indicated
that phosvitin alone is capable of promoting osteoblast differen-
tiation and new osteoid deposition and co-inclusion of phosvitin
and ascorbate appears to enhance such occurrence. While there
was a similar level of ALP activity and amount of new osteoid
formation between ascorbate and phosvitin treated cultures, the
extent of calcium uptake or biomineralization appeared to be
different. These results suggest that the initial formation of the
new organic matrix has a common biological process for ascorbate
and phosvitin, whereas the biomineralization (Ca-P deposition)
step that follow this appears to be divergent. This latter case is
likely to be due to the regulatory effect of phosvitin on the Ca-P
crystal nucleation which is a known characteristic of ECM phos-
phoproteins during biomineralization. These different stages
involved in the overall bone formation and its mineralization are
ascorbate
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β-Glycerolphosphate + Na ascorbate
β-Glycerolphosphate + Phosvitin
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Insoluble cell layer 
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Fig. 10. LC–ESI–MS total base-peak ion abundance of the trypsin digested ECM and
insoluble mineralizing osteoblast cell layers generated in the absence and presence
of ascorbate or phosvitin. (Inset) pictorial representation of the acid insoluble cell
layers with clear visible white pellets showing the major quantitative ECM
differences between the controls versus those in the presence of ascorbate or
phosvitin, red circled areas. (A) An example of LC–ESI–MS total base-peak ion
abundance profile of trypsin digested osteoblast ECM for samples derived from
media alone or β-glycerolphosphate cultures. (B) LC–ESI–MS total base-peak ion
abundance profile of trypsin digested osteoblast ECM for sample derived from β-
glycerolphosphate+ascorbate cultures. (C) LC–ESI–MS total base-peak ion abun-
dance profile of trypsin digested osteoblast ECM for sample derived from β-
glycerolphosphate+phosvitin cultures. The total ion intensities of controls ∼5!
lower than those derived from cultured in the presence of ascorbate or phosvitin
correlating with the ECM pellet sizes indicated in the (inset).
J. Liu et al. / Developmental Biology 381 (2013) 256–275270
Table 1
LC–ESI–MS/MS analysis and identification of the critical/abundant proteins in the osteoblast cell layers of mineralizing cultures in the absence and presence of β-glycerolphosphate (β-GP), ascorbate and phosvitin. The most
abundant typical bone ECM proteins collagen type I alpha 1 and alpha 2 chains and collagen type III with expected multiple hydroxyprolines were defined in the trypsin digested calvarial osteoblast cell layers in samples derived
from ascorbate and or phosvitin treated samples. In those same samples vimentin, “marker for epithelial to mesenchymal transition”, was also identified clearly. These proteins were not identified in the corresponding controls of
media alone and or β-GP treated samples. Asterisks (*) indicate hydroxylated proline residues, and MH+ refers to peptide mass.
Media alone (β-GP) β-GP+ascorbate (vitamin C) β-GP+phosvitin
Protein name Peptides Peptides Peptides MH+ Peptides MH+
Collagen type I alpha-2 Not identified Not identified R.VGAP*GPAGAR.G 868.5 R.P*GPIGPAGPR.G 934.5
R.SGHP*GPVGPAGVR.G 1203.6 R.PGP*IGPAGPR.G 934.5
R.GSP*GEP*GSAGPAGP*PGLR.G 1608.8 R.GIP*GPVGAAGATGPR.G 1293.7
R.GSP*GEPGSAGP*AGPP*GLR.G 1608.8 R.GIPGP*VGAAGATGPR.G 1293.7
R.GIP*GPVGAAGATGPR.G 1293.9 R.GEPGP*AGSVGPVGAVGPR.G 1576.8
R.TGPP*GPSGITGP*PGPP*GAAGK.E 1817.9 K.GATGLP*GVAGAP*GLP*GPR.G 1592.9
R.GDGGP*P*GMTGFPGAAGR.T 1533.7 K.GATGLP*GVAGAP*GLPGP*R.G 1592.9
R.TGEIGASGPP*GFAGEK.G 1490.7 K.GATGLP*GVAGAPGLP*GP*R.G 1592.9
R.GDGGPP*GMTGFP*GAAGR.T 1533.7 N.IGFPGP*KGPSGDP*GK.P 1442.7
R.GDGGP*PGMTGFP*GAAGR.T 1533.7 R.GQPGIAGALGEP*GPLGIAGPP*GAR.G 2142.1
R.GEPGP*AGSVGPVGAVGPR.G 1576.8 R.GSP*GEPGSAGP*AGPP*GLR.G 1608.8
K.GATGLP*GVAGAP*GLP*GPR.G 1592.9
K.GATGLP*GVAGAP*GLPGP*R.G 1592.9
K.GATGLP*GVAGAPGLP*GP*R.G 1592.9
L.P*GIDGRPGP*IGP*AGPR.G 1561.8
R.GLP*GEFGLP*GPAGPR.G 1453.8
R.GLP*GEFGLPGP*AGPR.G 1453.8
Collagen type I alpha 1 Not identified Not identified R.EP*GPSGLP*GPP*GER.G 1451.7 R.GETGPAGPAGPIGPAGAR.G 1532.8
R.EP*GPSGLPGP*P*GER.G 1451.7 R.GVQGPPGP*AGPR.G 1105.6
R.EP*GPSGLP*GP*PGER.G 1451.7 R.GAAGPP*GATGFP*GAAGR.V 1443.7
R.GAAGPP*GATGFP*GAAGR.V 1443.7 R.GAAGP*PGATGFP*GAAGR.V 1443,7
R.GAAGPP*GATGFP*GAAGR.V 1443.7
VGPP*GPSGNAGPP*GP*PGPVGK. 1840.9
Collagen type III alpha 1 Not identified Not identified R.GPP*GTAGTP*GLR.G 1112.6 R.GETGP*AGP*SGAP*GPAGAR.G 1554.5
K.DGSSGHP*GPIGP*PGPR.G 1516.7 R.GEP*GP*QGHAGAQGPP*GPP*GNN.G 1956.9
K.DGSSGHP*GPIGPP*GPR.G 1516.7
R.GETGP*AGP*SGAP*GPAGAR.G 1554.7
R.GPAGPIGP*PGPAGQP*GDKGEGGAP*GLP*GIAGPR.G. 2920.5
R.GEMGPAGIP*GAP*GLLGAR.G 1652.9
Collagen type XII alpha 1 Not identified Not identified R.GEVQTVTFDADEAK.T 1509.7 Not identified
K.GLTSSEPVSVMEK.T 1363.7
R.DYRPQVGVIADPSSK.T 1631.8
R.HVFIVDDFESFEK.I 1611.8
Fibronectin 1 R.WSRPQAPITGYR.I R.WSRPQAPITGYR.I R.WSRPQAPITGYR.I 1431.8 K.VFAVHQGR.E 913.5
K.GLAFTDVDVDSIK.I K.GLAFTDVDVDSIK.I K.GLAFTDVDVDSIK.I 1379.7 K.LGVRPSQGGEAPR.E 1323.7
L.LISWEPPAVSVR.Y L.LISWEPPAVSVR.Y R.SSPVVIDASTAIDAPSNLR.F 1913.0 L.VQTAVTNIDRPK.G 1341.8
R.SSPVVIDASTAIDAPSNLR.F R.SSPVVIDASTAIDAPSNLR.F L.LISWEPPAVSVR.Y 1353.8 R.HVLQSASAGSGSFTDVR.T 1718.9
R.VTDATETTITISWR.T R.VTDATETTITISWR.T R.VTDATETTITISWR.T 1593.8 R.FTNIGPDTMR.V 1151.6
K.VFAVHQGR.E 913.5 K.IAWESPQGQVSR.Y 1357.7
R.HVLQSASAGSGSFTDVR.T 1718.9 R.WSRPQAPITGYR.I 1431.8
R.WLPSTSPVTGYR.V 1363.7 R.YSPVKNEEDVAEL.S 1492.7
R.TFYQIGDSWEK.F 1373.6 K.FTQVSPTTL.T 993.5
K.DLQFVEVTDVK.V 1292.7 R.WLPSTSPVTGYR.V 1363.7
K.GLAFTDVDVDSIK.I 1379.7 R.TFYQIGDSWEK.F 1373.6
K.DLQFVEVTDVK.V 1292.7
R.SSPVVIDASTAIDAPSNLR.F 1913.0
K.GLAFTDVDVDSIK.I 1379.7
L.LISWEPPAVSVR.Y 1353.8
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some of the reasons how our live multicellular bone organ culture
system responsive to external stimuli by its resident stem cells
undergoing differentiation which may give rise to some diver-
gence in the observations in Fig. 6 as compared to Fig. 7B.
Interestingly, our live bone cultures appear to simulate the events
that arise from intermittent PTH treatment of osteoporosis which
leads to stimulation of bone formation. In the presence of
ascorbate or phosvitin bone cultures respond to PTH by significant
differentiation of osteoblasts and formation of new osteoid/bone.
These results suggest that inclusion of factors that stimulate
osteoblast differentiation in bone organ cultures takes precedence
over PTH-induced osteoclast differentiation.
It has been demonstrated that phosvitin bound to collagen
substrate can promote nucleation of Ca-P (Onuma, 2005), and can
bind 127 mol of Ca+2/mol of phosvitin (Grizzuti and Perlmann,
1973). The possibility of Ca+2 binding to phosvitin may lead to the
observed uptake of Ca+2 in our bone organ cultures can be
excluded. This is because the solid phosvitin was first dissolved
in the culture media to give stock solution which will render the
phosvitin to be saturated with Ca+2 at this stage since there is
excess supply of Ca+2 in the culture media. Aliquots of this was
further diluted 200! in the working culture media to be used. In
addition, based on the above calcium binding capacity of phosvi-
tin, our calculations indicate that even without the above experi-
mental approach the potential amount of Ca+2 that could bind to
phosvitin can only account for o10% that of the total Ca+2 up-take
from the media for both bone organ cultures and cultured
osteoblasts. Importantly, our work with cultured osteoblasts
clearly supported and confirmed the bone organ culture studies
with mineralization of the osteoblasts in the presence of ascorbate
or phosvitin to the same extent. In this latter case the quantitative
Ca+2 deposition in the mineralizing cell layer was also determined
in conjunction with the Ca+2 uptake from the media. The results
confirmed that the Ca+2 up-take from the media were correlative
with the Ca+2 depositions to the newly synthesized ECM. It is
interesting to note that neither the role of phosvitin in egg shell
(predominantly calcium carbonate) formation has not been
defined nor its presence in this mineralized environment. Other
phosphoproteins including those specific to egg shell have been
proposed for this activity such as ovocleidin-17 and -116, and
ovocalyxin-32 and -36 (Hincke et al., 2003, 1995; Gautron et al.,
2007; Mann et al., 2002).
Our striking results with bone organ culture systems led us to
design and synthesize a collagen peptide analog with multiple
prolyl-hydroxylase recognition sites to provide additional direct
supporting evidence. Use of this peptide under test tube chemistry
conditions in the absence and presence of ascorbate or phosvitin
together with mass spectroscopic analysis provided direct evi-
dence in support of the unique properties of phosvitin that can
mirror those of ascorbate in facilitating hydroxylation of proline
residues. These observations were further confirmed by use of
cultured mineralizing calvarial osteoblasts for the first time with
phosvitin. In this latter cell culture system we have established
clearly that cultured osteoblasts behaved physiologically and
biochemically the same manner toward exposure to “ascorbate or
phosvitin” in terms of osteoblast differentiation, synthesis of
dominant bone ECM proteins such as collagen type I alpha 1
and alpha 2 chains, generation of critically important hydroxypro-
lines in collagens and general biomineralization. The use of mass
spectrometric analytical approaches to analyze with high precision
the details of the mineralized osteoblast ECM components
provided ultimate confirmatory results that phosvitin stimu-
lates osteoblast differentiation, collagen synthesis, hydroxyproline
formation and regulation of biomineralization. These studies also
led to the identification of vimentin (an important marker for
epithelial to mesenchymal transition), and collagen type IIITa
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(a fibrillar collagen associated with collagen type I in bone), in
both ascorbate and phosvitin treated cultures which signify the
critical role of phosvitin in connective tissue and bone organo-
genesis.
Conclusions
Overall, our studies culminated in the discovery of an impor-
tant and unique bioactivity for phosvitin in the collagen synthesis
and formation of new osteoid/bone in the absence of ascorbate, a
biological function that has avoided discovery for many decades
due to lack of an appropriate model system until now. To the best
of author's knowledge there has been no other naturally occurring
biomolecule to date that has shown to have such a capacity except
ascorbate. In essence our live neonatal mouse calvarial model
systems developed with bone remodeling stages dissociated have
uniquely positioned us to truly decipher biological events and test
bioactive molecules in a manner that cannot be achieved as easily
by in vivo animal or in vitro cell culture models. This is particularly
significant with regards to bone biology since in any animal model
studies the circumstances in vivo very frequently preclude clear
determination of the outcome of the designed experimental
perturbations. For instance, in vivo there is continual “bone turn-
over” involving resorption and formation ongoing simultaneously
such that the impact of altering one or the other requires long
term study to reveal itself. Interestingly, the ex-vivo live mouse
calvarial bone models, in addition to several other advantages
discussed recently by Curtin et al. (2012), have a major advantage
within the context of the present study because although mice can
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Fig. 11. LC–ESI–MS/MS sequence analyses of the collagen type I alpha 2 chain derived from trypsin digested ECM of mineralizing osteoblast cell layers cultured in the
presence of ascorbate or phosvitin. (MS/MS spectrum of collagen type I alpha 2 chain peptide identified in trypsin digested acid insoluble ECM of mineralizing osteoblasts
cultured in the presence of (A) ascorbate and (B) phosvitin. The series of b and y fragmentation ions are labeled and the hydroxyproline residues succinctly defined by the
loss of mass 113 Da (–P–OH) between y6 and y7, y12 and y13 and b11 and b12. The peptide sequence, GATGLP*GVAGAP*GLP*GPR, contained three hydroxyproline residues
indicated by the asterisks (*) was identified in ECM of mineralizing osteoblasts cultured in the presence of ascorbate or phosvitin.
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biosynthesize ascorbate, this takes place in the liver and hence our
cultured bones are devoid of a natural ascorbate source which
indirectly reflects a system with specific gene product such as
ascorbate is knocked-out. Complementing those studies use of the
synthetic collagen peptide analog and cultured calvarial osteo-
blasts provided results that augmented the bone organ culture
work and confirmed through multiple direct evidence the capacity
of phosvitin to stimulate differentiation of osteoblasts, collagen
synthesis, hydroxyproline formation, and biomineralization. The
implications of the current findings are very significant and broad.
From an evolutionary point of view egg yolk phosvitin has been
serving a vital role individually or in combination with ascorbate
in general embryogenesis during the development of egg embryos
since the evolution of the first vertebrates, fish (∼450 million years
ago) and dinosaurs and birds (∼200 million years ago) which all
relied on an ex-vivo egg embryo development for reproduction.
Whereas in those species of passeriform birds, teleost fish and
reptiles in which the gene for the enzyme in the last step of
ascorbate synthesis has been inactivated, the present work pro-
vided first specific evidence for a potential biomolecule enabling
the connective tissue, organ and skeletal system formation during
their egg embryo development in the absence of ascorbate. The
implication for contemporary times is the discovery of a naturally
occurring biomolecule which can stimulate the differentiation of
resident local progenitor/stem cells to osteoblastic lineage, stable
collagen synthesis and hence formation of connective tissue and
new bone. This latter phenomenon opens new research avenues
with major scientific interest in a wide range of applications in
tissue engineering and regenerative medicine/dentistry.
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Effect of Corticotomies with Different Instruments on 
Cranial Bone Biology Using an Ex Vivo Calvarial  
Bone Organ Culture Model System
Different corticotomy surgical procedures have been developed to shorten 
orthodontic treatment times by stimulating bone remodeling. Although all 
corticotomy procedures involve physical injury to the bone, the clinical outcomes 
can vary. Using an ex vivo calvarial bone organ culture model system, the authors 
evaluated the biologic response of bone to different corticotomies. Bone injuries 
were generated in 276 calvaria dissected from 5- to 7-day-old neonatal mice 
using a piezoelectric knife, a bur, and a handheld screw device. The responses 
were evaluated using chemical, biochemical, and global histomorphometric 
analyses. Injuries generated by the three approaches induced varying degrees 
of bone remodeling activities; however, the piezoelectric knife led to the 
most extensive impact in both bone resorption and formation models. Int J 
Periodontics Restorative Dent 2016;36(suppl):s123–s136. doi: 10.11607/prd.2701 
Over the past few years, the popu-
larity of accelerated orthodontics 
has increased, with interest from 
patients as well as dental profes-
sionals. This interest is a result of 
adult patients wanting to shorten 
treatment times as much as pos-
sible. Since 2000, numerous dental 
surgical procedures have become 
available. Although effective, some 
of these techniques are also quite 
invasive, as they require extensive 
flap elevations and bur-generated 
osseous injury. These procedures 
have the potential to generate post-
surgical discomfort as well as post-
operative complications. Introduced 
in 2009, piezocision is a minimally 
invasive procedure that combines 
microincisions with selective tunnel-
ing that allow for hard- or soft-tissue 
grafting and piezoelectric bone de-
cortication.1–3 Micro-osteoperfora-
tion of the alveolar bone is another 
minimally invasive technique that 
involves micro-osteoperforations 
of the alveolar plate, through the 
gingiva, using a handheld screw-
type device. 4 All of these surgical 
techniques aimed at accelerating 
orthodontic tooth movement take 
advantage of the regional accelera-
tory phenomenon, which was first 
described by Frost.5–7 The regional 
acceleratory phenomenon involves 
intentional surgical injury to the 
bone that starts a cascade of physi-
ologic events leading to an increase 
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in bone turnover with concomitant 
demineralization and bone resorp-
tion, with remineralization and new 
bone formation at the site of the 
bone injury. The response of bone 
to injury is dependent on many fac-
tors, such as the degree of injury, 
age, and type of injury, all of which 
impact bone cells differently. A 
procedure that yields minimal and 
superficial physical injury with no 
additional stimulatory capacity, such 
as micro-osteoperforation of the al-
veolar bone alone using a handheld 
screw-type device, may not be suf-
ficient. A classic corticotomy proce-
dure with gingival flap and extensive 
bone injury by dental bur, on the 
other hand, may produce sufficient 
impact, but this impact is at the 
expense of vast areas of damage. 
The techniques used in piezocision 
appear to take advantage of the 
bone’s inherent biologic response 
mechanisms of stimulating bone 
cells in addition to injury through 
high-frequency vibrations. However, 
to the authors’ knowledge, biologic 
bone responses to different cort-
ictomy techniques have yet to be 
compared.
The aim of the present study 
was to compare biologic responses 
of bone to different surgical ap-
proaches using an ex vivo calvarial 
bone organ culture model system. 
Bone injuries were generated using 
a rotating bur, a piezoelectric knife, 
and a handheld screw-type device. 
These bone organ culture models, 
under controlled conditions, allow 
for either osteoblast differentiation 
and bone formation or osteoclast 
differentiation and bone resorption 
in response to external stimuli. 
Materials and methods
The present study was approved by 
the Institutional Animal Care and 
Use Committee at Boston Medi-
cal Center, Boston University. Cal-
varia from 5- to 7-day-old neonatal 
CD-1 mice (n = 276) (Charles River 
Laboratories) were dissected un-
der sterile conditions, cut to pro-
duce a trapezoid structure (1 cm 
× 0.6 cm), and washed briefly in 
culture medium. The live bone 
organ culture medium consisted 
of Dulbecco modified Eagle me-
dium supplemented with 5 mg/mL 
bovine serum albumin (Sigma), 100 
U/mL penicillin, 100 µg/mL strep-
tomycin, and 250 ng/mL ampho-
tericin B (Gibco). The addition of 
1 nM parathyroid hormone to the 
growth medium induced the cal-
varial bone to undergo osteoclastic 
bone resorption (bone resorption 
assay), whereas the culture medium 
supplemented with 1 mM sodium 
ascorbate (Sigma) and no parathy-
roid hormone induced bone forma-
tion (bone apposition assay). These 
models were developed and used 
for other bone resorption and appo-
sition studies, the detailed method-
ologies of which can be found in the 
literature.8–10 
Comparative effects of 
piezoelectric, bur, and 
handheld screw perforation 
injury on bone resorption 
The isolated calvaria were cultured 
in the media for 48 hours before 
the injury procedures. The calvarial 
bone organs were primed to un-
dergo osteoclastic bone resorption 
using a low dose of parathyroid hor-
mone. The injuries were created by 
using a piezotome with a BS1 insert 
(Satelec, Acteongroup), a bur (1 mm 
in diameter, Komet carbide round 
bur mounted on a high-speed 
handpiece), and a handheld screw 
perforation device (TruFix, ACE Sur-
gical). All injuries were standardized 
so that each had the same size and 
depth of bone perforation damage. 
Calvaria were divided into the fol-
lowing six groups, with 26 calvaria 
per group (n = 156): (1) media only 
(negative control); (2) piezotome 
sham injury (the piezotome was 
placed and allowed to vibrate in 
media for 5 seconds with no injury); 
(3) piezotome injury; (4) bur sham 
injury (the bur was mounted on the 
high-speed handpiece and allowed 
to spin in media for 5 seconds with 
no injury); (5) bur injury; and (6) screw 
perforation injury (Fig 1). 
After the 10-day postinjury cul-
ture period, 10 calvaria from each 
group underwent neutral red stain-
ing and silver nitrate counterstain-
ing, and another 10 were processed 
for tartrate-resistant acid phospha-
tase (TRAP) activity. The remaining 
six whole calvaria were fixed in a 
10% formalin solution, decalcified, 
and stained with hematoxylin and 
eosin stain for histologic analysis.  
Neutral red staining to visualize 
osteoclast activity and silver 
nitrate staining for bone 
resorption
Neutral red has been used for the 
staining of live osteoclasts.8–12 After 
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the 10-day postinjury culture pe-
riod, 10 calvaria were incubated for 
an additional 45 minutes at 37°C 
with neutral red stain (70 µg/mL; 
Sigma). The mature multinucleated 
resorptive osteoclasts were evalu-
ated microscopically in all groups. 
After microscopic evaluation, neu-
tral red–stained samples were 
washed in phosphate-buffered sa-
line, fixed in a 10% formalin solu-
tion overnight, and counterstained 
with a 2% silver nitrate solution 
(Sigma-Aldrich) for 20 minutes to 
reveal gross mineral loss and bone 
resorption areas.9–12 
TRAP activity
To assay TRAP activity, which is a 
marker for osteoclast numbers and 
activity, the enzyme was released 
from the cellular layer of the calvaria 
using a 250 μL/calvaria lysis buffer 
(0.15-M sodium chloride/30 mM so-
dium bicarbonate; pH level, 8.0; con-
taining 0.5% Nonidet P-40 (Sigma) 
and keeping the calvaria on ice for 
1 hour with frequent agitation fol-
lowed by centrifugation to remove 
calvarial bone and debris. Cell ex-
tracts were used immediately for 
assay. Measurements of duplicates 
were made using 50 µL of each cal-
varial cell extract in duplicate with 
250 µL of 0.1-M sodium acetate buf-
fer with a pH level of 5.0, contain-
ing 50 mM tartaric acid, 3 mM zinc 
chloride, and 16 mM p-nitropheny-
phosphate (Sigma) for 30 minutes at 
37°C using a 96-well microplate. At 
the end of the incubation time, 10 μL 
of 2-M sodium hydroxide was add-
ed to each well, and absorbance at 
405 nm was measured. The hydro-
lysis of the substrate and amount of 
p-nitrophenol released was calcu-
lated using the extinction coefficient 
ε405 nm = 12,500 mol-1 l cm-1 to cal-
culate the concentration in mol l-1. 
This information, together with time 
of incubation, was used to calcu-
late the rate of substrate hydrolysis 
in terms of µmols l-1 min-1 and nor-
malized for the protein content (per 
mg of protein) of the calvarial cell 
extract. The protein content of the 
cell extracts was determined with a 
modified method of Lowry micro-
protein assay using bicinchoninic 
acid.13
Global histomorphometric 
analysis
The calvarial bones stained with 
neutral red and counterstained 
Fig 1 Photographs of the different 
corticotomy surgical injury procedures.  
(a) Piezotome sham injury (media pulse 
treatment). (b) Piezotome injury. (c) Bur 
injury. (d) Handheld screw-type perforation 
injury.
a
Live calvarial bone
Piezotome handpiece
c
Live calvarial bone
Bur handpiece Stainless steel grid
d
Live calvarial bone
Screw  
handpiece
Stainless steel grid
b
Live calvarial bone
Piezotome handpiece
Stainless steel grid
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with silver nitrate were microscopi-
cally evaluated at low magnification 
(×2.5) to measure the quantitative 
degree of osteoclastic bone resorp-
tion.10 
Comparative effects of 
piezoelectric, bur, and 
handheld screw perforation 
injury on bone formation
The calvarial bone organs were 
primed to undergo osteoblastic 
new osteoid and bone formation in 
the presence of 1 mM sodium ascor-
bate (150 μg/mL). Calvaria from a 
new set of animals were divided 
into the same 6 groups and under-
went the same injury procedures. 
The calvaria (n = 120) were placed 
on stainless steel grids as previ-
ously described.9 The media were 
changed every 2 days, and the used 
media were stored at 4°C for cal-
cium analyses.9,10 After the 10-day 
postinjury culture period, 8 calvaria 
from each group underwent hema-
toxylin and eosin stain for histologic 
analysis, and the remaining 12 cal-
varia from each group underwent 
neutral red staining followed by sil-
ver nitrate counterstaining. 
Statistics 
Chemical, biochemical, and quanti-
tative histomorphometric data were 
presented as mean ± standard de-
viation (SD). The original data sets 
were evaluated for group variance 
using the Shapiro-Wilk test and 
found to have normal distribution; 
hence, parametric statistical analy-
sis was applied. The statistical sig-
nificance of the differences between 
control vs treatment groups and 
between different treatment groups 
were evaluated using a two-tailed 
paired t test with unequal variance. 
The differences between groups 
were considered statistically signifi-
cant at P < .05. 
Results
Injury impact on bone 
resorption
Histologic evaluation 
Fig 2 shows histologic sections 
with hematoxylin and eosin stain 
after 10 days of postinjury bone 
cultures. No osteoclastic bone re-
sorption was noticed in the parietal 
bone in the media-only group, and 
few osteoclastic resorption areas 
were found in the bur sham injury 
group and tacks with injury (Figs 
2a, 2b, and 2c). Calvaria in the bur 
injury group had increased levels of 
osteoclastic resorption in the pari-
etal bone at the site of injury (Fig 
2d). Surprisingly, elevated levels of 
osteoclastic resorption were ob-
served in the piezotome sham ther-
apy group (Fig 2e). The impact of 
piezotome injury was substantial in 
parietal bones at the site of injury, 
as well as extending to the contra-
lateral parietal bone separated by 
the midsuture (Fig 2f). Although all 
injuries induced osteoclastic bone 
resorption within the immediate 
proximity of the injury, piezotome 
also had a substantial effect on os-
teoclast differentiation and bone 
resorption at a distance. This effect 
can be attributed to the combined 
and synergistic effects of injury and 
high-frequency vibrations.
Quantitative analysis of changes in 
media calcium and TRAP activity
Fig 3a shows total cumulative 
changes in media calcium for all 
groups over a 10-day culture period. 
Calvaria in the media-only group 
exhibited minimal calcium release. 
Variable levels of calcium release 
were found in the other groups, with 
calvaria in the piezotome sham inju-
ry and piezotome injury groups ex-
hibiting the highest levels, reflective 
of major bone resorption. The bur 
injury and screw perforation injury 
groups showed significantly lower 
levels of calcium release, reflective 
of low levels of bone resorption. 
These data are consistent with the 
histologic observations shown in Fig 
2. The quantitative TRAP enzyme 
activity was consistent with these re-
sults (Fig 3b). The results for calcium 
release and TRAP activity were ana-
lyzed using a two-tailed paired t test 
with unequal variance to show sta-
tistical significance (Figs 3a and 3b).
Global visualization of osteoclast 
formation with neutral red stain
Figure 4 shows osteoclasts with neu-
tral red stain and resorption activities 
with silver nitrate stain. No osteo-
clasts were observed in the control 
group (Figs 4a and 4b). In contrast, 
groups with injury sites showed vari-
able levels of numerous and distinct 
neutral red–stained multinucle-
ated osteoclasts (Figs 4 to 7), with 
maximum osteoclast formation and 
bone resorption observed in the 
piezotome groups (sham and injury). 
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The bur injury and screw perforation 
injury groups had significantly lower 
levels of osteoclasts than the other 
groups. Interestingly, piezotome 
injury on one parietal-bone hemi-
sphere induced significant osteo-
clast formation and bone resorption 
at a distance (the contralateral non-
injured parietal bone) (Figs 4d, 4e, 
4g, 5a, and 5b). Contrarily, bur and 
screw perforation injuries did not 
result in the same phenomenon 
Fig 2 Histologic cross-sections of calvarial bones subjected to different corticotomy surgical injury procedures in the bone resorption 
model. (a) Media only (untreated control) showed no osteoclastic bone resorption. (b) Bur sham injury (pulse only media) showed low-
level osteoclastic bone resorption. (c) Screw perforation injury showed some osteoclastic bone resorption. (d) Bur injury showed moderate 
osteoclastic bone resorption. (e) Piezotome sham injury (pulse only in media for 5 s) showed significant osteoclastic bone resorption. (f) 
Piezotome injury showed substantial osteoclastic bone resorption including some regions of bone completely dissolved. Per = periosteum, 
End = endosteum, OstRA = osteoclastic resorption areas (hematoxylin and eosin stain; ×200 magnification).
Fig 3 Quantitative calcium release analysis for bone loss and quantitative tartrate-resistant acid phosphatase (TRAP) enzyme activity for 
osteoclast quantification in the calvarial bone resorption model. (a) Quantitative calcium analysis of media from calvarial cultures subjected 
to different corticotomy surgical injury procedures. (b) Quantitative TRAP enzyme activity analysis as a measure of osteoclast numbers in 
calvaria subjected to different corticotomy surgical injury procedures: media only (unstimulated control); piezotome sham injury (pulse only 
in media for 5 s), piezotome injury, bur sham injury (pulse only media); bur injury; and screw perforation injury. 
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(Figs 6 and 7). Furthermore, the 
piezotome sham injury group had 
osteoclastic activity higher than that 
of the media only group (Figs 4 and 
5). After the neutral red–stained 
calvaria was counterstained with sil-
ver nitrate, those in the media-only 
group showed no resorption areas 
(Fig 4c), whereas those in the other 
groups showed clear but different 
degrees of resorption areas (Figs 4c, 
4f, 5c, 5f, 6c, 6f, 7c, and 7f). These 
data were consistent with the ob-
servations from neutral red staining, 
histologic observations, and calcium 
level changes in the media. 
Quantitative histomorphometric 
analysis of calvarial bones in the 
resorption model system 
We evaluated the silver nitrate–
stained calvaria at ×2.5 magnifica-
tion to determine the quantitative 
global bone resorption areas.10 
The microscopic unit area mea-
surements for the degree of bone 
resorption reflected by the light 
transparency (white regions) rela-
tive to the black areas were con-
verted to % resorption areas by 
setting the highest resorption area 
as 100% and calculating the oth-
ers relative to that. Figure 8 shows 
Fig 4 Bone resorption model using mouse calvarial bone organ cultures subjected to 
media only (no treatment control), piezotome sham injury (media pulse control), piezotome 
injury, bur injury, and screw perforation injury. (a to c). Media alone (no treatment control). 
(a and b) Neutral red (NR)–stained calvaria at low (×25) and high (×100) magnifications. 
(c) Stained calvaria counterstained with silver nitrate (magnification ×25). (d to f) Calvaria 
treated with piezotome sham injury. (d and e) Neutral red–stained calvaria at low (×25) 
and high (×100) magnifications. (f) Neutral red–stained calvaria counterstained with silver 
nitrate (magnification ×100). (g) Higher magnification of a multinucleated resorptive 
osteoclast (×200). NO-MN-OSC = no multinucleated osteoclasts; MN-OSC = multinucleated 
osteoclast; No-RA = no resorption areas; OSC-RA = osteoclast resorption areas. 
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that the piezotome injury group 
had higher osteoclast differentia-
tion and bone resorption than the 
bur and screw perforation injury 
groups, consistent with the global 
neutral red stain observations of 
multinucleated osteoclasts.
Impact of injury on bone 
formation
Histologic evaluation 
Figure 9 shows histologic sections 
after the 10-day postinjury culture 
period. The media only group had 
some osteoblastic activity and new 
osteoid formation (Fig 9a). How-
ever, the piezotome sham injury 
and piezotome injury groups had 
extensive osteoblast differentiation 
and new osteoid formation (Figs 
9b to 9d). This effect was far reach-
ing, as it included parietal bones of 
the second hemisphere that had no 
injury (Fig 9e). These findings were 
quite distinct from those observed 
in the bur injury group, where the 
immediate injury site had signifi-
cant osteoblast differentiation and 
new osteoid formation that stayed 
Fig 5 (a to c) Nondefect parietal side of 
calvaria. Neutral red (NR)–stained calvaria at 
(a) low (×25) and (b) high (×100) magnifica-
tions. (c) NR-stained calvaria counterstained 
with silver nitrate (magnification ×25). (d to f). 
Defect side of calvarial parietal hemisphere 
subjected to piezotome injury directly. NR-
stained calvaria at (d) low (×25) and (e) high 
(×100) magnifications, and (f) NR-stained 
calvaria counterstained with silver nitrate 
(magnification ×25). Higher magnification 
(×100) of (g) the piezotome injury region and 
(h) osteoclastic bone resorption region.  
MN-OSC = multinucleated osteoclast;  
OSC-RA = osteoclast resorption areas. 
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localized to the site (Figs 9a and 9b). 
Similar findings were found for the 
screw perforation injury group, but 
with an even lesser degree of osteo-
blast differentiation and new oste-
oid formation (Figs 9c and 9d).
Global visualization of osteoclast 
formation and possible bone 
resorption 
Figure 10 shows results of global 
silver nitrate–stained calvaria when 
calvarial bone organ cultures were 
primed to undergo bone formation. 
The media alone, piezotome sham 
injury, and piezotome injury groups 
showed no osteoclastic bone re-
sorption in the parietal bones of the 
calvaria. However, the bur and screw 
perforation injury groups showed 
some degree of bone resorption 
activities. The changes in the me-
dia calcium levels were distinct and 
confirmed results from global silver 
nitrate staining (Fig 11). The media 
calcium changes were clear calcium 
uptake by both piezotome sham in-
jury and piezotome injury groups, 
consistent with the histologic obser-
vations. These data demonstrated 
significant stimulation of the calvari-
al bones by the piezotome, resulting 
in significant osteoblast differentia-
tion and new bone formation within 
the immediate bone injury region 
and beyond. These findings were 
Fig 6 (a to c) Nondefect parietal side of cal-
varia. Neutral red (NR)–stained calvaria at (a) 
low (×25) and (b) high (×100) magnification. 
(c) NR-stained calvaria counterstained with 
silver nitrate (magnification ×25). (d to f). 
Defect side of calvarial parietal hemisphere 
subjected to bur injury directly. NR-stained 
calvaria at (d) low (×25) and (e) high (×100) 
magnifications, and (f) NR-stained calvaria 
counterstained with silver nitrate (magnifica-
tion ×2). (g, h) Higher magnification of the 
bur injury region (×100). MN-OSC = multi-
nucleated osteoclast; OSC-RA = osteoclast 
resorption areas.
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Fig 7 (a to c). Nondefect parietal side 
of calvaria. Neutral red (NR)–stained 
calvaria at (a) low (×25) and (b) high 
(×100) magnifications, with no apparent 
multinucleated osteoclasts. (c) NR-stained 
calvaria counterstained with silver nitrate 
(magnification ×25), showing very few 
resorption areas. (d to f). Defect side of 
calvarial parietal hemisphere subjected to 
screw-type perforation injury directly. NR-
stained calvaria at (d) low (×25) and (e) high 
(×100) magnifications, with a few di- and 
trinucleated osteoclasts, and (f) NR-stained 
calvaria counterstained with silver nitrate 
(magnification ×25), showing resorption 
areas. (g, h) Higher magnification (×100) 
of the screw-type perforation injury region. 
MNOSC = multinucleated osteoclast. OSC-
RA = osteoclast resorption areas.
Fig 8 Global osteoclastic bone resorption determined by 
histomorphometric analysis of the silver-stained whole cal-
varial bones at low magnification. Calvaria in each treatment 
group stained with neutral red and counterstained with silver 
nitrate where the digital images (×25 magnification) were 
transformed to black and white images and different shades 
of these were used to determine the degree of resorption. 
All of the groups showed increased levels of bone resorption 
relative to media alone with no treatment. Piezotome sham 
injury resulted in a similar level of bone resorption induction 
as injury by bur and screw type perforation device. However, 
piezotome injury resulted in significantly higher levels of 
bone resorption induction (P = .001) than bur and screw-
type perforation. 
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not observed in the bur and screw 
perforation injury groups, in which 
the media calcium changes were 
similar to those of the media alone 
group. The overall results suggest 
that the piezotome effects are not 
simply a result of bone injury—they 
are also a result of high-frequency 
vibration on bone stem, progenitor, 
osteoblast, and osteocyte cells.
Discussion
The clinical significance of acceler-
ating orthodontic tooth movement 
has been conceptualized for almost 
Fig 9 Hematoxylin and eosin (HE) histologic evaluation of cross-sections of calvarial bones subjected to different surgical injuries in the 
bone organ culture model system. (a) Media only (untreated controls) showing some osteoblast differentiation and new osteoid (HE; mag-
nification ×200). (b) Piezotome sham injury (pulse only in media for 5 s) with numerous osteoblast differentiation and new osteoid forma-
tion on both periosteal and endosteal sides of the calvaria (HE; magnification ×200). (c) Piezotome immediate injury site with substantial 
and extensive osteoblast differentiation and new osteoid formation (HE; magnification ×100). (d) Piezotome injury side with substantial 
and extensive osteoblast differentiation and new osteoid formation on both periosteal and endosteal sides of the parietal bone of the cal-
varia (HE; magnification ×200). (e) Piezotome noninjury parietal side of the same calvaria showing significant osteoblast differentiation and 
new osteoid formation (HE; magnification ×200). (f) Bur immediate defect site with significant osteoblast differentiation and new osteoid 
formation limited to the defect region only (blue line) (HE; magnification ×200). (g) Bur defect parietal bone side showing extended region 
with minimal osteoblast differentiation and new osteoid formation beyond the immediate defect site (blue circled line) (HE; magnification 
×100). (h) Hand-held screw perforation immediate injury site with some osteoblast differentiation and new osteoid formation (HE; magnifi-
cation ×100). (i) Hand-held screw perforation bone side showing extended region with minimal osteoblast differentiation and new osteoid 
formation beyond the immediate defect site (HE; magnification ×200). Per = periosteum, End = endosteum.
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a century, and a number of surgical 
and physical approaches have been 
used, in conjunction with conven-
tional orthodontics, to this effect.14 
Of these approaches, bur corticoto-
my has been one of the most com-
monly used in the clinical setting, but 
because of its major surgical impact 
on patients and associated risks, this 
technique has not been widely em-
braced by dental professionals and 
patients. Piezoelectric technologies 
are an alternative, less invasive, and 
potentially more effective approach 
to accelerating orthodontic tooth 
movement.1–3 The piezoelectric knife 
combines alveolar bone corticoto-
my with high-frequency mechanical 
vibration. The use of piezotome in 
piezocision-assisted orthodontics 
has resulted in similar, and in some 
cases better, results than the other 
forms of corticotomies.15 However, 
to date, a clear understanding of the 
molecular mechanisms by which pi-
ezocision provides enhanced tooth 
movement is still lacking. 
It is well known that osteocytes 
are the major mechanosensors in 
bone responsible for sending sig-
nals that influence general bone 
remodeling through induction of os-
teoclastic bone resorption or osteo-
blastic bone formation. These two 
processes are tightly coupled and 
operate in combination with osteo-
cytes to provide the ultimate biolog-
ic outcome, which may be bone loss 
or bone gain depending on whether 
the skeleton in vivo is subjected to 
normal gravitational and mechanical 
load. One of the major limitations 
that has prevented effective study 
of corticotomy-assisted orthodontic 
tooth movement has been the lack 
of an appropriate ex vivo model 
system containing all the necessary 
cellular and bone microenvironment 
components to closely simulate 
the in vivo bone biology. To evalu-
ate the observed divergent clinical 
Fig 10 Mouse calvarial bone organ culture model subjected to different surgical injury procedures using 
piezotome, bur, and handheld screw type perforation devices followed by silver nitrate staining and 
quantitative calcium uptake analysis for new bone formation. (a to h). The silver nitrate–stained calvaria for 
different treatment regimens shows distinct absence and presence of osteoclastic bone resorption areas 
indicated by light transparency and the corresponding injury generated by use of piezotome, bur, and screw-
type perforations. (a) Media alone. (b) Piezotome (pulse only in media). (c) Piezotome, defect side.  
(d) Piezotome, nondefect side. (e) Bur, defect side. (f) Bur, nondefect side. (g) Screw perforation, defect side. 
(h) Screw perforation, nondefect side.
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outcomes, the authors have used 
a well-established live craniofacial 
bone organ culture model.8–10 De-
spite the obvious differences in age 
and precise location of the bone at 
which orthodontic tooth movement 
occurs, the biologic events that oc-
cur with respect to bone remodel-
ing are fundamentally the same. The 
different age of the bone predomi-
nantly affects the response time and 
the density of osteoblast and osteo-
clast differentiation. 
The aim of the current study 
was to discern and highlight the 
specific and clinically relevant ef-
fects of different injury protocols on 
bone remodeling. The use of live 
neonatal (5- to 7-day-old) calvarial 
bone organ culture model systems 
in the present study was based es-
sentially on the inherent characteris-
tics of the bone being a craniofacial 
bone, which undergoes repair and 
development by means of an in-
tramembranous mechanism (direct 
bone formation) with no intermedi-
ate cartilage formation (similar to the 
Fig 11 Quantitative calcium analysis of media from 
calvaria subjected to different treatments. A signifi-
cant uptake of calcium occurred for groups treated 
with piezotome sham injury and piezotome injury. 
Media only, bur, and screw perforation procedures 
showed no significant calcium uptake, consistent 
with the histologic results in Fig 9. 
maxilla and mandible). The system, 
under specifically defined culture 
conditions, permits intricate defini-
tion of the effects of external stimuli. 
Furthermore, neonatal calvaria have 
unique properties for rapid cellular, 
physiologic, and biochemical re-
sponses to external stimuli, which 
require a very short experimental 
time frame because of their highly 
responsive characteristics and rich 
stem cell population ready to spin 
into action at an unprecedented 
rate. This latter property is the rea-
son for the present study’s bone 
organ culture time frame of only 
10 days after bone injury. This time 
frame was sufficient to see the 
bones’ cellular, chemical, and bio-
chemical responses, which can peak 
within 4 to 5 days of external stimuli. 
Thus, the model used in the pres-
ent study permitted the use of the 
large number of live bone samples 
required to obtain statistical signifi-
cance of the data, without the high 
costs and ethical issues associated 
with more traditional models.  
Finally, the live bone organ mi-
croenvironment used in the present 
study can be used for the two bone 
remodeling stages (ie, osteoclastic 
bone resorption and osteoblastic 
bone formation) separately. There-
fore, we were able to uncover critical 
hidden biologic responses related 
to the individual bone remodeling 
stage, which would otherwise be 
lost. This bone microenvironment 
is easily accessible for the cellular, 
chemical, and biochemical analytical 
evaluations, providing clear results 
and interpretations of the outcome 
of the experimental perturbations. 
The presence of this bone micro-
environment with mineralized bone 
matrix, osteocytes, mesenchymal 
stem cells, osteoblasts, and osteo-
clast precursors that are responsive 
to the external stimuli provided the 
capabilities to evaluate the impact 
of a piezotome-generated surgical 
injury and mechanical load (high-
frequency vibration, 30 Hz) com-
pared with bur and handheld screw 
perforation injuries. The piezotome 
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corticotomy appears to generate 
for the same surgical injury a much 
greater degree of demineralization 
than the bur or screw perforation-
type corticotomies. This finding 
could be a result of the additive ef-
fect of the osteocytes’ response to 
the high-frequency vibrations from 
the piezotome that couples with and 
amplifies the natural response to the 
surgical injury. Similarly, in the sec-
ond phase of this bimodal response 
(the regional acceleratory phenom-
enon), bone apposition seemed to 
be enhanced when using the piezo-
tome compared with the other two 
devices. The piezoelectric effect is 
the conversion of electrical energy 
to mechanical energy by means of 
a crystalline material. Piezoelectric-
driven cutting, high-speed bur cut-
ting, and handheld screw cutting 
are all forms of mechanical energy. 
The transmission or absorption of 
energy (as it passes through matter) 
and its interaction with the matter 
(in this instance, bone) depends on 
both the type of energy and the re-
sponse of the bone to the energy. 
The response of the bone may de-
pend on frequency, energy density, 
and other characteristics of this en-
ergy, such as potential tuning to the 
natural resonance frequency of the 
bone cells and the mineral phase. 
Our study with live bone or-
gan models showed the impact of 
high-frequency vibration on bone 
resorption and bone formation 
consistent with the effects of high-
frequency vibration on osteocytes, 
osteoclast precursors, and osteo-
blasts. Although the observations in 
the literature on using isolated cell 
culture systems are varied, emerg-
ing facts indicate that both anabolic 
and catabolic effects are possible, 
depending on the vibrational fre-
quency and the types and environ-
ment of cells used,16–19 as well as 
whether the whole body is being 
subjected to vibration.20–25 A num-
ber of such studies have been car-
ried out in vitro using bone-isolated 
cell cultures such as mesenchymal 
cells, preosteoblasts and osteo-
blasts, osteoclast precursors and 
osteoclasts, and osteocyte-like cells 
to investigate effects of low magni-
tude (< 1 g, g = 9.8 m/s2) and high-
frequency vibration (20–100 Hz) on 
expression of soluble factors that 
have major roles in regulating bone 
remodeling by means of the osteo-
cyte-osteoblast-osteoclast coupling 
phenomenon. The complexity and 
interplay between different bone 
cells observed in studies performed 
in vivo and in vtro thus highlight the 
need to define the precise signaling 
pathways, the deciphering of which 
remains a major scientific interest. 
Conclusions
Within the limits of this study, not all 
corticotomies had the same effect 
on the bone. Piezotome, bur, and 
screw perforation injuries induced 
varying degrees of bone remodeling 
activities; however, piezotome led to 
the most extensive impact in both 
bone resorption and formation mod-
els. In the bone resorption model, 
the piezotome induced higher lev-
els of calcium release, TRAP activity, 
osteoclast differentiation, and bone 
resorption. Similarly, under the bone 
formation model, piezotome led to 
substantially higher levels of osteo-
blast differentiation and new osteoid 
formation. The consistent advantag-
es and greater impact of the piezo-
tome is the result of the synergism 
of bone injury and high-frequency 
(30 Hz) mechanical vibration. 
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